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(57) ABSTRACT
The present invention relates to parasitic nematode trans-
glutaminase proteins; to parasitic nematode transglutami-
nase nucleic acid molecules, including those that encode
such transglutaminase proteins; to antibodies raised against
such transglutaminase proteins; and to compounds that
inhibit parasitic nematode transglutaminase activity. The
present invention also includes methods to obtain such
proteins, nucleic acid molecules, antibodies, and inhibitory
compounds. Also included in the present invention are
therapeutic compositions comprising such proteins, nucleic
acid molecules, antibodies and/or inhibitory compoundsas
well as the use of such therapeutic compositions to protect
animals from diseases caused by parasitic nematodes. This
invention also relates to the surprising discovery that para-
sitic nematode transglutaminase proteins have protein dis-
ulfide isomerase activity. Accordingly, this invention relates
further to inhibitors of the protein disulfide isomerase activ-
ity of said transglutaminases.
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CROSS REFERENCE TO RELATED
APPLICATIONS
This application is a continuation-in-part of application
US.Ser. No. 08/781,420,filed Dec. 3, 1996, now USS. Pat.
No. 6,248,872, entitled “PARASITIC NEMATODE
TRANSGLUTAMINASE PROTEINS, NUCLEIC ACID
MOLECULES, AND USES THEREOF”.
FIELD OF THE INVENTION
The present invention relates to parasitic nematode trans-
glutaminase nucleic acid molecules, proteins encoded by
such nucleic acid molecules, antibodies raised against such
proteins, and inhibitors of such proteins. The present inven-
tion also includes therapeutic compositions comprising such
nucleic acid molecules, proteins, antibodies, inhibitors, and
combinations thereof, as well as the use of these composi-
tions to protect animals from diseases caused by parasitic
nematodes.
BACKGROUND OF THE INVENTION
Parasitic nematode infections in animals, including
humans, are typically treated by chemical drugs. One dis-
advantage with chemical drugsis that they must be admin-
istered often. For example, dogs susceptible to heartworm
are typically treated monthly. Repeated administration of
drugs, however, often leads to the developmentofresistant
nematode strains that no longer respond to treatment.
Furthermore, manyof the chemical drugs cause harmful side
effects in the animals being treated, and as larger doses
become required due to the build up of resistance, the side
effects become even greater. Moreover, a number of drugs
only treat symptomsofa parasitic disease but are unable to
prevent infection by the parasitic nematode.
An alternative method to prevent parasitic nematode
infection includes administering a vaccine against a parasitic
nematode. Although many investigators have tried to
develop vaccines based on specific antigens, it is well
understood that the ability of an antigen to stimulate anti-
body production does not necessarily correlate with the
ability of the antigen to stimulate an immune response
capable of protecting an animal from infection, particularly
in the case of parasitic nematodes. Although a number of
prominent antigens have been identified in several parasitic
nematodes, including in Dirofilaria, there is yet to be a
commercially available vaccine developed for any parasitic
nematode.
The life cycle of parasitic nematodes generally includes
development through four molts, the last two molts taking
place in the host animal. Molting is a complex process
involving a variety of different mechanisms. However, a
lack of understanding of the basic biology, metabolism and
biochemistry of parasitic nematodes has resulted in the
identification of few targets for chemotherapy or vaccines.
As an example of the complexity of parasitic nematodes,
the life cycle of D. immitis, the nematode that causes
heartworm, includes a variety of life forms, each of which
presents different targets, and challenges, for immunization.
Adult formsof the parasite are quite large and preferentially
inhabit the heart and pulmonary arteries of an animal.
Sexually mature adults, after mating, produce microfilariae














system of the dog. One method of demonstrating infection
in the dog is to detect the circulating microfilariae. If a dog
is maintained in an insect-free environment,thelife cycle of
the parasite cannot progress. However, when microfilariae
are ingested by a female mosquito during blood feeding on
an infected dog, subsequent development of the microfi-
lariae into larvae occurs in the mosquito. The microfilariae
go through twolarval stages (L1 and L2)andfinally become
mature third stage larvae (L3) which can then be transmitted
back to the dog throughthe bite of the mosquito.It is this L3
stage, therefore, that accounts for the initial infection. As
early as three days after infection, the L3 molt to the fourth
larval (LA) stage, and subsequently to the fifth stage, or
immature adults. The immature adults migrate to the heart
and pulmonary arteries, where they mature and reproduce,
thus producing the microfilariae in the blood. “Occult”
infection with heartworm in dogsis defined as that wherein
no microfilariae can be detected, but the existence of the
adult heartworms can be determined through thoracic
examination.
Heartworm not only is a major problem in dogs, which
typically cannot even develop immunity uponinfection(i.e.,
dogs can become reinfected even after being cured by
chemotherapy), but is also becoming increasingly wide-
spread in other companion animals, such as cats andferrets.
Heartworm infections have also been reported in humans.
Other parasitic nematodeic infections are also widespread,
and all require better treatment, including a preventative
vaccine program. O. volvulus, for example, causes
onchocerciasis (also known as river blindness) in humans.
Up to 50 million people throughout the world are reported
to be infected with O. volvulus, with over a million being
blinded due to infection.
Although many investigators have tried to develop vac-
cines based on specific antigens, it is well understood that
the ability of an antigen to stimulate antibody production
does not necessarily correlate with the ability of the antigen
to stimulate an immune response capable of protecting an
animal from infection, particularly in the case of parasitic
nematodes. Although a numberof prominent antigens have
been identified in several parasitic nematodes, including in
Dirofilaria and Onchocerca, there is yet to be an effective
vaccine developed for any parasitic nematode.
In just the past few years, there has developed an interest
in the identification of larval stage-specific enzymes as
potential targets for treatment or prevention of nematode
diseases. Nematode transglutaminase-catalyzed reactions
have recently been identified as possibly important for the
growth, development and survival of nematodes, including
Acanthocheilonema vitae, Brugia malayi, and Onchocerca
volvulus. See, for example, Mehta, 1992, Mol. Biochem.
Parasitol., 53, 1-16; Lustigman, 1995, AntimicrobialAgents
and Chemother. 39:9, 1913-1919; Lustigman, 1993, Para-
sitology Today, 9:8, 294-297. However, until now, no com-
pounds or methods based on specific known targets in
parasitic nematode development have been designed for
treating or preventing parasitic nematode disease.
There remains a need to identify an efficacious composi-
tion that protects animals against diseases caused by para-
sitic nematodes and that, preferably, also protects animals
from infection by such nematodes.
SUMMARYOF THE INVENTION
The present invention relates to novel products and pro-
cesses for prevention and treatment of parasitic nematode
infection. According to the present invention there are
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provided parasitic nematode transglutaminase proteins and
mimetopes thereof; nematode nucleic acid molecules,
including those that encode such proteins; antibodies raised
against parasitic nematode transglutaminase proteins(i.e.,
anti-parasitic nematode transglutaminase antibodies); and
other compounds that inhibit parasitic nematode trans-
glutaminaseactivity or the protein disulfide isomerase activ-
ity of parasitic nematode transglutaminase (i.e, inhibitory
compoundsor inhibitors).
The present invention also includes methodsto obtain the
proteins, mimetopes, nucleic acid molecules, antibodies and
inhibitory compoundsherein described. Also included in the
present invention are therapeutic compositions comprising
such proteins, mimetopes, nucleic acid molecules,
antibodies, inhibitory compounds, or mixtures thereof, as
well as the use of such therapeutic compositions to protect
animals from diseases caused by parasitic nematodes.
One embodiment of the present invention is an isolated
nucleic acid molecule that hybridizes understringent hybrid-
ization conditions with a parasitic nematode transglutami-
nase gene. Preferred parasitic nematode transglutaminase
genes of the present invention are transglutaminase genes
from Brugia malayi, Dirofilaria immitis, and Onchocerca
volvulus. Such nucleic acid molecules are referred to as
nematode transglutaminase nucleic acid molecules. A para-
sitic nematode transglutaminase gene preferably includesat
least one of the following nucleic acid sequences: SEQ ID
NO:5, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID
NO:10, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14,
SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:30, SEQ ID
NO:31, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:35,
SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID
NO:40, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:45,
SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:49, SEQ ID
NO:50, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:54,
SEQ ID NO:56, SEQ ID NO:57 or SEQ ID NO:59.
Another embodiment of the present invention is an iso-
lated nucleic acid molecule that hybridizes under stringent
hybridization conditions with a Dirofilaria immitis (D.
immitis) transglutaminase gene such nucleic acid molecules
are referred to as Dirofilaria immitis (or D. immitis) trans-
glutaminase nucleic acid molecules. A D. immitis trans-
glutaminase gene preferably includes one of the following
nucleic acid sequences: SEQ ID NO:5, SEQ ID NO:7, SEQ
ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:12,
SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:27, SEQ ID
NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32,
SEQ ID NO:34, SEQ ID NO:46, SEQ ID NO:48, SEQ ID
NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:53,
SEQ ID NO:54 or SEQ ID NO:56. A preferred D. immitis
transglutaminase protein includes at least a portion of a
protein represented by SEQ ID NO:2, SEQ ID NO:3, SEQ
ID NO:4, SEQ ID NO:6, SEQ ID NO:11, SEQ ID NO:28 or
SEQ ID NO:33, SEQ ID NO:47, SEQ ID NO:52 or SEQ ID
NO:55.
The present invention also relates to recombinant
molecules, recombinant viruses and recombinantcells that
include a transglutaminase nucleic acid molecule of the
present invention. Also included are methods to produce
such nucleic acid molecules, recombinant molecules,
recombinant viruses and recombinant cells.
Another embodiment of the present invention includes a
non-native nematode transglutaminase protein encoded by a
nucleic acid molecule that hybridizes understringent hybrid-
ization conditions with a parasitic nematode transglutami-














capable of eliciting an immune response when administered
to an animal and/or of having parasitic nematode trans-
glutaminase or protein disulfide isomerase (PDI) activity, or
both. A preferred nematode transglutaminase protein is
encoded by a nucleic acid molecule that hybridizes under
stringent conditions with a nucleic acid molecule including
either SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:12, SEQ
ID NO:14, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:34,
SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:42, SEQ ID
NO:45, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:53,
SEQ ID NO:56 or SEQ ID NO:59. A preferred nematode
transglutaminase protein includes at least a portion of a
protein represented by SEQ ID NO:1, SEQ ID NO:2, SEQ
ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:11,
SEQ ID NO:28, SEQ ID NO:33, SEQ ID NO:36, SEQ ID
NO:41, SEQ ID NO:44, SEQ ID NO:47, SEQ ID NO:52,
SEQ ID NO:55 or SEQ ID NO:58.
Another embodiment of the present invention includes a
non-native D. immitis transglutaminase protein encoded by
a nucleic acid molecule that hybridizes under stringent
conditions with a D. immitis transglutaminase gene. A
preferred D. immitis transglutaminase protein is capable of
eliciting an immune response when administered to an
animal and/or of having parasitic nematode transglutami-
nase activity. A preferred D. immitis transglutaminase pro-
tein is encoded by a nucleic acid molecule that hybridizes
under stringent conditions with a nucleic acid molecule
including either SEQ ID NO:7, SEQ ID NO:9, SEQ ID
NO:12, SEQ ID NO:14, SEQ ID NO:29, SEQ ID NO:31,
SEQ ID NO:34, SEQ ID NO:48, SEQ ID NO:50, SEQ ID
NO:53 or SEQ ID NO:56. A preferred D. immitis trans-
glutaminase protein includesat least a portion of a protein
represented by SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4,
SEQ ID NO:6, SEQ ID NO:11, SEQ ID NO:28, SEQ ID
NO:33, SEQ ID NO:47, SEQ ID NO:52 or SEQ ID NO:55.
The present invention also relates to mimetopes of para-
sitic nematode transglutaminase proteins as well as to iso-
lated antibodies that selectively bind to parasitic nematode
transglutaminase proteins or mimctopes thereof. Also
included are methods, including recombinant methods, to
produce proteins, mimetopes and antibodies of the present
invention.
Another embodimentof the present invention is a method
to identify a compound capable of inhibiting nematode
transglutaminase activity. The method includesthe steps of:
(a) contacting an isolated nematode transglutaminase pro-
tein with a putative inhibitory compound underconditions in
which, in the absence of the compound, the protein has
nematode transglutaminase activity; and (b) determining if
the putative inhibitory compound inhibits the nematode
transglutaminase activity. Also included in the present
invention is a test kit to identify a compound capable of
inhibiting nematode transglutaminase activity. Such a test
kit includes an isolated nematode transglutaminase protein
having nematode transglutaminase activity and a means for
determining the extent of inhibition of the nematode trans-
glutaminase activity in the presence of a putative inhibitory
compound.
The present invention also includes an inhibitor of nema-
tode transglutaminase activity identified by its ability to
inhibit the activity of a nematode transglutaminaseandbyits
inability to substantially inhibit mammalian transglutami-
nase. Examples of such inhibitors are substrate analogs of
nematode transglutaminase, active site inhibitors of nema-
tode transglutaminase, and antibodies that specifically rec-
ognize nematode transglutaminase.
Another embodimentof the present invention is a method
to identify a compound capable of inhibiting protein disul-
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fide isomerase (PDI) activity. The method includesthe steps
of: (a) contacting an isolated nematode transglutaminase
protein with a putative PDI inhibitory compound under
conditions in which, in the absence of the compound, the
protein has nematode PDIactivity; and (b) determining if
the putative inhibitory compound inhibits the nematode PDI
activity. Also included in the present invention is a test kit
to identify a compound capable of inhibiting nematode PDI
activity. Such a test kit includes an isolated nematode PDI
protein having nematode PDI activity and a means for
determining the extent of inhibition of the nematode PDI
activity in the presence of a putative inhibitory compound.
The present invention also includes an inhibitor of nema-
tode PDI activity identified by its ability to inhibit the PDI
activity of a nematode transglutaminase protein and byits
inability to substantially inhibit mammalian PDI. Examples
of such inhibitors are substrate analogs of nematode PDI,
active site inhibitors of nematode PDI, and antibodies that
specifically recognize parasitic nematode transglutaminase.
Yet another embodiment of the present invention is a
therapeutic composition that is capable of protecting an
animal from disease caused by a parasitic nematode. Such a
therapeutic composition includes an excipient and one or
more of the following protective compounds: an isolated
nematode transglutaminase protein or a mimetope thereof;
an isolated nucleic acid molecule that hybridizes under
stringent hybridization conditions with a nematode trans-
glutaminase gene; an isolated antibodythat selectively binds
to a nematode transglutaminase protein; an inhibitor of
nematode transglutaminase protein activity identified by its
ability to (a) inhibit nematode transglutaminaseactivity, and
(b) not substantially inhibit mammalian transglutaminase
activity; an inhibitor of nematode PDI protein activity
identified by its ability to (a) inhibit nematode PDI activity,
and (b) not substantially inhibit mammalian PDI activity; or
any combinations thereof. A preferred therapeutic compo-
sition of the present invention also includes an adjuvant, a
carrier, or both. Preferred nematode transglutaminase
nucleic acid molecule compounds of the present invention
include naked nucleic acid vaccines recombinantvirus vac-
cines and recombinantcell vaccines. Also included in the
present invention is a method to protect an animal from
disease caused by a parasitic nematode comprising the step
of administering to the animal at least one protective com-
pound of the present invention.
Yet another embodiment of the present invention is a
method to produce a transglutaminase protein, the method
comprising culturing a cell transformed with a nucleic acid
molecule that hybridizes under stringent hybridization con-
ditions with a nematode transglutaminase gene.
DETAILED DESCRIPTION OF THE
INVENTION
The present invention provides for isolated parasitic
nematode transglutaminase proteins, isolated parasitic
nematode transglutaminase nucleic acid molecules, antibod-
ies directed against parasitic nematode transglutaminase
proteins, and other inhibitors of nematode transglutaminase
activity. As used herein, the terms isolated parasitic nema-
tode transglutaminase proteins and isolated parasitic nema-
tode transglutaminase nucleic acid molecules refer to nema-
tode transglutaminase proteins and nematode
transglutaminase nucleic acid molecules derived from para-
sitic nematodes. The proteins and nucleic acid molecules of
the present invention can be obtained from their natural











binant nucleic acid technology (also referred to herein as
recombinant DNA technology) or chemical synthesis. The
terms non-native parasitic nematode transglutaminase pro-
tein or non-native parasitic nematodeprotein, as used herein,
refer to a parasitic nematode transglutaminase protein which
is produced either synthetically or by transcribing a molecu-
larly cloned or chemically synthesized parasitic nematode
transglutaminase or nucleic acid molecule of the present
invention (in other words, by recombinant DNA
technology). Also included in the present inventionis the use
of these proteins, nucleic acid molecules, antibodies and
other inhibitors as therapeutic compositions to protect ani-
mals from parasitic nematode diseases as well as in other
applications, such as those disclosed below. An entirely
unexpected finding with respect to nematode transglutami-
nase proteins of the present invention, herein disclosed for
the first time, is that a nematode transglutaminase protein
has protein disulfide isomerase (PDI) activity.
Parasitic nematode transglutaminase proteins and nucleic
acid molecules of the present invention have utility because
they represent novel targets for anti-parasite vaccines and
drugs. The products and processes of the present invention
are advantageous because they enable the inhibition of
crucial steps in nematode molting that involve nematode
transglutaminase. While not being bound by theory, it is
believed that nematode transglutaminase protein activity is
essential for successful development of nematode larvae. In
addition, the unexpected finding that nematode trans-
glutaminase proteins have PDI activity supports the use of
transglutaminase proteins of the present invention having
PDIactivity as targets for potential anti-parasite vaccines or
therapeutics.
One embodiment of the present invention is an isolated
protein comprising a D. immitis transglutaminaseprotein.It
is to be noted that the term “a” or “an” entity refers to one
or more of that entity; for example, a protein refers to one
or more proteins or at least one protein. The terms “a” (or
“an”), “one or more” and “at least one” can be used
interchangeably herein. It is also to be noted that the terms
“comprising”, “including”, and “having” can be used inter-
changeably. Furthermore, a compound “selected from the
group consisting of” refers to one or more of the compounds
in the list that follows, including mixtures (i.e.,
combinations) of two or more of the compounds.
According to the present invention, an isolated, or bio-
logically pure, protein, is a protein that has been removed
from its natural milieu. Accordingly, “isolated” and “bio-
logically pure” do not necessarily reflect the extent to which
the protein has been purified. An isolated protein of the
present invention can be obtained from its natural source,
can be produced using recombinant DNA technology or can
be produced by chemical synthesis. When an isolated pro-
tein of the present invention is produced using recombinant
DNAtechnology or produced by chemical synthesis, the
protein is referred to herein as either an isolated protein or
as a non-native protein.
As used herein, an isolated parasitic nematode trans-
glutaminase protein can be a full-length protein or any
homolog of such a protein. An isolated protein of the present
invention, including a homolog, can be identified in a
straightforward manner by the protein’s ability to elicit an
immune response against parasitic nematode transglutami-
nase proteins, to exhibit transglutaminaseactivity, or to have
any combination of these characteristics. Examples of para-
sitic nematode transglutaminase homologs include parasitic
nematode transglutaminase proteins in which amino acids
have been deleted (e.g., a truncated version of the protein,
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suchas a peptide), inserted,inverted, substituted, derivatized
(e.g., by glycosylation, phosphorylation, acetylation,
myristoylation, prenylation, palmitoylation, amidation,
addition of glycerophosphatidyl inositol), or any combina-
tion of the above, so that the homolog includesat least one
epitope capable of eliciting an immune response against a
parasitic nematode transglutaminase protein. In other words,
when the homolog is administered to an animal as an
immunogen, using techniques knownto those skilled in the
art, the animal will produce an immuneresponse againstat
least one epitope of a natural parasitic nematode trans-
glutaminase protein. The ability of a protein to effect an
immune response can be measured using techniques known
to those skilled in the art. Techniques to measure parasitic
nematode transglutaminase activity are also known to those
skilled in the at, and are described in the Examples.
Parasitic nematode transglutaminase protein homologs
can be the result of natural allelic variation or natural
mutation. Nematode transglutaminase protein homologs of
the present invention can also be produced using techniques
known in the art including, but not limited to, direct modi-
fications to the protein or modifications to the gene encoding
the protein using, for example, classic or recombinant DNA
techniques to effect random or targeted mutagenesis.
Isolated proteins of the present invention have the further
characteristic of being encoded by nucleic acid molecules
that hybridize under stringent hybridization conditions to a
gene encoding a D. immitis, a B. malayi or an O. volvulus
nematode transglutaminase protein(i.e., to a. D. immitis, a B.
malayi or an O. volvulus nematode transglutaminase gene).
As used herein, stringent hybridization conditions refer to
standard hybridization conditions under which nucleic acid
molecules, including oligonucleotides, are used to identify
molecules having similar nucleic acid sequences. Stringent
hybridization conditions typically permitisolation of nucleic
acid molecules having at least about 70% nucleic acid
sequence identity with the nucleic acid molecule being used
as a probe in the hybridization reaction. Standard conditions
are disclosed, for example, in Sambrook et al., 1989,
Molecular Cloning: A Laboratory Manual, Cold Spring
Harbor Labs Press. The reference Sambrooketal., ibid., is
incorporated by reference herein in its entirety. Formulae to
calculate the appropriate hybridization and wash conditions
to achieve hybridization permitting 30% or less mismatch of
nucleotides are disclosed, for example, in Meinkoth etal.,
1984, Anal. Biochem. 138, 267-284; Meinkothetal., ibid.,
is incorporated by reference herein in its entirety.
As used herein, a parasitic nematode transglutaminase
gene includesall nucleic acid sequencesrelated to a natural
parasitic nematode transglutaminase gene including, for
example, regulatory regions that control production of the
nematode transglutaminase protein encoded by that gene
(such as, but not limited to, transcription, translation or
post-translation control regions), as well as the coding
region itself. A D. immitis gene can include nDiTG,,,,
nDiTG,,,7,, nDiTG,,,, nDiTG,,,7, nDiTG,,., or
nDiTG,494; a B. malayi gene can include nBmTG,,, or
nBmTG,,,, and an O. volvulus gene can include nOvTG,,,.
In one embodiment, a parasitic nematode transglutaminase
gene of the present invention includes the nucleic acid
sequence SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:10,
SEQ ID NO:13, SEQ ID NO:27, SEQ ID NO:30, SEQ ID
NO:32, SEQ ID NO:35, SEQ ID NO:38, SEQ ID NO:40,
SEQ ID NO:43, SEQ ID NO:46, SEQ ID NO:49, SEQ ID
NO:51, SEQ ID NO:54 or SEQ ID NO:57, as well as the
complementof these sequences (i.e. SEQ ID NO:7, SEQ ID














SEQ ID NO:3 1, SEQ ID NO:34, SEQ ID NO:37, SEQ ID
NO:39, SEQ ID NO:42, SEQ ID NO:45, SEQ ID NO:48,
SEQ ID NO:50, SEQ ID NO:53, SEQ ID NO:56 or SEQ ID
NO:59, respectively). The nucleic acid sequence SEQ ID
NO:8 represents the deduced sequence of the coding strand
of the apparent coding region of a cDNA (complementary
DNA) molecule denoted herein as nDiTG,,;, the production
of which is disclosed in the Examples. The complement of
SEQ ID NO:8 (represented herein by SEQ ID NO:9) refers
to the nucleic acid sequence of the strand complementary to
the strand having SEQ ID NO:8, the sequence of which can
easily be determined from SEQ ID NO:8 by those skilled in
the art. Likewise, a nucleic acid sequence complement of
any nucleic acid sequence of the present invention refers to
the nucleic acid sequence of the nucleic acid strand that is
complementary to (i.e., can form a double helix with) the
strand for which the sequenceis cited.
Nucleic acid sequence SEQ ID NO:13 represents the
deduced sequence of the coding strand of a cDNA nucleic
acid molecule denoted herein as nDiTG,,,,, the production
of which is disclosed in the Examples. The complement of
SEQ ID NO:13 is represented herein by SEQ ID NO:14.
It should be noted that because nucleic acid and amino
acid sequencing technology is not entirely error-free, SEQ
ID NO:5, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:13,
SEQ ID NO:27, SEQ ID NO:30, SEQ ID NO:32, SEQ ID
NO:35, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:43,
SEQ ID NO:46. SEQ ID NO:49, SEQ ID NO:51, SEQ ID
NO:54 and SEQ ID NO:57,as well as other nucleic acid and
protein sequences presented herein, represent apparent
nucleic acid sequences of the nucleic acid molecules encod-
ing a parasitic nematode transglutaminase protein of the
present invention, and apparent amino acid sequencesof the
proteins of the present invention, respectively.
In another embodiment, a nematode transglutaminase
gene can be anallelic variant that includes a similar but not
identical sequence to SEQ ID NO:5, SEQ ID NO:7, SEQ ID
NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:12, SEQ
ID NO:13, SEQ ID NO:14, SEQ ID NO:27, SEQ ID NO:29,
SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID
NO:34, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:38,
SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:42, SEQ ID
NO:43, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:48,
SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID
NO:53, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:57 or
SEQ ID NO:59. An allelic variant of a nematode trans-
glutaminase gene including SEQ ID NO:5, SEQ ID NO:7,
SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID
NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:27,
SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID
NO:32, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:37,
SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID
NO:42, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:46,
SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID
NO:51, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:56,
SEQ ID NO:57 or SEQ ID NO:59, is a gene that occurs at
essentially the same locus (or loci) in the genomeas the gene
including SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:8, SEQ
ID NO:9, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:13,
SEQ ID NO:14, SEQ ID NO:27, SEQ ID NO:29, SEQ ID
NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:34,
SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:38, SEQ ID
NO:39, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:43,
SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:49, SEQ ID
NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:53,
SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:57 or SEQ ID
NO:59, but which, due to natural variations caused by, for
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example, mutation or recombination, has a similar but not
identical sequence. Allelic variants typically encode proteins
having similar activity to that of the protein encoded by the
gene to which they are being compared. Allelic variants can
also comprise alterations in the 5’ or 3' untranslated regions
of the gene (e.g., in regulatory control regions). Allelic
variants are well knownto those skilled in the art and would
be expected to be found within a given parasitic nematode,
or among a group of two or more parasitic nematodes,
because of the diploid nematode genome.
The minimum size of a nematode transglutaminase pro-
tein homolog of the present invention is a size sufficient to
be encoded by a nucleic acid molecule capable of forming
a stable hybrid (i.e., hybridize under stringent hybridization
conditions) with the complementary sequence of a nucleic
acid molecule encoding the corresponding natural protein.
The size of the nucleic acid molecule encoding such a
protein homolog is dependent on nucleic acid composition
and percent homology between the nucleic acid molecule
and a complementary sequence. It should also be noted that
the extent of homology required to form a stable hybrid can
vary depending on whether the homologous sequences are
interspersed throughout the nucleic acid molecules or are
clustered (i.e., localized) in distinct regions on the nucleic
acid molecules. The minimumsize of nucleic acid molecules
that can form stable hybrids under standard hybridization
conditions is typically at least about 12 to about 15 nucle-
otides in length if the nucleic acid molecules are GC-rich,
and at least about 15 to about 17 bases in length if they are
AT-rich. Therefore, the minimum size of a nucleic acid
molecule used to encode a nematode transglutaminase pro-
tein homolog of the present invention is from about 12 to
about 18 nucleotides in length. Accordingly, the minimum
size of a nematode transglutaminase protein homolog of the
present invention is from about 4 to about 6 amino acids in
length. There is no limit, other than a practical limit, on the
maximum size of a nucleic acid molecule of the present
invention because nucleic acid molecules of the present
invention can include a portion of a gene, an entire gene,
multiple genes, or portions thereof. The preferred size of a
protein encoded by a nucleic acid molecule of the present
invention depends on whether a full-length, fusion,
multivalent, or functional portion of a protein is desired.
Suitable parasitic nematodes from whichto isolate nema-
tode transglutaminase proteins of the present invention
(including isolation of the natural protein or production of
the natural or non-native protein by recombinantor synthetic
techniques) include filarioid, ancylostomatoid, ascaridoid,
diochtophymatoid, dracunculoid, metastrongyloid,
oxyuroid, physalopteroid, rhabtitoid, spiruroid, strongyloid,
thelazioid, trichinelloid, and trichostrongyloid nematodes.
Particularly preferred nematodes are those of the genera
Dirofilaria, Onchocerca, Brugia, Acanthocheilonema,
Aelurostrongylus, Ancylostoma, Angiostrongylus, Ascaris,
Bunostomum,Capillaria, Chabertia, Cooperia, Crenosoma,
Dictyocaulus, Dioctophyme, Dipetalonema, Dracunculus,
Enterobius, Filaroides, Haemonchus, Lagochilascaris, Loa,
Mansonella, Muellerius, Necator, Nematodirus,
Oesophagostomum, Ostertagia, Parafilaria, Parascaris,
Physaloptera, Protostrongylus, Setaria, Spirocerca,
Stephanofilaria, Strongyloides, Strongylus, Thelazia,
Toxascaris, Toxoeara, Trichinella, Trichostrongylus,
Trichuris, Uncinaria, and Wuchereria. Particularly preferred
are filarioid nematodes including Dirofilaria, Onchocerca,
Brugia, Acanthocheilonema, Dipetalonema, Loa,
Mansonella, Parafilaria, Setaria, Stephanofilaria, and














canis being even more preferred, and D. immitis being
particularly preferred.
A preferred parasitic nematode transglutaminase protein
of the present invention is a compoundthat is not substan-
tially toxic to host animals (that is, does not substantially
inhibit host animal transglutaminase; the term, “does not
substantially inhibit” as used herein can be used inter-
changeably with the term, “inability to substantially inter-
fere”; a compound that does not substantially inhibit host
animal transglutaminase activity is one that, when admin-
istered to a host animal, the host animal showsnosignificant
adverse effects attributable to the compound) and which,
when administered to an animal in an effective manner, is
capable of protecting that animal from disease caused by a
parasitic nematode. In accordance with the present
invention, the ability of a nematode transglutaminase protein
of the present invention to protect an animal from disease by
a parasitic nematoderefers to the ability of that protein to,
for example, treat, ameliorate or prevent disease caused by
parasitic nematodes. In particular, the phrase, “protect an
animal from disease by a parasitic nematode,” refers to
reducing the potential for parasitic nematode population
expansion in the host animal by inhibiting parasitic nema-
tode molting and subsequent growth. Nematode molting is
an essential step in the life cycle and development ofall
nematodes, and characterizes the progression of the nema-
tode larvae through the developmentoflarval stages to the
adult. A host animal, as used herein, is an animal in which
a parasitic nematode can live and multiply. In one
embodiment, a nematode transglutaminase protein of the
present invention can elicit an immune response (including
a humoral or cellular immune response, or both) against a
parasitic nematode.
Suitable nematodesto target with therapeutic compounds
of the present invention include any nematodes that are
essentially incapable of molting, or are inhibited in the
ability to molt, in a host animal when a nematode trans-
glutaminase protein of the present invention, or inhibitor of
such a protein, has been administered to that animal.
Accordingly, a nematode to target includes any nematode
that produces a protein having one or more epitopes that can
be neutralized by either a humoral or a cellular immune
response, or both, elicited by a nematode transglutaminase
protein of the present invention, or that produces a protein
that can be targeted by a compound that otherwise inhibits
nematode transglutaminaseactivity, thereby resulting in the
decreased ability of the nematode to cause disease in an
animal. Preferred nematodes to target include parasitic
nematodesdisclosed herein as being useful in the production
or isolation of parasitic nematode transglutaminase proteins
of the present invention.
The present invention also includes mimetopes of para-
sitic nematode transglutaminase proteins of the present
invention. As used herein, a mimetope of a parasitic nema-
tode transglutaminase protein of the present invention refers
to any compoundthat is able to mimic the activity of such
a parasitic nematode transglutaminase protein (e.g., has the
ability to elicit an immune response against a parasitic
nematode transglutaminase protein of the present invention
or ability to inhibit parasitic nematode transglutaminase
activity). The ability to mimic the activity of a parasitic
nematode transglutaminase protein is likely to be the result
of a structural similarity between the parasitic nematode
transglutaminase protein and the mimetope.It is to be noted,
however, that the mimetope need not have a structure similar
to a parasitic nematode transglutaminase protein as long as
the mimetope functionally mimics the protein. Mimetopes
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can be, but are not limited to: peptides that have been
modified to decrease their susceptibility to degradation;
anti-idiotypic and/or catalytic antibodies, or fragments
thereof; non-proteinaceous immunogenic portions of an
isolated protein (e.g., carbohydrate structures); synthetic or
natural organic or inorganic molecules, including nucleic
acids; and/or any other peptidomimetic compounds. Mime-
topes of the present invention can be designed using
computer-generated structures of parasitic nematode trans-
glutaminase proteins of the present invention. Mimetopes
can also be obtained by generating random samples of
molecules, such as oligonucleotides, peptides or other
organic molecules, and screening such samples by affinity
chromatography techniques using the corresponding binding
partner, (e.g., an anti- parasitic nematode transglutaminase
antibody). A preferred mimetope is a peptidomimetic com-
pound that is structurally and/or functionally similar to a
parasitic nematode transglutaminase protein of the present
invention, particularly to the active site of the parasitic
nematode transglutaminase protein.
One embodiment of a parasitic nematode transglutami-
nase protein of the present invention is a fusion protein that
includes a parasitic nematode transglutaminase protein-
containing domain attached to one or more fusion segments.
Suitable fusion segments for use with the present invention
include, but are not limited to, segments that can: enhance a
protein’s stability; act as an immunopotentiator to enhance
an immune response against a nematode transglutaminase
protein; assist in purification of a nematode transglutaminase
protein (e.g., by affinity chromatography); or any combina-
tion of the abovelisted functions. A suitable fusion segment
can be a domain of any size that has the desired function
(e.g., imparts increased stability, imparts increased immu-
nogenicity to a protein, or simplifies purification of a
protein). Fusion segments can be joined to amino or car-
boxyl termini, or both, of the nematode transglutaminase-
containing domain of the protein and can be susceptible to
cleavage in order to enable straightforward recovery of a
nematode transglutaminase protein. Fusion proteins are
preferably produced by culturing a recombinantcell trans-
formed with a fusion nucleic acid molecule that encodes a
protein including the fusion segment attached to either or
both of the carboxyl or amino terminal ends of a nematode
transglutaminase-containing domain. Preferred fusion seg-
ments include a metal binding domain(e.g., a poly-histidine
segment); an immunoglobulin binding domain(e.g., Protein
A; Protein G; T cell; B cell; Fe receptor; or complement
protein antibody-binding domains); a sugar binding domain
(e.g., a maltose-binding domain); a “tag” domain (e.g., in at
least a portion of B-galactoside, a strep tag peptide, other
domains that can be purified using compoundsthat bind to
the domain, such as monoclonal antibodies), or any combi-
nation of the above listed fusion segments. More preferred
fusion segments include metal binding domains, such as a
poly-histidine segment; a maltose-binding domain; a strep
tag peptide, such as that available from Biometra in Tampa,
Fla.; and an S10 peptide.
In another embodiment, a parasitic nematode trans-
glutaminase protein of the present invention also includesat
least one additional protein segment that is capable of
protecting an animal from one or more diseases such a
multivalent protective protein can be produced by culturing
a cell transformed with a nucleic acid molecule comprising
two or more nucleic acid domains joined together in such a
mannerthat the resulting nucleic acid molecule is expressed
as a multivalent protective compound containingat least two














tecting an animal from diseases caused, for example, by at
least one other infectious agent.
Examples of multivalent protective compounds include,
but are not limited to, a parasitic nematode transglutaminase
protein of the present invention attached to one or more
compounds protective against one or more other infectious
agents,particularly an agent that infects humans,cats, dogs,
cattle, sheep pigs, goats or horses, such as, but notlimitedto:
viruses(e.g., adenoviruses,caliciviruses, coronaviruses,dis-
temperviruses, hepatitis viruses, herpesviruses, immunode-
ficiency viruses, infectious peritonitis viruses, leukemia
viruses, oncogenic viruses, panleukopenia viruses, papil-
loma viruses, parainfluenza viruses, parvoyiruses, rabies
viruses, and reoviruses, as well as other cancer-causing or
cancer-related viruses); bacteria (e.g., Actinomyces,
Bacillus, Bacteroides, Bordetella, Bartonella, Borrelia,
Brucella, Campylobacter, Capnocytophaga, Clostridium,
Corynebacterium, Coxiella, Dermatophilus, Enterococcus,
Ehrlichia, Escherichia, Francisella, Fusobacterium,
Haemobartonella, Helicobacter, Klebsiella, L-form bacteria,
Leptospira, Listeria, Mycobacteria, Mycoplasma,
Neorickettsia, Nocardia, Pasteurella, Peptococcus,
Peptostreptococcus, Proteus, Pseudomonas, Rickettsia,
Rochalimaea, Salmonella, Shigella, Staphylococcus,
Streptococcus, and Yersinia; fungi and fungal-related micro-
organisms (e.g., Absidia, Acremonium, Alternaria,
Aspergillus, Basidiobolus, Bipolaris, Blastomyces, Candida,
Chlamydia, Coccidioides, Conidiobolus, Cryptococcus,
Curvalaria, Epiderinophyton, Exophiala, Geotrichum,
Histoplasma, Madurella, Malassezia, Microsporum,
Moniliella, Mortierella, Mueor, Paecilomyces, Penicillium,
Phialemonium, Phialophora, Prototheca, Pseudallescheria,
Pseudomicrodochium, Pythium, Rhinosporidium, Rhizopus,
Scolecobaidium, Sporothrix, Stemphylium, Trichophyton,
Trichosporon, and Xylohypha); and other parasites (e.g.,
Babesia, Balantidium, Besnoitia, Cryptosporidium, Eimeria,
Encephalitozoon, Entamoeba, Giardia, Hammondia,
Hepatozoon, Isospora, Leishmania, Microsporidia,
Neospora, Nosema, Pentatrichomonas, Plasmodium,
Pneumocystis, Sarcocystis, Schistosoma, Theileria,
Toxoplasma, and Trypanosoma, as well as other nematode
parasites, including, but not limited to those disclosed
herein). In one embodiment, a parasitic nematode trans-
glutaminase protein of the present invention is attached to
one or more additional compoundsprotective against para-
sitic nematode disease. In another embodiment one or more
protective compounds, such as those listed above, can be
included in a multivalent vaccine comprising a parasitic
nematode transglutaminase protein of the present invention
and one or more other protective molecules as separate
compounds.
A preferred isolated protein of the present invention is a
protein encoded by a nucleic acid molecule that hybridizes
under stringent hybridization conditions with nucleic acid
molecule nDiTG,,,, nDiTG,);, nDiTG,,47., nDiTG,,,,,
onDiTG,,43, nDiTG,;, nDiITG,2,, nDITG,497, nDiTG,<1,
nDitG,4,, NDITG,,,¢, nBMTG,,5, nBMTG,,7,, nBMTG,50,
nBmTG,,7, or nOvTG,,,. A further preferred isolated pro-
tein is encoded by a nucleic acid molecule that hybridizes
under stringent hybridization conditions with a nucleic acid
molecule having nucleic acid sequence SEQ ID NO:7, SEQ
ID NO:9, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:29,
SEQ ID NO:31, SEQ ID NO:34, SEQ ID NO:37, SEQ ID
NO:39, SEQ ID NO:42, SEQ ID NO:45, SEQ ID NO:48,
SEQ ID NO:50, SEQ ID NO:53, SEQ ID NO:56 or SEQ ID
NO:59.
Translation of SEQ ID NO:5 suggests that nucleic acid
molecule nDiTG,,, encodesa partial-length parasitic nema-
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tode transglutaminase protein of about 235 amino acids,
referred to herein as PDiTG,,, represented by SEQ ID
NO:6, assuming an open reading frame havinga first codon
spanning from about nucleotide 1 through about nucleotide
3 of SEQ ID NO:5. The coding region encoding PDiTG,,;
is represented by nucleic acid molecule nDiTG.,,, having
the nucleic acid sequence represented by SEQ ID NO:8 (the
coding strand) and SEQ ID NO:9 (the complementary
strand). The deduced amino acid sequence (represented by
SEQ ID NO:6) suggests a protein having a molecular weight
of about 27.2 kilodaltons (kD) and an estimated pI of about
5.07.
The amino acid sequence of PDiTG,,. includes a thiore-
doxin family active site from residues about 24 to 30.
Thioredoxins participate in various redox reactions through
the reversible oxidation of an active center disulfide bond
Holmgren, A., 1985 Annual Review of Biochemistry, 54,
237-271. Anumberof eukaryotic proteins contain domains
evolutionarily related to thioredoxin.
Translation of SEQ ID NO:10 suggests that nucleic acid
molecule nDiTG,,, encodesa partial-length parasitic nema-
tode transglutaminase protein of about 368 amino acids,
referred to herein as PDiTG3,g represented by SEQ ID
NO:11, assuming an open reading frame havinga first codon
spanning from about nucleotide 2 through about nucleotide
4 of SEQ ID NO:10, and a putative stop codon spanning
from about nucleotide 1105 through nucleotide 1107 of SEQ
ID NO:10. The coding region encoding PDiTG3¢.
(including a putative stop codon) is represented by nucleic
acid molecule nDiTG,,,,, having the nucleic acid sequence
represented by SEQ ID NO:13(the coding strand) and SEQ
ID NO:14 (the complementary strand). The deduced amino
acid sequence SEQ ID NO:11 suggests a protein having a
molecular weight of about 42.6 kD and an estimated pI of
about 5.71.
The amino acid sequence of PDiTG., (ie., SEQ ID
NO:11) includes: i) a thioredoxin family active site detected
from residues 268 to 274; ii) an endoplasmic reticulum (ER)
targeting sequence from residues 365 to 368 (KEEL)
(proteins that permanently reside in the lumen of ER seem
to be distinguished from newly synthesized secretory pro-
teins by the presence of the C-terminal sequence Lys-Asp-
Glu-Leu (KDEL);see, for example, Munroet al., 1987, Cell
48,899-907; Pelham, 1990, Trends in Biochemical Sciences,
15,483-486; and iii) a tachykinin family signature from
residues 186 to 202 (tachykinins are a group ofbiologically
active peptides that excite neurons, evoke behavioral
responses, are potent vasodilators, and contract many
smooth muscles; see, for example, Maggio, 1988, Annual
Review of Neurosciences, 11,13-28.
Morepreferred parasitic nematode transglutaminase pro-
teins of the present invention include proteins comprising
amino acid sequencesthat are at least about 80%, preferably
at least about 85%, more preferably at least about 90%, and
even more preferably at least about 95% identical to amino
acid sequence SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3,
or SEQ ID NO:4. These sequences are described in the
Examples. Even more preferred parasitic nematode trans-
glutaminase proteins of the present invention include pro-
teins comprising amino acid sequencesthatare at least about
50%,preferably at least about 60%, more preferablyat least
about 70%, more preferably at least about 80%, more
preferably at least about 90%, and even more preferably at
least about 95% identical to amino acid sequence SEQ ID
NO:6, SEQ ID NO:11, SEQ ID NO:28, SEQ ID NO:33,
SEQ ID NO:36, SEQ ID NO:41, SEQ ID NO:44, SEQ ID














Morepreferred parasitic nematode transglutaminase pro-
teins of the present invention include proteins encoded by a
nucleic acid molecule comprising at least a portion of
nDiTG.,,, nDiTG.);, nDiTG,,,,, nDiTG,,9,, nDiTG,,,,
nDiTG,;, NDITG,59, nDITG,497, NDITG1gg, NDITG,404,
oDiTG,,,5,.nBmTG,,), nBmTG,,7,, 1BmTG,,,, nBmMTG,,,
and nOvTG,,,, or at least a portion of allelic variants of
these nucleic acid molecules. In one embodiment, a pre-
ferred nematode transglutaminase protein of the present
invention is encoded byatleast a portion of SEQ ID NO:5,
SEQ ID NO:8, SEQ ID NO:10, or SEQ ID NO:13, SEQ ID
NO:27, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:35,
SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:41, SEQ ID
NO:46, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:54 or
SEQ ID NO:57, and has an amino acid sequence that
includesat least a portion of SEQ ID NO:6, SEQ ID NO:11,
SEQ ID NO:28, SEQ ID NO:33, SEQ ID NO:36, SEQ ID
NO:41, SEQ ID NO:44, SEQ ID NO:47, SEQ ID NO:52,
SEQ ID NO:55 or SEQ ID NO:58. Also preferred is a
protein encoded by an allelic variant of a nucleic acid
molecule comprising at least a portion of SEQ ID NO:5,
SEQ ID NO:8, SEQ ID NO:10, or SEQ ID NO:13, SEQ ID
NO:27, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:35,
SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:43, SEQ ID
NO:46, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:54 or
SEQ ID NO:57.Particularly preferred proteins of the present
invention are those comprising an amino acid sequence
selected from the group consisting of SEQ ID NO:1, SEQ ID
NO:2, SEQ ID NO: 3, SEQ ID NO: 4,SEQ ID NO:6, SEQ
ID NO:11, SEQ ID NO:28, SEQ ID NO:33, SEQ ID NO:36,
SEQ ID NO:41, SEQ ID NO:44, SEQ ID NO:47, SEQ ID
NO:52, SEQ ID NO:55 or SEQ ID NO:58, and proteins
encoded by an allelic variant of a nucleic acid molecule
encoding any of these amino acid sequences. Also preferred
is an isolated D. immitis transglutaminase protein. An iso-
lated D. immitis transglutaminase protein of the present
invention can be either native or can be chemically synthe-
sized or produced in a cell transformed with a nucleic acid
molecule encoding a D. immitis transglutaminase protein.
Another embodiment of the present invention is an iso-
lated nucleic acid molecule that hybridizes under stringent
hybridization conditions with a parasitic nematode trans-
glutaminase gene, and particularly with a D. immitis, B.
malayi or O. volvulus transglutaminase gene. The identify-
ing characteristics of such a gene are herein described. A
nucleic acid molecule of the present invention can include
an isolated natural parasitic nematode transglutaminase gene
or a homologthereof, the latter of which is described in more
detail below. A nucleic acid molecule of the present inven-
tion can include one or more regulatory regions, full-length
or partial coding regions, or any combinations thereof. The
minimum size of a nucleic acid molecule of the present
invention is the minimum size that can form a stable hybrid
with a parasitic nematode transglutaminase gene under
stringent hybridization conditions. Suitable and preferred
parasitic nematodes are disclosed above.
In accordance with the present invention, an isolated
nucleic acid molecule is a nucleic acid molecule that has
been removed from its natural milieu (i.e., that has been
subjected to human manipulation) and can include DNA,
RNA,orderivatives of either DNA or RNA.As used herein,
the term, “isolated,” does not reflect the extent to which the
nucleic acid molecule has been purified. An isolated para-
sitic nematode transglutaminase nucleic acid molecule of the
present invention can beisolated from its natural source or
can be produced using recombinant DNAtechnology(e.g.,
polymerase chain reaction (PCR) amplification, cloning) or
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chemical synthesis. Isolated nematode transglutaminase
nucleic acid molecules can include, for example, natural
allelic variants and nucleic acid molecules modified by
nucleotide insertions, deletions, substitutions, inversions,
variants created during PCR amplification, or any combina-
tion of the above modifications. According to the present
invention, acceptable modifications to nematode trans-
glutaminase nucleic acid molecules do not substantially
interfere with the nucleic acid molecule’s ability to encode
a nematode transglutaminase protein of the present inven-
tion or to form stable hybrids understringent conditions with
natural parasitic nematode transglutaminase geneisolates.
A parasitic nematode transglutaminase nucleic acid mol-
ecule homolog can be produced using a number of methods
known to those skilled in the art (see, for example, Sam-
brooket al., ibid.). For example, nucleic acid molecules can
be modified using a variety of techniques including, but not
limited to, classic mutagenesis and recombinant DNAtech-
niques (e.g., site-directed mutagenesis, chemical treatment,
restriction enzyme cleavage, ligation of nucleic acid
fragments, and PCR amplification), or synthesis of oligo-
nucleotide mixtures and ligation of mixture groups to
“build” a mixture of nucleic acid molecules and combina-
tions thereof. Nucleic acid molecule homologs can be
selected by hybridization with a nematode transglutaminase
gene or by screening expression products of the nematode
transglutaminase nucleic acid molecule homologs for the
function of a protein encoded by the nucleic acid molecule
(e.g., the ability to elicit an immuneresponseagainstat least
one epitope of a parasitic nematode transglutaminase protein
or parasitic nematode transglutaminase activity).
An isolated nucleic acid molecule of the present invention
can include a nucleic acid sequence that encodesat least one
parasitic nematode transglutaminase protein of the present
invention; examples of such proteins are herein disclosed.
Although the phrase “nucleic acid molecule” primarily
refers to the physical nucleic acid molecule and the phrase
“nucleic acid sequence” primarily refers to the sequence of
nucleotides in the nucleic acid molecule, the two phrases can
be used interchangeably, especially with respect to a nucleic
acid molecule, or a nucleic acid sequence, being capable of
encoding a parasitic nematode transglutaminase protein.
A preferred nucleic acid molecule of the present
invention, when administered to an animal, is substantially
not toxic to the animal and is capable of protecting that
animal from disease caused by a parasitic nematode. As will
be disclosed in more detail below, such a nucleic acid
molecule can be, or encode, an antisense RNA, a molecule
capable of triple helix formation, a ribozyme, or other
nucleic acid-based drug compound. In additional
embodiments, a nucleic acid molecule of the present inven-
tion can encode a protective protein (e.g., a nematode
transglutaminase protein of the present invention), the
nucleic acid molecule being delivered to the animal, for
example, by direct injection (i.e, as a composition compris-
ing a naked nucleic acid molecule of the present invention)
or in a vehicle such as a recombinant virus vaccine or a
recombinant cell vaccine.
One embodiment of the present invention is a parasitic
nematode transglutaminase nucleic acid molecule that
hybridizes under stringent hybridization conditions with
nucleic acid molecule nDiTG,,,;, and preferably with a
nucleic acid molecule having nucleic acid sequence SEQ ID
NO:5 or SEQ ID NO:7. Such a nucleic acid molecule would
also hybridize with nDiTG,,;, and thus would also hybrid-
ize with SEQ ID NO:8 or SEQ ID NO:9. Comparison of














sequence of the coding strand of nDiTG,,7) with nucleic
acid sequences reported in GenBank™ indicates that SEQ
ID NO:5 showed the most homology (i.e., about 37%
identity) with human clone PA3 (GenBank™ accession
number JO5016), a protein disulfide isomerase related to
protein (Erp72) mRNA.
Another embodiment of the present invention is a para-
sitic nematode transglutaminase nucleic acid molecule that
hybridizes under stringent hybridization conditions with
nucleic acid molecule nDiTG,,,5;, and preferably with a
nucleic acid molecule having nucleic acid sequence SEQ ID
NO:10 or SEQ ID NO:12. Such a nucleic acid molecule
would also hybridize with nDiTG,,,,, and thus would also
hybridize with SEQ ID NO:13 or SEQ ID NO:14. Com-
parison of nucleic acid sequence SEQ ID NO:10 (ie., the
nucleic acid sequence of the coding strand of nDiTG,,.7)
with nucleic acid sequences reported in GenBank™ indi-
cates that SEQ ID NO:10 showed the most homology(i.e.,
about 63% sequence identity) with a human epithelial cell
mRNA for ER-60 protease (GenBank™ accession number
D83485), spanning from nucleotide about 1143 to about
1458 of the ER-60 protease.
Preferred parasitic nematode transglutaminase nucleic
acid molecules include nucleic acid molecules having a
nucleic acid sequencethatis at least about 70%, preferably
at least about 75%, morepreferably at least about 80%, more
preferably at least about 85%, even more preferably at least
about 90% and even more preferably at least about 95%
identical to nucleic acid sequence SEQ ID NO:5, SEQ ID
NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ
ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:27,
SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID
NO:32, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:37,
SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID
NO:42, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:46,
SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID
NO:51, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:56,
SEQ ID NO:57 or SEQ ID NO:59.
Another preferred embodiment of the present invention
includesat least a portion of a nucleic acid sequence SEQ ID
NO:5, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID
NO:10, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14,
SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:30, SEQ ID
NO:31, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:35,
SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID
NO:40, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:45,
SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:49, SEQ ID
NO:50, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:54,
SEQ ID NO:56, SEQ ID NO:57 or SEQ ID NO:59that is
capable of hybridizing with a nematode transglutaminase
gene of the present invention, as well as allelic variants
thereof. Such nucleic acid molecules can include nucleotides
in addition to those included in the sequenceslisted above,
such as, but not limited to, a full-length gene, a full-length
coding region, a nucleic acid molecule encoding a fusion
protein, or a nucleic acid molecule encoding a multivalent
protective compound. Particularly preferred nucleic acid
molecules include nDiTG,),, nDiTG,9;, nDiTG,,,>,
nDiTG,457, NDITG,43, nDITG,5,, nDITG,497, nDITG,921,
nDiTG,494, nNDiTG,,,5, nBmMTG,,5,, nBmTG,,,,
nBmTG,,., nBMTG,,, or nOvTG,,,, andallelic variants of
these nucleic acid molecules. Also particularly preferred
nucleic acid molecules include those including SEQ ID
NO:5, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID
NO:10, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14,
SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:30, SEQ ID
NO:31, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:35,
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SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID
NO:40, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:45,
SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:49, SEQ ID
NO:50, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:54,
SEQ ID NO:56, SEQ ID NO:57 or SEQ ID NO:59, and
allelic variants of these preferred nucleic acid molecules.
The present invention also includes a nucleic acid mol-
ecule encoding a protein havingat least a portion of SEQ ID
NO:6, SEQ ID NO:11, SEQ ID NO:28, REQ ID NO:33,
SEQ ID NO:36, SEQ ID NO:41, SEQ ID NO:44, SEQ ID
NO:47, SEQ ID NO:52, SEQ ID NO:55 or SEQ ID NO:58,
including allelic variants of these sequences and nucleic acid
molecules that have been modified to accommodate codon
usage properties of the cells in which such nucleic acid
molecules are to be expressed. Particularly preferred are
nucleic acid molecules that encode amino acid sequences
including those represented by SEQ ID NO:6, SEQ ID
NO:11, SEQ ID NO:28, SEQ ID NO:33, SEQ ID NO:36,
SEQ ID NO:41, SEQ ID NO:44, SEQ ID NO:47, SEQ ID
NO:52, SEQ ID NO:55 or SEQ ID NO:58, and allelic
variants of these nucleic acid molecules.
Knowing the nucleic acid sequences of certain parasitic
nematode transglutaminase nucleic acid molecules of the
present invention allows one skilled in the art to, for
example, (a) make copies of those nucleic acid molecules,
(b) obtain nucleic acid molecules including at least a portion
of such nucleic acid molecules (e.g., nucleic acid molecules
including full-length genes, full-length coding regions, regu-
latory control sequences, truncated coding regions), and (c)
obtain parasitic nematode transglutaminase nucleic acid
molecules from other parasitic nematodes. Such nucleic acid
molecules can be obtained in a variety of ways including
screening appropriate expression libraries with antibodies of
the present invention; traditional cloning techniques using
oligonucleotide probes of the present invention to screen
appropriate libraries DNA, or RNA; and PCR amplification
of appropriate libraries, DNA, or RNAusing oligonucleotide
primersof the present invention. Preferred libraries to screen
or from which to amplify nucleic acid molecule include
adult and larval stage parasitic nematode cDNAlibraries as
well as genomic DNAlibraries. Similarly, preferred DNAor
RNAsources to screen or from which to amplify nucleic
acid molecules include adult and larval stage parasitic
nematode cDNA, adult and larval mRNA, and genomic
DNA.Techniques to clone and amplify genesare disclosed,
for example, in Sambrooket al., ibid, as well as in the
Examples section.
The present invention also includes nucleic acid mol-
ecules that are oligonucleotides capable of hybridizing,
under stringent hybridization conditions, with complemen-
tary regions of other, preferably longer, nucleic acid mol-
ecules of the present invention such as those comprising
parasitic nematode transglutaminase genesorother parasitic
nematode transglutaminase nucleic acid molecules. Oligo-
nucleotides of the present invention can be RNA, DNA,or
derivatives of either. The minimum size of such oligonucle-
otides is the size required for formation of a stable hybrid
between an oligonucleotide and a complementary sequence
on a nucleic acid molecule of the present invention. Minimal
size characteristics are disclosed herein. The present inven-
tion includes oligonucleotides that can be used as, for
example, probes to identify nucleic acid molecules, primers
to produce nucleic acid molecules or therapeutic reagents to
inhibit nematode transglutaminase protein production or
activity (e.g., as antisense-, triplex formation-, ribozyme-
and/or RNA drug-based reagents). The present invention














animals from disease using one or more of such technolo-
gies. Appropriate oligonucleotide-containing therapeutic
compositions can be administered to an animal using tech-
niques knownto those skilled in the art.
One embodiment of the present invention includes a
recombinant vector, which includes at least one isolated
nucleic acid molecule of the present invention, inserted into
any vector capable of delivering the nucleic acid molecule
into a cell. Such a vector contains heterologous nucleic acid
sequences, that is nucleic acid sequences that are not natu-
rally found adjacent to nucleic acid moleculesof the present
invention and that preferably are derived from a species
other than the species from which the nucleic acid molecule
(s) are derived. The vector can be either RNA or DNA,either
prokaryotic or eukaryotic, and typically is a virus or a
plasmid. Recombinant vectors can be used in the cloning,
sequencing, and/or otherwise manipulation of parasitic
nematode transglutaminase nucleic acid molecules of the
present invention.
One type of recombinant vector, referred to herein as a
recombinant molecule, comprises a nucleic acid molecule of
the present invention operatively linked to an expression
vector. The phrase operatively linked refers to insertion of a
nucleic acid molecule into an expression vector in a manner
such that the molecule is able to be expressed whentrans-
formed into a cell. As used herein, an expression vectoris a
DNAor RNAvector that is capable of transforming a cell
and of effecting expression of a specified nucleic acid
molecule. Preferably, the expression vector is also capable
of replicating within the cell. Expression vectors can be
either prokaryotic or eukaryotic, and are typically viruses
(including viral genomes) or plasmids. Expression vectors
of the present invention include any vectors that function
(i.e., direct gene expression) in recombinant cells of the
present invention, including in bacterial, fungal,
endoparasite, insect, other animal, and plant cells. Preferred
expression vectors of the present invention can direct gene
expression in bacterial, yeast, insect and mammalian cells
and more preferably in the cell types disclosed herein.
In particular, expression vectors of the present invention
contain regulatory sequences such as transcription control
sequences, translation control sequences, origins of
replication, and other regulatory sequences that are compat-
ible with the recombinant cell and that control the expres-
sion of nucleic acid molecules of the present invention. In
particular, recombinant molecules of the present invention
include transcription control sequences. Transcription con-
trol sequences are sequences that control the initiation,
elongation, and termination of transcription. Particularly
important transcription control sequences are those that
control transcription initiation, such as promoter, enhancer,
operator and repressor sequences. Suitable transcription
control sequences include any transcription control
sequence that can function in at least one of the recombinant
cells of the present invention. Avariety of such transcription
control sequences are known to those skilled in the art.
Preferred transcription control sequences include those that
function in bacterial, yeast, insect and mammalian cells,
such as, but not limited to, tac, lac, trp, tre, oxy-pro,
omp/Ipp, rrnB, bacteriophage lambda(such as lambda p, and
lambda p, and fusions that include such promoters), bacte-
riophage T7, T7lac, bacteriophage T3, bacteriophage SP6,
bacteriophage SP01, metallothionein, alpha-mating factor,
Pichia alcohol oxidase, alphavirus subgenomic promoters
(such as Sindbis virus subgenomic promoters), antibiotic
resistance gene, baculovirus, Heliothis zea insect virus,
vaccinia virus, herpesvirus, raccoon poxvirus, other
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poxvirus, adenovirus, cytomegalovirus (such as intermedi-
ate early promoters), simian virus 40, retrovirus, actin,
retroviral long terminal repeat, Rous sarcoma virus, heat
ghock, phosphate andnitrate transcription control sequences
as well as other sequences capable of controlling gene
expression in prokaryotic or eukaryotic cells. Additional
suitable transcription control sequences include tissue-
specific promoters and enhancers as well as lymphokine-
inducible promoters (e.g., promoters inducible by interfer-
ons or interleukins). Transcription control sequences of the
present invention can also include naturally occurring tran-
scription control sequences naturally associated with para-
sitic nematodes, for example D. immitis.
Suitable and preferred nucleic acid molecules to include
in recombinant vectors of the present invention are as
disclosed herein. Particularly preferred nucleic acid mol-
ecules to include in recombinant vectors, and particularly in
recombinant molecules, include nDiTG,,,, nDiTG,,,,
nDiTG,472, nNDiITG,,9,, nDiTG,,,, nDiTG,.,, nDiTG,;,
oDiTG,497, NDiTG,.,,, nDiITG,45,, nDiTG,44.¢,
nBmTG,,5, nBmTG,,7,, nBmTG,;3,, nBmTG;,3, or
nOvTG,3,.
Recombinant molecules of the present invention mayalso
(a) contain secretory signals (i.e., signal segment nucleic
acid sequences) to enable an expressed nematode trans-
glutaminase protein of the present invention to be secreted
from the cell that produces the protein and/or (b) contain
fusion sequencesthat lead to the expression of nucleic acid
molecules of the present invention as fusion proteins.
Examples of suitable signal segments include any signal
segment capable of directing the secretion of a protein of the
present invention. Preferred signal segments include, but are
not limited to, tissue plasminogen activator (t-PA),
interferon, interleukin, growth hormone, histocompatibility
and viral envelope glycoprotein signal segments, as well as
natural signal segments. Suitable fusion segments encoded
by fusion segment nucleic acids are disclosed herein, In
addition, a nucleic acid molecule of the present invention
can be joined to a fusion segmentthat directs the encoded
protein to the proteosome, such as a ubiquitin fusion seg-
ment. Recombinant molecules may also include intervening
and/or untranslated sequences surrounding and/or within the
nucleic acid sequences of nucleic acid molecules of the
present invention. An example of a preferred intervening
sequence for eukaryotic gene expression os cytomegalovirus
intron A.
Another embodiment of the present invention includes a
recombinantcell transformed with one or more recombinant
molecules of the present invention. Transformation of a
nucleic acid molecule into a cell can be accomplished by any
method by which a nucleic acid molecule can be inserted
into the cell. Transformation techniques include, but are not
limited to, transfection, electroporation, microinjection,
lipofection, adsorption, and protoplast fusion. A recombi-
nant cell may remain unicellular or may grow into atissue,
organ or a multicellular organism. A nucleic acid molecule
of the present invention that has been transformed into a cell
is referred to herein as a transformed nucleic acid molecule.
Transformed nucleic acid molecules of the present invention
can remain extrachromosomalor can integrate into one or
more sites within a chromosome of the transformed (i.e.,
recombinant) cell in such a mannerthat their ability to be
expressedis retained. Preferred nucleic acid molecules with
which to transform a cell include parasitic nematode trans-
glutaminase nucleic acid molecules disclosed herein. Par-
ticularly preferred nucleic acid molecules with which to














nDiTG, 497, nDITG,49,, nBmTG,,7, nBmTG;,, or
nOvTG,,,. Also preferred are nDiTG,.,,, nDiTG,,,,
nDiTG,,72, nDiTG,,3, nDiTG,;, nDiTG,,4,., nBMTG335
and nBmTG,,9.
Suitable cells to transform include any cell that can be
transformed with a nucleic acid molecule of the present
invention. A transformedcell of the present invention is also
herein referred to as a recombinantcell. Suitable cells can be
either untransformed cells or cells that are already trans-
formed with at least one nucleic acid molecule (e.g., nucleic
acid molecules encoding one or moreproteins of the present
invention, other proteins useful in the production of multi-
valent vaccines, or a combination thereof). Suitable cells for
transformation according to the present invention can be
either a) endogenously(i.e., naturally) capable of producing
parasitic nematode transglutaminase proteins of the present
invention, or b) capable of producing such proteins after
transformation with at least one nucleic acid molecule of the
present invention. Cells of the present invention can be any
cell capable of producing at least one protein of the present
invention, and include bacterial, fungal (including yeast),
insect, other nematode, other and plant cells. Preferred cells
for transformation by nucleic acid molecules of the present
invention include bacterial, mycobacterial, yeast, parasite,
insect and mammalian cells. More preferred cells include
Salmonella, Escherichia, Bacillus, Listeria, Saccharomyces,
Spodoptera, Mycobacteria, Trichoplusia, BHK (baby ham-
ster kidney) cells, MDCKcells (normal dog kidneycell line
for canine herpesvirus cultivation), CRFK cells (normal cat
kidney cell line for feline heipesvirus cultivation), CV-1
cells (African monkey kidney cell line used, for example, to
culture raccoon poxvirus), COS (e.g., COS-7) cells, and
Vero cells. Particularly preferred cells for transformation are
Escherichia coli, including E. coli K-12 derivatives; Salmo-
nella typhi; Salmonella typhimurium, including attenuated
strains such as UK-1 ,3987 and SR-11 4072;
Spodopterafrugiperda; Trichoplusia ni; BHK cells; MDCK
cells; CRFK cells; CV-1 cells; COS cells; Vero cells; and
non-tumorigenic mouse myoblast G8 cells (e.g., ATCC CRL
1246). Additional appropriate mammalian cells suitable for
transformation by nucleic acid molecules of the present
invention include other kidney cell lines,other fibroblastcell
lines (e.g., human, murine or chicken embryo fibroblastcell
lines), myeloma cell lines, Chinese hamster ovary cells,
mouse NIH3T3 cells, LMTIK*"cells and/or HeLacells. In
one embodiment, the proteins may be expressed as heter-
ologous proteins in myelomacell lines employing immu-
noglobulin promoters.
A recombinantcell is preferably produced by transform-
ing a suitable cell with one or more recombinant molecules,
each comprising one or more nucleic acid molecules of the
present invention operatively linked to an expression vector
containing one or more transcription control sequences. The
phrase operatively linked refers to insertion of a nucleic acid
molecule into an expression vector in a mannersuchthat the
molecule is able to be expressed when transformed into a
suitable cell as described above.
A recombinant molecule of the present invention is a
molecule that can include at least one of any parasitic
nematode transglutaminase nucleic acid molecule herein
described, operatively linked to at least one of any transcrip-
tion control sequence capable of effectively regulating
expression ofthe nucleic acid molecule(s) in the cell suitable
for transformation, examples of which are disclosed herein.
A recombinantcell of the present invention includes any
cell transformed with at least one of any nucleic acid
molecule of the present invention. Suitable and preferred
US 6,309,644 B1
21
nucleic acid molecules as well as suitable and preferred
recombinant molecules with which to transform cells are
disclosed herein.
Recombinantcells of the present invention can also be
co-transformed with one or more recombinant molecules
including parasitic nematode transglutaminase nucleic acid
molecules encoding one or more proteins of the present
invention and one or more other nucleic acid molecules
encoding other protective compounds, as disclosed herein
(e.g., to produce multivalent vaccines).
Recombinant DNAtechnologies can be used to improve
expression of transformed nucleic acid molecules by
manipulating, for example, the number of copies of the
nucleic acid molecules within a transformed cell, the effi-
ciency with which those nucleic acid molecules are
transcribed, the efficiency with which the resultant tran-
scripts are translated, and theefficiency of post-translational
modifications. Recombinant techniques useful for increas-
ing the expression of nucleic acid molecules of the present
invention include, but are not limited to, operatively linking
nucleic acid molecules of the present invention to nucleic
acid molecules that direct the production of a high-copy
number of plasmids, integration of the nucleic acid mol-
ecules into one or more chromosomesin the transformed
cell, addition of vector stability sequences to plasmids
containing nucleic acid sequences of the present invention,
substitutions or modifications of transcription control sig-
nals (e.g., promoters, operators, enhancers), substitutions or
modifications of translational control signals (e.g., ribosome
binding sites, Shine-Dalgarno sequences), modification of
nucleic acid molecules of the present invention to corre-
spond to the codon usageof the transformedcell, deletion of
sequences that destabilize transcripts, and use of control
signals that temporally separate recombinant cell growth
from recombinant enzyme production during fermentation.
The activity of an expressed recombinant protein of the
present invention may be improved by fragmenting,
modifying, or derivatizing nucleic acid molecules encoding
such a protein.
Isolated nematode transglutaminase proteins of the
present invention can be produced in a variety of ways,
including production and recovery of natural proteins, pro-
duction and recovery of recombinantproteins, and chemical
synthesis of the proteins. In one embodiment, an isolated
parasitic nematode transglutaminase protein of the present
invention is produced by culturing a cell capable of express-
ing the protein under conditions effective to produce the
protein, and recovering the protein. A preferred cell to
culture is a recombinant cell of the present invention.
Effective culture conditions include, but are not limited to,
effective media, bioreactor, temperature, pH and oxygen
conditions that permit protein production. An effective
medium refers to any medium in whicha cell is cultured to
producea parasitic nematode transglutaminase protein of the
present invention. Such medium typically comprises an
aqueous medium having assimilable carbon, nitrogen and
phosphate sources, and appropriate salts, minerals, metals
and other nutrients, such as vitamins. Cells of the present
invention can be cultured in conventional fermentation
bioreactors, shake flasks, test tubes, microtiter dishes, and
petri plates. Culturing can be cared out at a temperature, pH
and oxygen content appropriate for a recombinantcell. Such
culturing conditions are within the expertise of one of
ordinary skill in theart.
Depending on the vector and transformed cell system
used for production, resultant proteins of the present inven-














secreted into the fermentation medium; be secreted into a
space between two cellular membranes, such as the peri-
plasmic space in F. coli; or be retained on the outer surface
of a cell or viral membrane. The phrase “recovering the
protein”, as well as similar phrases, can refer to collecting
the whole fermentation medium containing the protein and
need not imply additional steps of separation or purification.
Proteins of the present invention can be purified using a
variety of standard protein purification techniques, such as,
but not limited to, affinity chromatography, immunoaffinity
chromatography, thermoprecipitation, ammonium gulphate
precipitaion, ion exchange chromatography, filtration,
electrophoresis, hydrophobic interaction chromatography,
gel filtration chromatography, reverse phase
chromatography, concanavalin A chromatography, chro-
matofocusing and differential solubilization. Proteins of the
present invention are preferably retrieved in “substantially
pure” form. As used herein, “substantially pure” refers to a
purity that allows for the effective use of the protein as a
therapeutic composition or diagnostic. A therapeutic com-
position for animals, for example, should exhibit no sub-
stantial toxicity and preferably should be capable of stimu-
lating the production of antibodies in a treated animal.
The present invention also includesisolated(i.e., removed
from their natural Milieu) antibodiesthat selectively bind to
a parasitic nematode transglutaminase protein of the present
invention or a mimetope thereof (e.g., anti-parasitic nema-
tode transglutaminase antibodies). As used herein, the term
“selectively binds to” a nematode transglutaminase protein
refers to the ability of antibodies of the present invention to
preferentially bind to specified proteins and mimetopes
thereof of the present invention. Binding can be measured
using a variety of methods standard in the art including
enzyme immunoassays (e.g., ELISA), immunoblot assays,
etc.; see, for example, Sambrook et al., ibid. An anti-
parasitic nematode transglutaminase antibody preferably
selectively binds to a parasitic nematode transglutaminase
protein in such a wayasto reducethe activity of that protein.
Isolated antibodies of the present invention can include
antibodies in serum,or antibodies that have been purified to
varying degrees. Antibodies of the present invention can be
polyclonal or monoclonal, or can be functional equivalents
such as antibody fragments and genetically-engineered
antibodies, including single chain antibodies or chimeric
antibodies that can bind to more than one epitope.
A preferred method to produce antibodies of the present
invention includes (a) administering to an animal an effec-
tive amount of a protein (ranging in size from a peptide to
a full length protein) or mimetope thereof of the present
invention to produce the antibodies and (b) recovering the
antibodies. In another method, antibodies of the present
invention are produced recombinantly using techniques as
disclosed to produce parasitic nematode transglutaminase
proteins of the present invention. Antibodies raised against
defined proteins or mimetopes can be advantageous because
such antibodies are not substantially contaminated with
antibodies against other substances that might otherwise
cause interference in a diagnostic assay or side effects if used
in a therapeutic composition.
Antibodies of the present invention have a variety of
potential uses that are within the scope of the present
invention. For example, such antibodies can be used (a) as
therapeutic compoundsto passively immunize an animal in
order to protect the animal from parasitic nematodes sus-
ceptible to treatment by such antibodies, (b) as reagents in
assays to detect infection by such nematodes, (c) as tools to
screen expression libraries, (d) as tools to recover desired
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proteins of the present invention from a mixture of proteins
and other contaminants, and (e) for any combination of the
above listed uses. Furthermore, antibodies of the present
invention can be used to target cytotoxic agents to parasitic
nematodes of the present invention in order to directly kill
such nematodes. Targeting can be accomplished by conju-
gating (ie., stably joining) such antibodies to the cytotoxic
agents using techniques known to those skilled in theart.
Suitable cytotoxic agents are knownto those skilled in the
art.
One embodimentof the present invention is a therapeutic
composition that, when administered to an animal in an
effective manner, is capable of protecting that animal from
disease caused by a parasitic nematode. Therapeutic com-
positions of the present invention include an excipient and at
least one of the following protective compounds,an isolated
native nematode transglutaminase protein; an isolated non-
native nematode transglutaminase protein; a mimetope of a
nematode transglutaminase protein; an isolated nucleic acid
molecule that hybridizes under stringent hybridization con-
ditions with a nematode transglutaminase gene; an isolated
antibody that selectively binds to a nematode transglutami-
nase protein, an inhibitor of nematode transglutaminase
protein activity identified by its ability to inhibit nematode
transglutaminase activity and its inability to substantially
interfere with host animal transglutaminase activity, or a
mixture thereof (i.e., combination of at least two of the
compounds). The term “inability to substantially interfere
with” host animal transglutaminase activity, as used herein,
refers to the failure of a nematode transglutaminase inhibitor
compoundto inhibit host animal transglutaminaseactivity to
such a degree that such an inhibitor is not substantially toxic
to a host animal whenit is administered to that animal. The
inability to interfere with host animal transglutaminase
activity can be identified by transglutaminaseassay in vitro,
as described in the Examples section. Candidate inhibitors
can also be tested for toxicity in standard animal studies.
Preferred parasitic nematodesto target are herein disclosed.
Examples of proteins, nucleic acid molecules, antibodies
and inhibitors of the present invention are disclosed herein.
The present invention also includes a therapeutic compo-
sition comprising at least one nemtatode transglutaminase-
based compound of the present invention in combination
with at least one additional compoundprotective against one
or more infectious agents. Examples of such compounds and
infectious agents are disclosed herein.
Therapeutic compositions of the present invention can be
administered to any animal susceptible to such therapy,
preferably to mammals and birds, and more preferably to
dogs, cats, humans, ferrets, horses, cattle, sheep, goats and
pigs as well as other pets, food animals, work animals or zoo
animals. Preferred animals to protect against parasitic nema-
tode disease include dogs, cats, humans and ferrets, with
dogs, cats and humansbeingparticularly preferred.
Suitable inhibitors of nematode transglutaminase activity
include compoundsthat interact directly with a nematode
transglutaminaseprotein activesite, thereby inhibiting trans-
glutaminase activity, usually by binding to or otherwise
interacting with or otherwise modifying the nematodetrans-
glutaminase active site. Nematode transglutaminase inhibi-
tors can also interact with other regions of the nematode
transglutaminaseprotein to inhibit transglutaminaseactivity,
for example, byallosteric interaction. Inhibitors of nematode
transglutaminase can berelatively small compounds,or they
can be quite large, as in the case of anti-parasitic nematode
transglutaminase antibodies. Preferably, a nematode trans-














by its ability to inhibit the activity of a nematode
transglutaminase, and further by its failure to substantially
inhibit the activity of host animal transglutaminase. Methods
for measuring inhibition of transglutaminaseactivity, useful
for determining inhibition of either nematode or host animal
transglutaminase activity, are described in the Examples
section.
Inhibitors of a nematode transglutaminase can be used
directly as compounds in compositions of the present inven-
tion to treat host animals, provided that such compounds do
not substantially inhibit the activity of the host animal
transglutaminase.
Inhibitors of a nematode transglutaminase protein can
also be used to identify preferred types of nematode trans-
glutaminase proteins to target using compositions of the
present invention, for example by affinity chromatography.
For example, an inhibitor of the present invention could be
bound to a gel or afilter, or another substrate, and larval or
adult nematode extracts could be contacted with the bound
inhibitor. Those compounds in either larval or adult nema-
tode extracts that bound to or otherwise interacted with the
inhibitor could then be separated from the bound inhibitor
and further analyzed for nematode transglutaminaseactivity.
Preferred inhibitors of a nematode transglutaminaseofthe
present invention include, but are not limited to, nematode
transglutaminase substrate analogs and other molecules that
bind to a nematode transglutaminase (e.g., to an allosteric
site) in such a manner that nematode transglutaminase
activity of the nematode transglutaminase is inhibited. A
nematode transglutaminase substrate analog refers to a com-
pound that interacts with (e.g., binds to, associates with,
modifies) the active site of a nematode transglutaminase
protein. A preferred nematode transglutaminase substrate
analog inhibits nematode transglutaminase activity. Nema-
tode transglutaminase substrate analogs can be any inor-
ganic or organic composition, and can be, butare not limited
to, peptides, nucleic acids, and peptidomimetic compounds.
Nematode transglutaminase substrate analogs can be, but
need not be,structurally similar to a nematode transglutami-
nase protein’s natural substrate provided they can interact
with the active site of that nematode transglutaminase pro-
tein. Nematode transglutaminase substrate analogs can be
designed using computer-generated structures of nematode
transglutaminase proteins of the present invention or com-
puter structures of nematode transglutaminase proteins’
natural substrates. Substrate analogs Can also be obtained by
generating random samples of molecules (for example,
oligonucleotides, peptides, peptidomimetic compounds, or
other inorganic or organic molecules), and screening such
samples by affinity chromatography techniques using the
corresponding binding partner, (e.g., a nematode trans-
glutaminase or anti-nematode transglutaminase substrate
antibody). A preferred nematode transglutaminase substrate
analog is a peptidomimetic compound(i.e., a compoundthat
is structurally or functionally similar to a natural substrate of
a nematode transglutaminase of the present invention, par-
ticularly to the region of the substrate that interacts with the
nematode transglutaminase active site, but that inhibits
nematode transglutaminase activity upon interacting with
the nematode transglutaminase active site).
Parasitic nematode transglutaminase peptides, mimetopes
and substrate analogs, as well as other protective compounds
(nucleic acid molecules, proteins, antibodies, for example),
can be used directly as compounds in compositions of the
present invention to treat animals as long as such com-
pounds are not harmful to the animals being treated. Meth-




In accordance with the present invention, a host animal
(i.e., an animal that is infected with or is capable of being
infected by a parasitic nematode) is treated by administering
to the animal a therapeutic composition of the present
invention in such a mannerthat the composition itself ((e.g.,
an inhibitor of a nematode transglutaminase protein,
mimetope, a nematode transglutaminase synthesis suppres-
sor (i.e., a compound that decreases the production of
nematode transglutaminase in the nematode), a nematode
transglutaminase mimetope or an anti-parasitic nematode
transglutaminase antibody)) or a product generated by the
animal in response to administration of the composition
(e.g., antibodies produced in response to a parasitic nema-
tode transglutaminase protein or nucleic acid molecule
vaccine, or conversion of an inactive inhibitor “prodrug” to
an active inhibitor of a nematode transglutaminase protein)
contacts the nematode, thereby reducing transglutaminase
activity in the nematode. A host animalis preferably treated
in such a way that the compound or product thereof enters
the bodily fluids (e.g., blood and lymph systems) and/or
tissues of the animal. Parasitic nematodes are then exposed
to the composition or product when they are present in the
host animal. For example, nematode transglutaminase pro-
tein inhibitors administered to an animal are, administered in
such a waythat the inhibitors enter the blood andtissues of
the animal where parasitic nematodes will come in contact
with the inhibitors. In another embodiment, when a parasitic
nematode transglutaminase protein, mimetopes or nucleic
acid molecule vaccine is administered to a host animal, the
treated animal mounts an immune responseresulting in the
production of antibodies against the parasitic nematode
transglutaminase protein (i.e., anti-parasitic nematodetrans-
glutaminase antibodies) that circulate in the animal’s blood
stream and/or other bodily fluids thereby coming into con-
tact with parasitic nematodes.
In order to protect an animal from disease caused by a
parasitic nematode of the present invention, a therapeutic
composition of the present invention is administered to the
animal in an effective manner such that the composition is
capable of protecting that animal from a disease caused by
a parasitic nematode. Therapeutic compositions of the
present invention can be administered to animals prior to
infection in order to prevent infection (i.e., as a preventative
vaccine), or can be administered to animals after infection in
order to treat disease caused by the parasitic nematode(i.e.,
as a therapeutic vaccine), or both techniques may be used.
Therapeutic compositions of the present invention pref-
erably are formulated in an excipient that the animal to be
treated can tolerate. Examples of such excipients include
water, saline, Ringer’s solution, dextrose solution, Hank’s
solution, and other aqueous physiologically balanced salt
solutions. Nonaqueous vehicles, such as fixed oils, sesame
oil, ethyl oleate, or triglycerides may also be used. Other
useful formulations include suspensions containing viscos-
ity enhancing agents, such as sodium
carboxymethylcellulose, sorbitol, or dextran. Excipients can
also contain minor amounts of additives, such as substances
that enhanceisotonicity and chemicalstability. Examples of
buffers include phosphate buffer, bicarbonate buffer and Tris
buffer, while examples of preservatives include, m-or
o-cresol, formalin and benzyl alcohol. Standard formula-
tions can either be liquid injectables or solids that can be
taken up in a suitable liquid as a suspension or solution for
injection. Thus, in a non-liquid formulation, the excipient
can comprise dextrose, human serum albumin,
preservatives, etc., to which sterile water or saline can be














In one embodimentof the present invention, a therapeutic
composition can include an adjuvant. Adjuvants are agents
that are capable of enhancing the immuneresponse of an
animalto a specific antigen. Suitable adjuvants include, but
are not limited to, cytokines, chemokines, and compounds
that induce the production of cytokines and chemokines
(e.g., granulocyte macrophage colony stimulating factor
(GM-CSF), granulocyte colony stimulating factor (G-CSF),
macrophage colony stimulating factor (M-CSF), colony
stimulating factor (CSF), erythropoietin (EPO), interleukin
2 (IL-2), interleukin-3 (IL-3), interleukin 4 (IL-4), interleu-
kin 5 (IL-5), interleukin 6 (IL-6), interleukin 7 (IL-7),
interleukin 8 (IL-8), interleukin 10 (IL-10), interleukin 12
(IL-12), interferon gamma,interferon gammainducing fac-
tor I (IGIF), transforming growth factor beta, RANTES
(regulated upon activation, normal T-cell expressed and
presumably secreted), macrophage inflammatory proteins
(e.g., MIP-1 alpha and MIP-1 beta), and leishmania elon-
gation initiating factor (LEIF)); bacterial components(e.g.,
endotoxing, in particular superantigens, exotoxins and cell
wall components); aluminum-based salts; calcium-based
salts; silica; polynucleotides; toxoids; serum proteins, viral
coat proteins; block copolymer adjuvants (e.g., Hunter’s
Titermax™ adjuvant (Vaxcel™, Inc. Norcross, Ga.), Ribi
adjuvants (Ribi ImmunoChem Research, Inc., Hamilton,
Mont.): and saponins and their derivatives (e.g., Quil A
(Superfos Biosector A/S, Denmark). Protein adjuvants of the
present invention can be delivered in the form of the protein
themselves or of nucleic acid molecules encoding such
proteins using the methods described herein. In addition to
the foregoing adjuvants, when an isolated nucleic acid
molecule of the present invention is used as a protective
compoundin the therapeutic composition, one or more DNA
adjuvants can be operatively linked to that nucleic acid
molecule using molecular biology techniques known to
those skilled in theart.
In one embodimentof the present invention, a therapeutic
composition can include a carrier. Carriers include com-
pounds that increase the half-life of a therapeufic composi-
tion in the treated animal. Suitable carriers include, but are
not limited to, polymeric controlled release vehicles, biode-
gradable implants, liposomes,bacteria, viruses, othercells,
oils, esters, and glycols.
One embodiment of the present invention is a controlled
release formulation that is capable of slowly releasing a
composition of the present invention into an animal. As used
herein, a controlled release formulation comprises a com-
position of the present invention in a controlled release
vehicle. Suitable Controlled release vehicles include, but are
not limited to, biocompatible polymers, other polymeric
matrices, capsules, microcapsules, microparticles, gels
(including hydrogels), bolus preparations, osmotic pumps,
diffusion devices, liposomes, lipospheres, and transdermal
delivery systems. Other controlled release formulations of
the present invention include liquids that, upon administra-
tion to an animal, form a solid or a gel in situ. Preferred
controlled release formulations are biodegradable (i.e.,
bioerodible).
A preferred controlled release formulation of the present
invention is capable of releasing a composition of the
present invention into the blood of the treated animal at a
constant rate sufficient to attain dose levels of the compo-
sition effective to protect an animal from disease caused by
parasitic nematodes. The therapeutic composition is prefer-
ably released over a period of time ranging from about 1 to
about 12 months. A controlled release formulation of the
present invention is capable of effecting a treatment prefer-
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ably for at least about 1 month, more preferably for at least
about 3 months, even more preferably for at least about 6
months, even more preferably for at least about 9 months,
and even morepreferably for at least about 12 months.
Acceptable protocols to administer therapeutic composi-
tions in an effective manner include the specification of
individual dose size, number of doses, frequency of dose
administration, and mode of administration, Determination
of such protocols can be accomplished by those skilled in the
art. A suitable single dose is a dose that is capable of
protecting an animal from disease when administered one or
more times over a suitable time period. For example, a
preferred single dose of a protein, mimetope or antibody
therapeutic composition is from about 1 microgram (4g) to
about 10 milligrams (mg) of the therapeutic composition per
kilogram body weight of the animal. Booster vaccinations
can be administered from about 2 weeks to several years
after the original administration. Booster administrations
preferably are administered when the immune response of
the animal becomesinsufficient to protect the animal from
disease. A preferred administration schedule is one in which
from about 10 xg to about 1 mg of the therapeutic compo-
sition per kg body weight of the animal is administered from
about one to about two times over a time period of from
about 2 weeks to about 12 months. Modes of administration
can include, but are not limited to, subcutaneous,
intradermal, intravenous,intranasal, oral, intraocular, trans-
dermal and intramuscular routes.
According to one embodiment, a nucleic acid molecule of
the present invention can be administered to a host animal in
a fashion enabling expression of that nucleic acid molecule
into a protective protein or protective RNA (e.g., antisense
RNA,ribozyme,triple helix forms or RNA drug)in the host
animal. Nucleic acid molecules can be delivered to an
animalusing a variety of methods including, but not limited
to, (a) administering a naked (i.e., not packaged in a viral
coat or cellular membrane) nucleic acid vaccine (e.g., as
naked DNA or RNA molecules, such as is taught, for
example in Wolff et al., 1990, Science 247, 1465-1468) or
(b) administering a nucleic acid molecule packaged as a
recombinant virus vaccine or as a recombinantcell vaccine
(i.e., the nucleic acid molecule is delivered by a viral or
cellular vehicle)).
A naked nucleic acid vaccine of the present invention
includes a nucleic acid molecule of the present invention and
preferably includes a recombinant molecule of the present
invention that preferably is replication, or otherwise
amplification, competent. A naked nucleic acid vaccine of
the present invention can comprise one or more nucleic acid
molecules of the present invention in the form of, for
example, a bicistronic recombinant molecule, having, for
example, one or more internal entry sites. Preferred naked
nucleic acid vaccines include at least a portion of a viral
genome(i.e., a viral vector). Preferred viral vectors include
those based on alphaviruses, poxviruses, adenoviruses,
herpesviruses, and retroviruses, with those based on alphavi-
ruses (such as Sindbis or Semliki virus), species-specific
herpesviruses and species-specific poxviruses being particu-
larly preferred. Any suitable transcription control sequence
can be used, including those disclosed as suitable for protein
production. Particularly preferred transcription control
sequence include cytomegalovirus intermediate early
(preferably in conjunction with intron-A), Rous Sarcoma
Virus long terminal repeat, and tissue-specific transcription
control sequences,as well as transcription control sequences
endogenous to viral vectors if viral vectors are used. The















Naked nucleic acid vaccines of the present invention can
be administered in a variety of ways, with intramuscular,
subcutaneous, intradermal, transdermal, intranasal,
intraocular and oral routes of administration being preferred.
A preferred single dose of a naked nucleic acid vaccines
ranges from about 1 nanogram (ng) to about 100 yg,
depending on the route of administration and method of
delivery, as can be determined by those skilled in the art.
Suitable delivery methods include, for example, by
injection, as drops, by aerosolization and by topical appli-
cation. Naked DNA of the present invention can be con-
tained in an aqueous excipient (e.g., phosphate buffered
saline) alone or in a carrier (e.g., lipid-based vehicles).
A recombinant virus vaccine of the present invention
includes a recombinant molecule of the present invention
that is packaged in a viral coat and that can be expressed in
an animal after administration. Preferably, the recombinant
molecule is packaging-deficient, encodes an attenuated
virus, or both. A number of recombinantviruses can be used
including, but not limited to, those based on alphaviruses,
poxviruses, adenoviruses, herpesviruses, and retroviruses.
Preferred recombinant virus vaccines are those based on
alphaviruses (such as Sindbis virus), raccoon poxviruses,
species-specific herpesviruses and species-specific poxvi-
ruses. An example of methodsto produce and use alphavirus
recombinant virus vaccinesis disclosed in PCT Publication
No. WO 94/17813, by Xiong etal., published Aug. 18, 1994,
whichis incorporated by reference herein in its entirety. An
example of methods to produce and use racoon poxvirus
recombinant virus vaccines is disclosed in U.S. Pat. No.
5,266,314, to Esposito, et al., issued November 30, 1993,
which is incorporated by reference herein in its entirety.
When administered to an animal, a recombinant virus
vaccine of the present invention infects cells within the
immunized animal and directs the production of a protective
protein or RNA nucleic acid molecule that is capable of
protecting the animal from disease caused by a parasitic
nematode as disclosed herein. For example, a recombinant
virus vaccine comprising a parasitic nematode transglutami-
nase nucleic acid molecule of the present invention is
administered according to a protocol that results in the
animal producing a sufficient immune response to protect
itself from disease caused by a parasitic nematode. A pre-
ferred single dose of a recombinant virus vaccine of the
present invention is from about 1x10* to about 1x10’ virus
plaque forming units (pfu) per kilogram body weightof the
animal. Administration protocols are similar to those
described herein for protein-based vaccines, with
subcutaneous, intramuscular, intranasal and oral administra-
tion routes being preferred.
A recombinant cell vaccine of the present invention
includes recombinant cells of the present invention that
express at least one protein of the present invention. Pre-
ferred recombinant cells for this embodiment include
Salmonellia, F. coli, Ligteria, Mycobactenum,S. frugiperda,
yeast, (including Saccharomyces cerevisiae), BHK, CV-1,
myoblast G8, COS (e.g., COS-7), Vero, MDCK and CRFK
recombinantcells. Recombinantcell vaccines of the present
invention can be administered in a variety of ways but have
the advantage that they can be administered orally, prefer-
ably at doses ranging from about 10® to about 10** cells per
kilogram body weight. Administration protocols are similar
to those described herein for protein-based vaccines.
Recombinantcell vaccines can comprise wholecells, cells
stripped of cell walls or cell lysates.
The efficacy of a therapeutic composition of the present
invention to protect an animal from disease caused by a
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parasitic nematode can be tested in a variety of ways
including, but not limited to, detection of protective anti-
bodies (using, for example, proteins or mimetopes of the
present invention), detection of cellular immunity within the
treated animal, or challenge of the treated animal with the
parasitic nematode to determine whether the treated animal
is resistant to disease. Challenge studies can include implan-
tation of chambers including parasitic nematodelarvae into
the treated animal, or direct administration of larvae to the
treated animal, or both. In one embodiment, therapeutic
compositions can be tested in animal models such as mice.
Such techniques are knownto those skilled in theart.
One preferred embodimentof the present inventionis the
use of parasitic nematode transglutaminaseproteins, nucleic
acid molecules, antibodies and inhibitory compoundsof the
present invention, to protect an animal from heartworm.It is
particularly preferred to prevent L3 that are delivered to the
animal by the mosquito intermediate host from maturing
into adult worms. Preferred therapeutic compositions are
those that are able to inhibit at least one step in the portion
of the parasite’s development cycle that includes L3, third
molt, L4, fourth molt, immature adult prior to entering the
host animal’s tissues or circulatory system. In dogs, this
portion of the development cycle is about 70 days. Particu-
larly preferred therapeutic compositions include nematode
transglutaminase-based therapeutic compositions of the
present invention, particularly because D. immitis trans-
glutaminase is necessary for D. immitis larval molting and
development, as disclosed herein. These preferred therapeu-
tic compositions include nematode transglutaminase nucleic
acid molecules, nematode tranglutaminase proteins and
mimetopes thereof, anti-nematode transglutaminase
antibodies, and inhibitors of nematode transglutaminase
activity that fail to substantially inhibit host animal trans-
glutaminase activity. Particularly preferred are D. immitis
forms of any of the therapeutic compositions of the present
invention. Therapeutic compositions are administered to
animals in a mannereffective to protect the animals heart-
worm. Additional protection may be obtained by adminis-
tering additional protective compounds, including other
nematode proteins, nucleic acid molecules, antibodies and
inhibitory compounds,as disclosed herein and elsewhere.
One therapeutic composition of the present invention
includes an inhibitor of nematode transglutaminase activity
that does not substantially inhibit host animal transglutami-
nase activity. In other words, in one embodiment, a thera-
peutic composition of the present invention includes a
compound capable of substantially interfering with the func-
tion of a nematode transglutaminase susceptible to inhibition
by an inhibitor of nematode transglutaminase activity. The
term, “substantially interfering with the function of nema-
tode transglutaminase,” as used herein, refers to the ability
of an inhibitor compound to interfere with a nematode
transglutaminase activity to such a degree that development
of heartworm in a host animal is impaired. For example, an
isolated protein or mimetope thereof, is administered in an
amount and mannerthat elicits (i.e., stimulates) an immune
response that is sufficient to protect the animal from the
disease. Similarly, an antibody of the present invention,
when administered to an animal in an effective manner, is
administered in an amount so as to be present in the animal
at a titer that is sufficient to protect the animal from the
disease, at least temporarily. Oligonucleotide nucleic acid
molecules of the present invention can also be adminstered
in an effective manner, thereby reducing expression of
parasitic nematode transglutaminase proteins in order to
interfere with development of parasitic nematodes targeted














An inhibitor of nematode transglutaminaseactivity can be
identified using parasitic nematode transglutaminase pro-
teins of the present invention. One embodiment of the
present invention is a method to identify a compoundthat is
capable of inhibiting nematode transglutaminase activity,
but that does not substantially inhibit host animal trans-
glutaminase activity. Such a method includes thesteps of (a)
contacting (e.g., combining, mixing) an isolated nematode
transglutaminase protein with a putative inhibitory com-
pound under conditions in which, in the absence of the
compound,the protein has nematode transglutaminaseactiv-
ity; (b) determining if the putative inhibitory compound
inhibits the nematode transglutaminase activity; and (c)
repeating steps (a) and (b), but substituting host animal
transglutaminase for nematode transglutaminase. Putative
inhibitory compoundsto screen for include small organic
molecules, antibodies (including fragments and mimetopes
thereof) and substrate analogs. Methods to determine nema-
tode and host animal transglutaminase activities are known
to those skilled in the art; see, for example, citations in the
background section and references included therein.
The present invention also includesa test kit to identify a
compound capable of inhibiting nematode transglutaminase
activity of a parasitic nematode. Such a test kit includes an
isolated nematode transglutaminase protein having trans-
glutaminase activity and a means for determining the extent
of inhibition of transglutaminase activity in the presence of
(i.e., effected by) a putative inhibitory compound. Com-
pounds determined to inhibit nematode transglutaminase
activity are also screened to identify those that are not
substantially toxic to host animals.
Nematode transglutaminase inhibitors isolated by the
method or by the test kit described, or by both, can be used
to inhibit any nematode transglutaminasethat is susceptible
to such an inhibitor. Preferred parasitic nematode trans-
glutaminase proteins to inhibit are those produced by D.
immitis, B. malayi or O. volvulus. A particularly preferred
transglutaminase inhibitor of the present invention is
capable of protecting an animal from heartworm. Effective
amounts and dosing regimens can be determined using
techniques known to those skilled in theart.
Another therapeutic composition of the present invention
includes an inhibitor of nematode PDIactivity that does not
substantially inhibit host animal PDI activity. In other
words, in one embodiment, a therapeutic composition of the
present invention includes a compound capable of substan-
tially interfering with the function of nematode trans-
glutaminase PDI activity susceptible to inhibition by an
inhibitor of nematode PDI activity. The term, “substantially
interfering with the function of nematode transglutaminase
PDI activity,” as used herein, refers to the ability of an
inhibitor compoundto interfere with a nematode PDI activ-
ity to such a degree that development of heartworm in a host
animal is impaired.
An inhibitor of nematode PDI activity can be identified
using parasitic nematode transglutaminase proteins of the
present invention. One embodimentof the present invention
is a method to identify a compound that is capable of
inhibiting nematode PDIactivity, but that does not substan-
tially inhibit host animal PDI activity. Such a method
includes the steps of (a) contacting (e.g., combining, mixing)
an isolated nematode transglutaminase protein (having PDI
activity) with a putative inhibitory compound under condi-
tions in which, in the absence of the compound,the protein
has nematode PDI activity; (b) determining if the putative
inhibitory compound inhibits the nematode PDI activity;
and (c) repeating steps (a) and (b), but substituting a host
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animal PDI for nematode PDI. Putative inhibitory com-
pound to screen for include small organic molecules, anti-
bodies (including fragments and mimetopes thereof) and
substrate analogs. Methods to determine nematode and host
animal PDI activities are knownto those skilled in the art;
see, for example, citations in the background section and
references included therein.
The present invention also includesa testkit to identify a
compound capable of inhibiting PDI activity of a parasitic
nematode. Such a test kit includes an isolated nematode
transglutaminase protein having PDI activity and a means
for determining the extent of inhibition of PDI activity in the
presence of (ie., effected by) a putative inhibitory com-
pound. Compounds determined to inhibit nematode PDI
activity are also screened to identify those that are not
substantially toxic to host animals.
Nematode PDIinhibitors isolated by the method or by the
test kit described, or by both, can be used to inhibit any
nematode PDI that is susceptible to such an inhibitor.
Preferred parasitic transglutaminase proteins to inhibit are
those produced by D. immitis, B. malayi or O. volvulus. A
particularly preferred PDI inhibitor of the present invention
is capable of protecting an animal from heartworm.Effective
amounts and dosing regimens can be determined using
techniques knownto those skilled in the art.
It is also within the scope of the present invention to use
isolated proteins, mimetopes, nucleic acid molecules and
antibodies of the present invention as diagnostic reagents to
detect infection by parasitic nematodes. Such diagnostic
reagents can be supplemented with additional compounds
that can detect other phases of the parasite’s life cycle.
Methods to use such diagnostic reagents to diagnose para-
sitic nematode infection are well known to those skilled in
the at. Suitable and preferred parasitic nematodes to detect
are those to which therapeutic compositions of the present
invention are targeted. A particularly preferred parasitic
nematode to detect using diagnostic reagents of the present
invention is D. immitis.
The following examples are provided for the purposes of
illustration and are not intended to limit the scope of the
present invention.
EXAMPLES
It is to be noted that these Examples include a numberof
molecular biology, microbiology, immunology and bio-
chemistry techniques familiar to those skilled in the art.
Disclosure of such techniques can be found, for example, in
Sambrooketal., ibid., Ausubel, et al.,1993, Current Proto-
cols in Molecular Biology, Greene/Wiley Interscience, New
York, N.Y., and related references. Ausubel, et al, ibid. is
incorporated by reference herein in its entirety. DNA and
protein sequence analyses were carried out using the
PC/GENE™ sequence analysis program (available from
Intelligenetics, Inc., Mountainview, Calif.) and the Wiscon-
sin Package™ Version 9.0 (available from the Genetics
Computer Group (GCG), Madison, Wis.). It should also be
noted that because nucleic acid sequencing technology, and
in particular the sequencing of PCR products,is not entirely
error-free, that the nucleic acid and deduced protein
sequences presented herein represent apparent nucleic acid
sequences of the nucleic acid molecules encoding D.
immitis, B. malayi, and O. volvulus transglutaminase pro-
teins of the present invention.
Example 1
This example describes a novel N-terminal amino acid
sequence of a transglutaminase protein purified from Brugia












encoded by that sequence to purify and partially characterize
a rare and novel transglutaminase protein from D. immitis.
Purification and partial characterization of a novel trans-
glutaminase protein from B. malayi has been previously
described See, Singh, et al., 1994, Eur J. Biochem., 225,
625-634 (incorporated herein by reference). The amino acid
sequence of this protein, referred to as SEQ ID NO:1, is
herein disclosed for the first time as follows:
(D)(G)DVMKFTDADFKE(G)IK(X)(Y)(D)
The amino acids in brackets are the most probable amino
acids at those positions, and the amino acid (X) at position
18 could not be detected.
A protein molecule corresponding to the N-terminal
sequence of the previously described 56-kD transglutami-
nase of B. malayi was synthesized commercially and is
herein denoted as PBmTG,,. The amino acid sequence of
this protein represents amino acids from about position 3
(amino acid residue A, or aspartic acid) through about
position 17 (amino acid residue K, or lysine). A cysteine
residue was added to the N-terminusof the synthetic peptide
(immediately before the aspartic acid residue at about posi-
tion 3) for the convenienceofits conjugation with the carrier
protein keyhold limpet hemocyanin (KLH) via
maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), as
follows. 5.0 mg of KLH in 50 mM phosphate buffer, pH 8.0,
was reacted with MBS (dissolved in dimethyl sulfoxide) at
a molarratio of 1 KLH:40 MBS.Thesolution wasstirred for
30 min at room temperature. The unreacted MBS was
removed bygelfiltration, and 5.0 mg of peptide hapten was
added to the MBS-activated KLH in 50 mM phosphate
buffer, pH 7.5. The solution wasstirred at room temperature
for 3 hr. Unconjugated peptide was removed bygelfiltra-
tion. The conjugation efficiency was 40%.
Anti-B. malayi transglutaminase peptide PBmTG,, anti-
serum was produced as follows. A rabbit was immunized
subcutaneously, first with approximately 150 ug of the
conjugated peptide mixed with Complete Freund’s
Adjuvant, and then with five subsequent immunizations of
the same dose mixed in Incomplete Freund’s Adjuvant.
Bleeding and immunization were performed at alternate
weeks Unusedantisera were preserved in 0.1% sodium azide
at 4° C. For immobilizing the anti-peptide antibodies on
Affigel-10 (available from Bio-Rad Laboratories, Hercules,
Calif.), the immunoglobulin G (IgG) fraction from this
antisera was collected by 40% ammonium sulfate precipi-
tation. Ammonium ions were removed on a NAP-25 column
(Sephadex G-25 available from Pharmacia Biotechnology,
Piscataway, NJ.) preequilibrated with 100 mM (3-[N-
morpholinoJpropanesulfonic acid) (MOPS) buffer, pH 7.5
(buffer A) to obtain a desalted IgG fraction.
A crude D. immitis extract preparation was prepared as
follows. All operations were performed at 4° C. unless
otherwise mentioned. Thirty-two frozen adult female worms
ofD. immitis (available from TRAlaboratories, Athens, Ga.)
were homogenized twice in a Pyrex homogenizer in 20 mM
Tris-HCI (pH 8.5) containing 0.1% Triton X-100, 2 mM
1,4-dithiothreitol, 1 mM EDTA, 1 mM phenylmethylsulfo-
nyl fluoride (PMSF), and 0.1 mM N-tosyl-L-lysine
chloromethane, The resulting 40 ml of homogenate was
sonicated as described in Singhetal., ibid. The extract was
frozen and thawed between sonications to maximize the
solubilization of membrane-bound enzyme. The extract was
centrifuged at 15,000 g for 20 min, and the supernatant (36
ml) was collected for further purification.
Anti-B. malayi peptide PmTG,5, antiserum produced as
described above, was found to react with a 56-kD protein
band in a western blot of a D. immitis extract. This reactivity
of anti-PBmTG,, antiserum could be completely inhibited
in the presence of excess synthetic peptide. In order to
monitor the progress of the purification process, Western
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blots were performed on samples of the extract after each
major step in the purification process as follows: Sodium
dodecyl sulfate (SDS)-polyacrylamide (10%) gel electro-
phoresis was performed according to the method of Laem-
mli (1970). Western blotting was performed by transferring
the protein bands to the nitrocellulose paper (0.47 uM,
available from Schleicher & Schuell, Keene, N.H.) using a
Semiphor dry blot apparatus (available from Hoefer Scien-
tific Instruments, San Francisco, Calif.). All solutions used
for membrane processing were made in phosphate buffered
saline (PBS), and incubations were done at room tempera-
ture unless otherwise noted. The membrane was blocked
with 5% nonfat dry milk for 1 hr. and incubated for 1 hr with
1000-fold diluted anti-PBmTG,, antiserum in 5% nonfat dry
milk. After two washes with 100 ml of PBST (PBS con-
taining 0.1% Tween 20) for 20 min each, the membrane was
incubated for 1 hr with 5000-fold diluted alkaline
phosphatase-linked anti-rabbit IgG (available from Kirkeg-
aard and Perry Laboratories, Gaithersburg, Md.) in 5%
nonfat dry milk. After two washes in 100 ml of PBSTfor 20
min each, the membrane wastreated with alkaline phos-
phatase color developmentreagent (available from Bio-Rad
Laboratories, Hercules, Calif.) as per manufacturer’s
instructions.
Following crude extract preparation, the first step in D.
immitis transglutaminase protein purification was thermo-
precipitation and ammonium sulfate precipitation as fol-
lows. The crude extract from adult female worms was
subjected to thermo-precipitation at 55° C. in a water bath
for 10 min with constant shaking. The precipitate was
discarded by centrifugation at 15,000 g for 20 min, and the
supernatant (31 ml) wasprecipitated at a 60% ammonium
sulfate cutoff. The precipitate was collected by centrifuga-
tion (15,000 g for 30 min) and wasdissolved in 2.5 ml of
buffer A. The ammonium ions in the preparation were
removed by passing the preparation through an NAP-25
column preequilibrated with buffer A. The final volume of
the D. immitis preparation obtained from the NAP-25 col-
umn was 3.5 ml.
The next step in D. immitis transglutaminase protein
purification, immunoaffinity chromatography, was accom-
plished as follows. The immunoglobulin fraction was con-
jugated to Affigel-10 according to the manufacturer’s
instructions. Specifically, 3.5 ml of the desalted IgG fraction
containing anti-B. malayi transglutaminase PBmTG,,
(containing 17.5 mgof protein), obtained as described above
in this Example, was added to 1 ml of Affigel-10 that was
previously washed with cold deionized water. The suspen-
sion was incubated and rotated overnight at 4° C. Next day,
the unbound IgG was removed by repeated washing with
buffer A.
The 3.5 ml D. immitis preparation obtained after ammo-
nium sulfate precipitation and desalting was incubated and
rotated with the IgG-bound Affigel-10 overnight at 4° C. The
slurry was then packed in a column,and the gel was washed
extensively with buffer A. Nonspecifically bound proteins
were removed by washing the gel with 0.5% Triton X-100
in buffer A to remove the nonspecific hydrophobic interac-
tions. This step was necessary before the specific elution of
transglutaminase at pH 2.8. The gel was washed again with
buffer A. D. immitis transglutaminase was eluted with 3 ml
of 100 mM glycine-HCl buffer (pH 2.8) with a flow rate of
10 ml/hr. The pH of the D. immitis transglutaminase-
containing collected fraction was immediately adjusted to
pH 8.0 by adding 300 wl of 1 M sodium bicarbonate; the
collected fraction was then subjected to overnight dialysis
against 100 mM Tris-HCI buffer (pH 8.5). The dialyzed
fraction was concentrated to 0.5 ml in a Centricon-10 tube
(available from Pharmacia Biotechnology Piscataway, N.J.),
and used for further characterization.
The eluted protein was enzymatically active and gave a













under denaturing conditions. The same 56 kD band was
detected by western blot analysis (described below) when
the anti-B. malayi transglutaminase peptide PBmTG,, anti-
body was used to detect protein.
A summary of the steps used in the purification of
transglutaminase from D. immitis is shown in Table 1. The
starting transglutaminaseactivity in 224 mgof initial soluble
protein obtained from 32 adult female worms was extremely
low. The specific activity in the crude extract obtained from
D. immitis was at least 5 times lower than that previously
reported for B. malayi transglutaminase preparation (Singh
et al., ibid.). Transglutaminase activity was determined in a
microtiter plate assay according to a recently published
procedure; see, Slaughter et al., 1992, Anal. Biochem. 205,
166-171 (incorporated herein by reference). One milliunit
(mU) transglutaminase activity is defined as the V,,,.
(AA,9;/min) generated in a microtiter plate assay by 0.74 ug
of purified guinea pig liver transglutaminase (available from
Sigma Chemical Co., T-5398). The effects of pH and tem-
perature on the transglutaminase activity and stability as
well as the effects of inhibitors, metal ions and other
cofactors on the enzyme activity were determined as
described by Singh et al., ibid. The amount of protein was
estimated according to the Bradford method (see Bradford,
1976, Anal. Biochem., 72, 248-254), using reagents avail-
able from Bio-Rad Laboratories, Hercules, Calif.
TABLE1
 
Summary of steps used for the purification of transglutaminase from




Total Total activ- activity fold
protein volume ity (mU/ purifi- Yield
Steps (ug) (ml) (mU) mg) cation (%)
1. Crude 224,200 36.0 42.6 0.19 1.0 100
exract
2. Thermo- 129,634 31.0 35.0 0.27 14 82
precipitation
3. (NH,)2SO4 11,157 3.5 26.8 2.33 12.2 63
precipitation





The D. immitis transglutaminase protein preparation pro-
tocol presented herein resulted in a high degree of purifica-
tion of D. immitis transglutaminase protein. The final prod-
uct was approximately 5 times purer than that previously
reported for B. malayi transglutaminase purified by the
lengthy conventional protocol of Singh et al., ibid. The
specific activity of the purified D. immitis enzyme was 2.0
U/mg protein, and is very close to that previously reported
for B. malayi transglutaminase. Although the enzyme was
stable over a wide pH range (data not shown), it was most
active in the basic pH range, between pH 8 and pH 9.5, as
are the other known transglutaminases. In contrast to mam-
malian. transglutaminases, the D. immitis enzyme, like the
transglutaminase isolated from B. malayi(see, Singh,etal.,
ibid.) was active and stable at high temperatures (data not
shown).
The effects of various reagents on the activity of the
transglutaminase purified from adult D. immitis worms are
shown In Table 2. The enzyme required calcium for its
activity, and chelating agents like EGTA and EDTA com-
pletely blocked the activity. Dithiothreitol and mercaptoet-
hanol increased the enzymeactivity substantially, whereas
iodoacetamide decreased the activity drastically, suggesting
that the enzyme requires at least one cysteine residue at the
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active site, like most of the transglutaminases; see, for
example, Folk et al., 1977, Adv. Protein Chem. 31, 1-133.
The effect of iodoacetamide was severe when the enzyme
was pretreated with calcium ions, suggesting that calcium
ions open the active site for high molecular weight sub-
strates like casein. The enzyme wasinhibited competitively
by amine donorsubstrate analogues like monodansyl cadav-
erine and putrescine, and by the active-site inhibitor cysta-
mine. High concentrations of sodium and potassium ions,
Tris and the end product of the reaction, ammonia, revers-
ibly inhibited the enzyme. The observation that Cbz-Gln-
Gly affects the enzyme activity only slightly (Table 2)
suggests that this compound is a poor amine acceptor
substrate for the enzyme. In contrast to mammalian tissue
type transglutaminageg (Folk et al., ibid.; Bergaminietal.,
1987, Biochim. Biophys. Acta 916, 149-151; Achyuthan et
al., 1987, J. Biol. Chem. 262, 1901-1906; Bergamini, 1988,
FEBS Lett. 239, 255-258; Lee et al., 1989, Biochem. Bio-
phys. Res. Commun. 162, 1370-1375), this enzyme wasnot
affected adversely by micromolar concentrations of GTP.
This suggests that GTP is not involved in the regulation of
this enzyme as in nematode, transglutaminase from B.
malayi (Singh et al., ibid.) and Limulus hemocyte trans-















Iodoacetamide (—Ca?**)§ 10 61
Iodoacetamide (+Ca?**)1 10 27
Tris-HCl (pH 8.5) 250 66
Tris-HCl (pH 8.5) 500 40
Na-CBZ-Gln-Gly 10 92






*The effect of metals, ions and other reagents on transglutaminase activity
was determined in the presence of CaCl, and dithiothreitol.
+The results shown are the average values from two independent experi-
ments each performedintriplicate. Standard deviation from the mean was
less than 5%.
Control tubes contained 10 mM CaCl, and 10 mMdithiothreitol.
§Iodoacetamide was preincubated with the enzyme in the absence ofcal-
cium overnight at 4° C., and the activity was determined in the presence
of 10 mM each of calcium and dithiothreitol after removal of iodoaceta-
mide by dialysis.
Modoacetamide was preincubated with the enzyme in the presence of 10
mMcalcium overnight at 4° C., and the activity was determined in the
presence of 10 mMeach of calcium and dithiothreitol after removal of
iodoacetamide by dialysis.
Example 2
This Example evaluated the effect of a numberof trans-
glutaminsae inhibitors on D. immitis larval viability in an in
vitro larval culture system.
The following transglutaminase inhibitors were tested at
the indicated final concentrations in the culture system:
(a) Monodansyl cadaverine (MDC), a knownhighaffinity
substrate analog, was tested at concentrations of 25, 50,















(b) Cystamine, a transglutaminase active site inhibitor,
wastested at concentrations of 25, 50, 75, 85 and 100
uM;
(c) Iodoacetamide was tested at concentrations of 2.5, 5
and 10 uM.
All inhibitors are available from Sigma Chemical Co,St.
Louis, Mo. Inhibitors were made in NI media (50% NCTC+
50% IMDM,available from GibcoBRL,Gaithersburg, Md.)
containing antibiotics and 20% SeruMax (available from
Sigma Chemical Co.).
The general protocol for the larval viability assays was as
follows: Briefly, 50 D. immitis L, larva were cultured for 6
days in vitro in 1 ml of NI media containing antibiotics and
20% SeruMax. In some assays, transglutaminase inhibitors
were added on different days of culture, and in other assays
the inhibitors were present for only 24 hours of culture. The
cultures were examined microscopically every 24 hours
until day 6 when the cultures were terminated. The number
of larvae that molted were determined by counting shed
cuticles.
Results of these studies are presented below in Tables 3,
4, and 5. All transglutaminase inhibitors tested in the present
study reduced in a dose-dependent mannerthe molting of D.
immitis L, larvae to Ly larvae (Table 3).
TABLE 3
 
Effect_of TGase inhibitors on molting of D. immitis L,
Concentration


















MDCand cystamine at 100 uM concentration completely
inhibited the molting process; Iodoacetamide at a final
concentration of 10 uM wasableto inhibit the molting of L,
to L,. In each case, complete inhibition of D. immitis
molting required the presence of inhibitors during the first
24-48 hr of the molting process (Tables 4 and 5). The
transglutaminase active site inhibitor (cystamine) was a very
effective inhibitor of larval molting even when added on day
2 during the culture (Table 5).
TABLE 4
 
Presence of TGase inhibitors during first 24 hr of D. immitis L; culture -
Effect on molting
Concentration














TABLE 5 TABLE 6
Molting of D. immitis L, in presence of TGase inhibitors added to culture Transglutaminase enzyme activity in D. immitis larvae and adults
on different days.
5 Amount Total activity
Inhibitor Day added Percent molted Parasite stage used (mU)
Monodansylcadaverine* 0 0 0 br L; 100 L; 38.9
(MDC) 1 18 48 br L, 100 L; 42.3
2 78 6 day Ly 100 Ly 27.6
Cystamine* 0 0 10 Male adult 60 ug 9.0




2 2 Example 4
None 70 is This Example describes the identification of native D.
 
*MDCand Cystamine were used at a concentration of 100 uM
+tIodoacetamide was used at a 10 “uM concentration
Example 3
This Example demonstrates that soluble adult and larval
D. immitis parasite extracts contain transglutaminaseactiv-
ity.
Larval and adult male and female heartworm parasites
were separately homogenized in buffer B (20 mM Tris/HCl
pH 8.5, containing 2 mM 1,4-dithiothreitol, 2 mM EDTA,1
mM phenylmethylulfonylfluoride, 0.1 mM N-tosyl-L-lysine
chloromethane and 0.1 mM N-tosyl-L-phenylalanine chlo-
romethane;all available from Sigma) for 20 min on ice. The
crude extracts thug obtained were sonicated continuously for
three 1-min periods, with 5-min intervals between each
sonication, using a pre-chilled small probe of the W-380
Ultrasonic Processor (available from Heat Systems-
Ultrasonics, Farmingdale, N.Y.). The third sonication was
done in the presence of 0.1% Triton X-100. The suspensions
were centrifuged at 15,000xg for 20 min. The supernatant
thus obtained (referred to herein as the parasite extracts, or
crude parasite extracts) was used to assay for transglutami-
nase activity.
Transglutaminase activity was determined in a microtiter
plate assay as described above in Example 1. In brief, the
microtiter plates were coated with 1% dimethylcasein
(available from Sigma) at room temperature overnight;
uncoated sites were blocked with 1% nonfat dry milk. The
reaction mixtures contained in total volumes of 200 ul each:
100 mM Tris/HCl pH 8.5, 10 mM CaCl,, 10 mM
dithiothreitol, 1 mM amine donor substrate 5(biotinamido)
pentylamine (BPT), (available from Sigma), and crude para-
site extracts. The reactions were performed at 37° C. for 2
hours and transglutaminase-catalyzed conjugation of BPT
into dimethylcasein was determined by streptavidin-
peroxidase and orthophenyldiamine as a reporter system.
The enzyme activity (expressed as mU) in extracts was
determined relative to the activity of purified guinea pig
liver transglutaminase (available from Sigma) tested in the
same microtiter plate. The results of this assay are given in
Table 6. There was detectable transglutaminase activity both
in larval and adult extracts. The activity in males was lower









immitis transglutaminase (DiTG) by immunoblot analysis.
Rabbit anti-B. malayi transglutaminase peptide PBmTG,,
antisera, produced as described in Example 1, was used to
identify a native D. immitis transglutaminase protein in D.
immitis extracts as follows.
The materials in crude extracts from D. immitis larvae and
adult male and female worms were separated by running 5
ug protein per lane on a 12-well 10% Tris-glycine SDS-
PAGEgel at 200 volts for 1 hour, and then transferred to a
nitrocellulose membrane by standard methods. After
transfer, the membrane was blocked in 5% dry milk for 1 hr
at 37° C. The membrane was then incubated with rabbit
anti-B. malayi transglutaminase peptide PBmTG., antibody
at a dilution of 1:2500 in Tris buffered saline. After 1 hr
incubation at room temperature, the blot was washed, and
antibody binding resolved using a peroxidase-labeled rabbit
IgG secondary antibody and the substrate nitroblue tetrazo-
lium chloride, 5-bromo-4-chloro-3-indolylphosphate
p-toluidine salt (NBT/BCIP) (available from Gibco BRL,
Gaithersburg, Md). Using this antibody, immunoblot analy-
sis of D. immitis adult male, female and larval extracts
identified a 56 kD native D. immitis protein (DiTG) similar
to the size of native Brugia protein (Singh et al., ibid.).
Example 5
This Example describes the amino acid sequence analysis
of the 56 kD D. immitis transglutaminase.
The native 56 kD D. immitis transglutaminase protein
from adult female D. immitis parasite extracts was separated
by two dimensional SDS-PAGE.Thefirst dimension was an
isoelectric focusing gel using a non-equilibrium pH gradient
containing ampholines of pI 5-8 (available from Pharmacia
Biotech, Uppsala, Sweden). The second dimension was run
on an 8% Tris-glycine gel; the resulting protein spots were
transferred to PVDF membrane,and the spot corresponding
to D. immitis transglutaninase was excised. 17 such spots
were then used for N-terminal sequence analysis using an
automated protein sequencer (ABI437A, available from
Applied Biosystems, Inc., Foster City, Calif.).
For internal amino acid sequence analysis, spots contain-
ing D. immitis transglutaminase were excised from Coo-
massie blue stained preparative two dimensional SDS-
PAGEgels of female D. immitis parasite extract. 48 such
spots were pooled and then subjected to trypsin digestion in
the gel. The digested protein sample was then separated
using high pressure liquid chromatography (HPLC).
Digested proteins were then sequenced as described above.
Preparation and sequencingofthe internal protein fragments
were performed by the Harvard Microchemistry Facility,
Cambridge, Mass.
The results of the amino acid sequence analysis of D.
immitis transglutaminase are given below. A partial
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N-terminal amino acid sequence of about 29 amino acids
was determined andis represented herein as SEQ ID NO:2:
DGDVMKFTDADFKEGIKPYDVLLVKFYAP
A homologysearch of a non-redundant protein sequence
database was performed on this amino acid sequence
through the National Center for Biotechnology Information
(NCBI) (National Library of Medicine, NationalInstitute of
Health, Baltimore, Md.) using the BLAST network. This
database includes SwissProt+PIR+SPupdate+GenPept+
GPUpdate+PDBdatabases. The search was performed using
SEQ ID NO:2 and showedsignificant homology to probable
protein disulfide isomerases (PDIs) spanning from amino
acid residue 1 through 29 of SEQ ID NO:2. The highest
scoring match of the homology search at the amino acid
level was GenBank™ accession number Z37139, Caenor-
abditis elegans clone C14B1.1. SEQ ID NO:2 showedabout
44% identity to residues 24 to 50 of the clone C14B1.1. SEQ
ID NO:2 also showed a near sequence identity to the B.
malayi peptide, PBmTG,,, SEQ ID NO:1.
The two internal D. immitis transglutaminase amino acid
sequences obtained as described above were characterized
as follows: A partial internal amino acids sequence of about
14 amino acids was determined andis represented herein as
SEQ ID NO:3:
YQYDLLPMFVVYGK
A homologysearch of a non-redundant protein sequence
database was performed on SEQ ID NO:3through the NCBI
using the BLAST network as described above. This database
includes SwissProt+PIR+SPupdate+GenPept+GPUpdates+
PDB.Results of the search showed nosignificant homology
of SEQ ID NO:3 to other proteins in the database.
Anotherpartial internal amino acid sequence of about 19
amino acids was determined and is represented herein as
SEQ ID NO:4:
MDATANDVPPPFOVQGFPT
A homologysearch of a non-redundant protein sequence
database was performed on this amino acid sequence using
the BLAST network through the NCBI, as described above.
The search was performed using SEQ ID NO:4 and showed
significant homologyto probable PDIs spanning from amino
acid residue 1 through 19 of SEQ ID NO:4. The highest
scoring match of the homology search at the amino acid
level was GenBank™accession number PC1298 (chicken
nuclear matrix 57 K protein). SEQ ID NO:4 showed about
78% identity to residues 42 to 60 of this chicken nuclear
matrix protein sequence.
Example 6
This Example describes the isolation and sequencing of a
nucleic acid molecule encoding a D. immitis transglutami-
nase protein.
AD. immitis transglutaminase nucleic acid molecule of
about 707 nucleotides, denoted nDiTG,,,, was identified by
polymerase chain reaction (PCR) amplification from D.
immitis first strand cDNA reverse transcribed from adult
female mRNAas follows. The following primers were used
to PCR amplify the D. immitis transglutaminase nucleic acid
molecule from the cDNA template: A sense primer spanning
nucleotides encoding amino acid residue number about 5
through amino acid residue number about 15 of SEQ ID
NO:2, and having the nucleic acid sequence 5' ATGAART-
TYACNGAYGCNGAYTTYAARGARGG 3' (denoted
herein as SEQ ID NO:15); and an anti-sense primer span-
ning nucleotides encoding amino acid residue numberabout
8 through amino acid residue number about 14 of SEQ ID
NO:3 and having the nucleic acid sequence 5' TTNCCR-















The PCR amplified D. immitis transglutaminase nucleic
acid molecule, referred to herein as nDiTG.,,,, was sepa-
rated from the rest of the PCR reaction products on a 1%
agarose gel at 60 v for 2 hr. After separation of the PCR
products, the band of interest was excised from the agarose
gel. The gel slice was then processed to release the DNA
using the QIAquickkit (available from Qiagen, Chatsworth,
Calif.) as per manufacturer’s instructions. The purified DNA
was then cloned into TA cloning vector (available from
Invitrogen, San Diego, Calif.) as per the manufacturer’s
instructions and submitted for automated sequence analysis.
The sequences of the two complementary strands of
nDiTG,,, are presented as SEQ ID NO:5 and SEQ ID NO:7.
Translation of SEQ ID NO:5yieldsa protein of about 235
aminoacids, denoted PDiTG,,,, the amino acid sequence of
which is presented in SEQ ID NO:6. The nucleic acid
molecule encoding PDiTG,,; is referred to herein as
nDiTG.,,, the nucleic acid sequence of whichis represented
in SEQ ID NO:8(the coding strand) and SEQ ID NO:9 (the
complementary strand). Based on its amino acid sequence,
PDiTG,,; has a predicted molecular weight of about 27.2
kD and an estimated pI of about 5.07.
Amino acid sequence of PDiTG,3; (ie. SEQ ID NO:6)
was analyzed using the PC/GENE™ (available from
Intelligenetics, Inc., Mountainview, Calif.) sequence analy-
sis program for sites and signatures. A thioredoxin family
active site was detected from residues about 24 to 30.
Thioredoxins participate in various redox reactions through
the reversible oxidation of an active center disulfide bond;
see, for example, Holmgren, ibid. A numberof eukaryotic
proteins contain similar domains evolutionarily related to
thioredoxin.
A homologysearch of a non-redundant protein sequence
database was performed through the NCBI using the
BLASTnetwork, as described above. The search performed
using SEQ ID NO:6 showedthat this sequence has signifi-
cant homology to protein disulfide isomerases (PDI), and
PDI-related proteins, of eukaryotic orgin, The homology
spans from about amino acid 1 through about amino acid
235 of SEQ ID NO:6. The highest scoring match of the
homology search at the amino acid level was GenBank™
accession number P38658, Schistosoma mansoni, probable
PDI ER-60 precursor. SEQ ID NO:6 showed about 37%
identity to P38658. At the nucleotide level, the coding
regions represented in SEQ ID NO:8, from nucleotide 7 to
246, were similar to that of the human clone PA3
(GenBank™accession number J05016), PDI-related protein
(Erp72) mRNA. SEQ ID NO:8 showed about 59% nucleic
acid identity spanning from nucleotide 589 to 828 of clone
PA3.
Example 7
The following experiment was performed in order to
confirm the D. immitis origin of the isolated DiITG cDNA
nucleic acid molecule nDiTG,,,, and in order to identify he
genomicrestriction fragments corresponding to nDiTG,,,.
A Southern blot containing about 10 zg of EcoRI and Xhol
restricted D. immitis genomic DNA was hybridized under
stringent conditions with nDiTG,,, DNA labeled with a
chemiluminescent label (ECL labeling kit, available from
Amersham, Arlington Heights, IIl.). The probe detected a
single band of about 11.7 kilobase pairs (kb) in the genomic
DNA digested with XhoI, where as in EcoRI digested
genomic DNA,the probe detected three bands at about 9.5,
1.07 and 0.43 kb,respectively.
Example 8
This Example describesthe isolation and characterization
of transglutaminase nucleic acid molecules of the present
invention from a D. immitis L, cDNAlibrary.
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D. immitis transglutaminase nucleic acid molecules were
cloned from a cDNAlibrary by nucleic acid screening using
D. immitis transglutaminase nucleic acid molecules of the
present invention as probes. Specifically, a 6 day D. immitis
larval cDNA library was constructed from 140,420 L, as
follows. D. immitis 6 day, L, larvae were cultured in NCTC
135:IMDM media and 20% Seru-MaX™ for 48 hours.
Larvae weresettled by gravity at 37° C. culture media were
removed and larvae were disrupted in 4 M guanidinium
thiocyanate, 1.5% sarkosyl, 0.5 M 2-mercaptoethanol. Total
RNA (290 ug) was recovered by the acid guanidinium-
thiocyanate-phenol-chloroform procedure (Chomezynski,et
al., 1987, Anal. Biochem. 162, pp. 156-159). Poly A* mRNA
(6.954 ug) was isolated with oligo(dT) cellulose using the
RiboSep Mini MRNAIsolation Kit (available from Collabo-
rative Research, Inc., Bedford, Mass.). The ZAP-cDNA®
Synthesis Kit (available from Stratagene, La Jolla, Calif.)
was used to synthesize cDNA, which wasthen ligated into
the Uni-ZAP XR vector (Stratagene), packaged and ampli-
fied to produce the L, CDNA library. The nucleic acid
molecule, nDiTG,,,, (represented herein by the sequences
SEQ ID NO:5 and SEQ ID NO:7) was labeled with a
chemiluminescentlabel as described in Example 7, and used
as a DNAprobeto screen the L, cDNA expression library.
A clone containing a D. immitis transglutaminase nucleic
acid molecule referred to herein as nDiTG,,,5 was plaque-
purified from the expression library using standard methods,
and then sequenced. The following nucleotide primers were
used to sequence this clone: a) two pBluescript™ vector
primers consisting of a sense T,X primer (denoted herein as
SEQ ID NO:17) having the nucleic acid sequence 5' AAT-
TAACCCTCACTAAAGGG 3'; and an antisense T,X
primer (denoted herein as SEQ ID NO:18) having the
nucleotide sequence, 5|' GTAATACGACTCACTATAGGGC
3'; and b) three internal primers including a sense primer
having the nucleic acid sequence 5' GAAAACCGTTAT-
CAGTATGATCT3' (denoted herein as SEQ ID NO:19), and
two antisense primers having the nucleic acid sequences 5'
CTGTGGAATGATTTAAATATTTATCC3' (denoted herein
as SEQ ID NO:20) and 5' GTCCATTTTTGCAATAACAA-
CACC3' (denoted herein as SEQ ID NO:21), respectively.
The resulting nucleic acid sequences of the two comple-
mentary DNA strands of nDiTG,,,, are referred to herein as
SEQ ID NO:10 and SEQ ID NO:12. The sense primer
represented by SEQ ID NO:19 spans nucleotides about
nucleotide 359 to about nucleotide 381 of SEQ ID NO:10;
the antisense primer represented by SEQ ID NO:20 spans
about nucleotide 1171 to about nucleotide 1192 of SEQ ID
NO:10; and the antisense primer SEQ ID NO:21 spans from
about nucleotide 878 to about nucleotide 901 of SEQ ID
NO:10.
Translation of SEQ ID NO:10 yields a protein of about
368 amino acids, denoted as PDiTG,,,, the amino acid
sequence of which is presented in SEQ ID NO:11. The
nucleic acid molecule encoding PDiTG,,, is referred to
herein as nDiTG,,,,, the nucleic acid sequence of whichis
represented in SEQ ID NO:13 (the coding strand) and SEQ
ID NO:14 (the complementary strand) assumingthatthefirst
codon spans from about nucleotide 2 through about nucle-
otide 5, and a putative stop codon spans from about nucle-
otide 1106 to about nucleotide 1108 (the stop codon included
in nDiTG,,57). The amino acid sequence of D. immitis
PDiTG,.. (i.e., SEQ ID NO:11) predicts that PDiTG,,., has
an estimated molecular weight of about 42.6 kD and an
estimated pI of 5.71.
The amino acid sequence of PDiTG., (ie., SEQ ID














identify sites and signatures. A number of interesting sites
were detected. They include: i) a thioredoxin family active
site detected from residues 268 to 274; ii) an endoplasmic
reticulum (ER) targeting sequence from residues 365 to 368
(KEEL); proteins that permanently reside in the lumen of
ER seem to be distinguished from newly synthesized secre-
tory proteins by the presence of the C-terminal sequence
Lys-Asp-Glu-Leu (KDEL), see Munroet al., ibid. Cell 48,
899-907; Pelham, ibid.; andiii) a tachykinin family signa-
ture from residues 186 to 202 (tachykinins are a group of
biologically active peptides that excite neurons, evoke
behavioral responses, are potent vasodilators, and contract
many smooth muscles; see, Maggio, 1988, AnnualReview of
Neurosciences 11, 13-28).
A homologysearch of a non-redundant protein sequence
database was performed on SEQ ID NO:11 using the
BLASTnetwork through the NCBI, as described above. The
search showedsignificant homology to PDI, and PDI-related
proteins of eukaryotic origins, spanning from about amino
acid 1 through about amino acid 368 of SEQ ID NO:11. The
highest scoring match of the homology search at the amino
acid level was to GenBank™ accession number D16234
(from amino acid residues 130 to 505), a human phospho-
lipase C-alpha clone. This match revealed about 47% iden-
tity spanning amino acid residues about 3 to about 368 of
SEQ ID NO:11. The nucleic acid coding region represented
in SEQ ID NO:13, from about nucleotide 717 to about
nucleotide 1032, was similar to that of human epithelial cell
mRNA for ER-60 protease (GenBank™ accession number
D83485), being about 63% identical to nucleotides 1143
through 1458 of the ER-60 protease sequence.
Example 9
This Example describes the identification of D. immitis
poly(A)” RNAtranscripts corresponding to nDiTG.7.
A Northern blot was performed as follows: D. immitis
adult female and male total RNA (8 “g) and adult female and
male poly(A)* RNA (0.5 ug) were electrophoresed on a 1%
formaldehyde gel and transferred to a N+ nylon membrane
(available from Amersham). The RNA wascross-linked to
the membrane using the Stratalinker (available from
Stratagene). The Northern blot was then hybridized with
peroxidase-labeled nDiTG,,, cDNA using the ECL direct
nucleic acid labeling and detection system (available from
Amersham) as per the manufacturer’s instructions. In each
of the four samples, the nDiTG,,., cDNA probe hybridized
to a single band of approximately 2613 nucleotides as
calculated by MacVector’s mobility program.
Example 10
This Example describes the PCR amplification and sub-
sequent isolation of a 5 nematode transglutaminase nucleic
acid molecule from D. immitis cDNAusing the nematode 22
nucleotide splice leader sequence as the primer.
Nematode transglutaminase nucleic acid molecules were
PCR amplified from D. immitis female adult cDNA using a
primer corresponding to the sequence of a nematode splice
leader (SL). Most, but not all nematode messenger RNAs
have the SL sequenceat their 5' ends, and the presence of the
5' SL sequence is indicative of an apparent full length
cDNA.See, for example Blaxter and Liu, 1996, Int. J.
Parasitol. 26, 1025-1033, which is incorporated herein by
reference. The two primers used in the PCR amplification
reaction were a sense primer representing the SL sequence,
having the nucleotide sequence 5' GGTTTAATTAC-
CCAAGTTTGAG 3' (herein denoted as SEQ ID NO:22)
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and an antisense primer having the sequence 5' TCCCTC-
CTTGAAGTCCGCATCTGTAAATTTCAT 3' (herein
denoted as SEQ ID NO:23; SEQ ID NO:23 represents
nucleotides from about, nucleotide 673 to about nuclceotide
705 of SEQ ID NO:9) PCR amplification of adult female
cDNAusing these primers resulted in the production of an
143 bp nucleic acid molecule (herein denoted as nDiTG,,,,).
Nucleic acid molecule nDiTG,,, was gel purified, cloned
into TA cloning vector(available from Invitrogen, Carlsbad,
Calif.) and sequenced using an automated DNA sequencer.
Sequence analysis of the nDiTG,,, coding strand (herein
denoted as SEQ ID NO:27) and the complementary strand
(herein denoted as SEQ ID NO:29 demonstrated that
nDiTG,,, had the SL sequenceat its 5' end. Translation of
SEQ ID NO:27yields a protein of about 40 amino acids,
herein denoted as PDiTG,,, the amino acid sequence of
which is presented in SEQ ID NO:28. The nucleic acid
molecule encoding PDiTG,, is referred to herein as
nDiTG,,,, the nucleic acid sequence of whichis represented
in SEQ ID NO:30 (the coding strand) and SEQ ID NO:31
(the complementary strand). The amino acid sequenceofD.
immitis PDiTG,, (i.e, SEQ ID NO:28) predicts that
PDiTG,, has an estimated molecular weight of about 4.5 kD
and an estimated pI of about 4.6. PC/GENE™ sequence
analysis of SEQ ID NO:27 predicts a translation product
having an N-terminal hydrophobic signal sequence spanning
from about amino acid residue 1 through about amino acid
residue 25 of SEQ ID NO:28, and having a predicted
cleavage site between about amino acid residue 25 and about
amino acid residue 26. The nucleic acid sequence of the
predicted mature protein product of PDiTG,, (after cleavage
at the predicted cleavagesite) is an approximately 15 amino
acid protein herein denoted as PDiTG,,; (the amino acid
sequence of which is represented by SEQ ID NO:52),
encoded by a nucleic acid molecule spanning from about
nucleotide 99 to about nucleotide 143 of SEQ ID NO:27(the
coding and complementary sequences of which are herein
designated as SEQ ID NO:51, and SEQ ID NO:53,
respectively).
Example 11
This Example describes the amplification and subsequent
isolation of a nematode transglutaminase nucleic acid mol-
ecule of the present invention from D. immitis female adult
cDNAusing primers designed for protein expression in the
pTrcHisB vector (available from Invitrogen).
Nematode transglutaminase nucleic acid molecules were
PCR amplified from D. immitis female adult cDNAusing the
following two primers in the PCR amplification reaction: a
sense primer (DiTG-Xhol) with the sequence, 5'
CCGAGCTCGAGAATGAAATTTACAGATGCGGAC 3'
(herein denoted as SEQ ID NO:24, Xholsite in bold; nucleic
acid residues 13 through 33 of this primer represent
sequence from about position 1 to about position 21 of SEQ
ID NO:5, while the remainder of the primer was designed to
include the restriction endonuclease cleavage site) and an
antisense primer (DiTG- HindIII) 5' CAGCCAAGCTTCT-
TACAATTCTTCCTTCTTCTTCGGTITTCC 3' (herein
denoted as SEQ ID NO:25; HindIII site in bold) for PCR
amplification. PCR amplification of D. immitis adult female
cDNA using these primers resulted in the production of a
1407 bp nucleic acid molecule (herein denoted as
nDITG,497).
The nucleic acid molecule designated nDiTG,,,7, was gel
purified, cloned into a TA cloning vector (available from














sequencer. The nucleic acid sequenceof the coding strand of
nDiTG,,5, is herein denoted as SEQ ID NO:32, and the
complementary strand is herein denoted as SEQ ID NO:34.
Translation of SEQ ID NO:32 yields a protein of about 468
amino acids, herein denoted as PDiTG,,., the amino acid
sequence of which is presented in SEQ ID NO:33. The
amino acid sequence of D. immitis PDiTG,.. (i.e., SEQ ID
NO:33) predicts that PDiTG,,, has an estimated molecular
weight of about 54.3 kD and an estimated pI of about 5.6.
The sequence of nDiTG,,), overlaps with that of
nDiTG,,, and nDiTG,,-,, allowing for the construction of
a composite transglutaminase sequence representing a full-
length nematode transglutaminase gene. The nucleic acid
molecule represented by this sequence (herein denoted as
nDiTG,..;,) includes both the nematode splice leader
sequence at the 5' end of the molecule, and the poly(A)*
sequence at the 3' end of the molecule. The nucleic acid
sequence of the coding and complementary strands of
nDiTG,,.., are herein represented by SEQ ID NO:46 and
SEQ ID NO:48, respectively. Translation of nDiTG,..,
yields an approximately 497 amino acid protein herein
denoted as PDiTG,,,, the amino acid sequence of which is
presented in SEQ ID NO:47. The nucleic acid molecule
encoding PDiTG,,, is referred to herein as nDiTG,,9,, the
nucleic acid sequence of which is represented in SEQ ID
NO:49(the coding strand) and SEQ ID NO:50 (the comple-
mentary strand).
Sequence analysis of SEQ ID NO:27 (the origin of the
sequence of the 5' end of nDiTGj,.,, i.e., SEQ ID NO:46)
predicts a translation product having an N-terminal hydro-
phobic signal sequence spanning from about amino acid
residue 1 through about amino acid residue 25 of SEQ ID
NO:46, and having a predicted cleavage site between about
amino acid residue 25 and about amino acid residue 26. The
nucleic acid sequenceof the predicted mature protein prod-
uct of nDiTG,,., (after cleavage at the predicted cleavage
site) is an approximately 472 amino acid protein herein
denoted as PDiTG,,, (the amino acid sequence of which is
represented by SEQ ID NO:55), encoded by a nucleic acid
molecule spanning from about nucleotide 99 to about nucle-
otide 1514 of SEQ ID NO:46 (the coding and complemen-
tary sequences of which are herein designated as SEQ ID
NO:54, and SEQ ID NO:56, respectively).
Example 12
This Example discloses the production of a recombinant
molecule and a recombinantcell of the present invention.
Recombinant molecule pTre-nDiTG,97, containing a D.
immitis transglutaminase nucleic acid molecule represented
by nucleotides from about 1 through about 1407 of SEQ ID
NO:32 operatively linked to tre transcription control
sequences and to a fusion sequence encoding a poly-
histidine segment comprising 6 histidine residues, was pro-
duced in the following manner. An about 1407 base nucleic
acid molecule including nucleotides spanning from about
nucleotides 1 through 1407 of SEQ ID NO:32 was PCR
amplified from nDiTG,,,7 using the primers DiTG-Xhol
sense primer 5' CCGAGCTCGAGAATGAAATTTACA-
GATGCGGAC3 '(herein denoted as SEQ ID NO:24; XhoI
site in bold) and DiTG-HindIII antisense primer 5'CAGC-
CAAGCTTCTTACAATTCTTCCTTCTTCT-
TCGGTTTTCC3' (herein denoted as SEQ ID NO:25; KpnI
site in bold). Recombinant molecule PHis-DiTG,,,, was
produced by digesting the nDiTG,,,7-containing PCR prod-
uct with XhoI and HindIII restriction endonucleases, gel
purifying the resulting fragment and directionally subclon-
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ing it into the expression vector pTrcHisB (available from
Invitrogen) that had been cleaved with Xhol and HindIII and
gel purified.
Recombinant molecule pTre-nDiTG,,,, was transformed
into FE. coli to form recombinant cell FE. coli:pTre-
nDiTG,,57, using standard techniques as disclosed, for
example, in Sambrooketal., ibid.
Example 13
This Example describes the production of a nematode
transglutaminase protein of the present invention in a
prokaryotic cell as well as studies to characterize that
protein.
Recombinantcell F. coli:pTre-nDiTG,,97 was cultured in
shake-flasks containing an enriched bacterial growth
medium containing 0.1 mg/ml ampicillin at about 37° C.
Whenthecells reached an ODgo. of about 0.5, expression of
D. immitis pTre-nDiTG,,, was induced by addition of about
0.5 mM isopropyl-B-D-thiogalactoside IPTG), and the cells
were cultured for about 3 hr. at about 37° C. Protein
production was monitored by SDS-PAGE of recombinant
cell lysates, followed by Coomassie blue staining, using
standard techniques. Recombinant cell E. coli:pTre-
nDiTG,,5, produced a fusion protein, herein denoted as
PHIS-PDiTG,,., that migrated with an apparent molcular
weight of about 60 kD.
Immunoblot analysis of recombinant cell F. coli:pTrc-
nDiTG,497 lysates indicated that the about 60 kD protein
was able to bind to a T, Tag® monoclonal antibody
(available from Novagen, Inc., Madison, Wis.) directed
against the fusion portion of the recombinant PHIS-
PDiTG,.,. fusion protein.
The PHIS-PDiTG,,. histidine fusion protein was sepa-
rated from F. coli proteins by cobalt chelation chromatog-
raphy with an imidazole gradient elution. Immunoblot
analysis of the FE. coli:pTrc-nDiTG,,7 lysates, column
eluate and column void volume indicated that the approxi-
mately 60 kD PHIS-PDiTG,<. protein isolated using cobalt
column chromatography wasableto selectively bind to a T,
Tag® monoclonalantibody. The fusion peptide expressed in
pIrcHisB contributes approximately 4 kD of vector-
encoded amino acid sequence to the recombinant protein;
and thus nDiTG, 4497 encodes a protein of approximately
55kD.
Example 14
This Example discloses the purification of a nematode
transglutaminase fusion protein of the present invention
from total cell lysates. Also described is the production of
anti-DiTG antibodies of the present invention.
Nematode transglutaminase fusion protein PHIS-
PDiTG,., was separated from EF. coli proteins by Talon™
Metal Affinity Resin Chromatography (available from
CLONTECHLaboratories, Inc., Palo Alto, Calif.) according
to the manufacturer’s instructions. The nematode trans-
glutaminase fusion protein was eluted using an imidazole
gradient, pooled and dialyzed against 1xPBS to produce
cobalt column-purified PHIg-PDiTG,,.. The dialyzed pro-
tein was concentrated using a 10K molecular weight cut off
Centrifugal Ultra-free® concentrator (available from Milli-
pore Corporation, Bedford, Mass.). The protein content of
the fusion protein was determined using a MicroBCA™
Protein Assay (available from Pierce, Rockford, Ill.). The
purified protein wastested for its purity by SDS PAGE and














Anti-PHIS-PDiTG,,. (anti-DiTG) antisera was produced
as follows: A rabbit was immunized subcutaneously,first
with approximately 75 ug of the purified PHIS-PDiTG,,.
(see above) protein with complete Freund’s Adjuvant
(available from Sigma, St. Louis, Mo.), and then with three
subsequent immunizations of the same dose of PHIS-
PDiTG,,, mixed in Incomplete Freund’s Adjuvant. Bleed-
ing and immunization were performed at alternate weeks.
Sera were separated and stored at -70° C. until use.
The immunoglobulin G (IgG) fraction (anti-DiTG IgG)
from anti-DiTG antisera was collected by 50% ammonium
sulfate precipitation. Ammonium ions were removed by
extensive dialysis in 0.1 M PBS, pH 7.2. The IgG content
was determined by measuring absorbance at OD.,,, and
comparing absorbance with that of a blank PBS control. The
anti-DiTG IgG had atiter of 1:124,000 as determined by
ELISA.
Example 15
This Example describes the PCR amplification and sub-
sequent isolation and characterization of transglutaminase
nucleic acid molecules from other related filarial Nematode
transglutaminase nucleic acid molecules from Brugia
malayi and Onchocerca volvulus were identified using stan-
dard PCR technology and methods as follows. In brief,
nematode transglutaminase nucleic acid molecules were
PCR amplified from B. malayi female adult cDNAusing two
primers, a sense primer representing the SL sequence, hav-
ing the nucleotide sequence, 5' GGTTTAATTAC-
CCAAGTTTGAG 3' (herein denoted as SEQ ID NO:22)
and an antisense primer 5' GCTGATGGACCTGCCTGTC-
CACGC3'(herein denoted as SEQ ID NO:26). PCR ampli-
fication of B. malayi adult female cDNAusing these primers
resulted in the production of a 440-bp nucleic acid molecule
(herein denoted as nBmTG,,,). Nematode transglutaminase
nucleic acid molecules were also amplified from B. malayi
femlae adult cDNA using primers corresponding to internal
sequences in the cDNA sequence of nDiTG,,,. (SEQ ID
NO:10). The two primers used were: i) a sense primer
spanning from about nucleotide 359 to about nucleotide 371
of SEQ ID NO:10, and having the nucleotide sequence 5'
GAAAACCGTTATCAGTATGATCT 3' (SEQ ID NO:19);
and ii) an antisense primer spanning from about nucleotides
878 to 901 of SEQ ID NO:10, and having the nucleotide
sequence 5' GTCCATTTTTGCAATAACAACACC3' (SEQ
ID NO:21). PCR amplification of adult female cDNAusing
these primers resulted in the production of a 537 bp nucleic
acid molecule (herein denoted as nBmTG,,,; this nucleic
acid molecule was previously identified in U.S. patent
application Ser. No. 08/781,420 as nBmTG;,.).
Transglutaminase nucleic acid molecules were also PCR
amplified from an O. volvulus larval cDNAlibrary using two
primers that represent internal sequences of nDiTG,,,,: a
sense primer spanning from about nucleotide 359 to about
nucleotide 371 of SEQ ID NO:10, and having the nucleotide
sequence 5' GAAAACCGTTATCAGTATGATCT 3' (SEQ
ID NO:19), and an antisense primer spanning from about
nucleotide 878 to about nucleotide 901 of SEQ ID NO:10,
and having the nucleotide sequence GTCCATTTTG-
CAATAACAACACC3' (SEQ ID NO:21). PCR amplifica-
tion of adult female cDNA using these primers resulted in
the production of a 537 bp nucleic acid molecule (herein
denoted as nOvTG,,,; this nucleic acid molecule was,
previously identified in U.S. patent application Ser. No.
08/781,420 as nOvTG,,,).
Nucleic acid molecules nBmTG,,, (the sequences of the
coding and complementary strands herein denoted as SEQ
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ID NO:35 and SEQ ID NO:37, respectively), nBmTG;3,
(the sequences of the coding and complementary strands
herein denoted as SEQ ID NO:42 and SEQ ID NO:44,
respectively), and nOvTG,,, (the sequences of the coding
and complementary strands herein denoted as SEQ ID
NO:43 and SEQ ID NO:45,respectively) were gel purified,
cloned into TA cloning vector and sequenced using an
automated DNAsequencer. Sequenceanalysis of nBmMTG,4,
coding and noncoding strands (represented by SEQ ID
NO:35 and SEQ ID NO:37, respectively) showed that
nBmTG,,, included the SL sequence at its 5’ end.
Furthermore, the entire sequences of nOvTG,;,, and
nBmTG,,, were, respectively, 98.9% and 87.7% identical in
the region spanning from about nucleotide 359 to about
nucleotide 901 of nDiTG,,,, (SEQ ID NO:10).
Translation of SEQ ID NO:35 yields a protein of about
139 amino acids, herein denoted as PBmTG,,,, the amino
acid sequence of which is presented in SEQ ID NO:36. The
nucleic acid molecule encoding PBmTG,,, is herein
referred to as nBmTG,,,,the nucleic acid sequence of which
is represented in SEQ ID NO:38 (the coding strand) and
SEQ ID NO:39 (the complementary strand). The aminoacid
sequence of D. immitis PBmTG,3, (.e., SEQ ID NO:36)
predicts that PBmTG,,. has an estimated molecular weight
of about 14.1 kD and an estimated pI of about 5.1.
PC/GENE™sequenceanalysis of SEQ ID NO:35 predicts
a translation product having an N-terminal hydrophobic
signal sequence spanning from about aminoacid residue 1
through about amino acid residue 26 of SEQ ID NO:36,and
having a predicted cleavage site between about amino acid
residue 26 and about amino acid residue 27. The nucleic acid
sequence of the predicted mature protein product of
nBmTG,,-, (after cleavage at the predicted cleavagesite) is
an approximately 113 amino acid protein herein denoted as
PBmTG,3, (the amino acid sequence of which is repre-
sented by SEQ ID NO:58), encoded by a nucleic acid
molecule spanning from about nucleotide 102 to about
nucleotide 440 of SEQ ID NO:35 (the coding and comple-
mentary sequences of which are herein designated as SEQ
ID NO:57, and SEQ ID NO:59,respectively).
Translation of SEQ ID NO:42 yields a protein of about
179 amino acids, herein denoted as PBmTG,,., the amino
acid sequence of which is presented in SEQ ID NO:43. The
amino acid sequence of D. immitis PBmTG,,, predicts that
PBmTG,,, has an estimated molecular weight of about 20.8
kD and an estimated pI of about 4.6. Translation of SEQ ID
NO:43 yields a protein of about 179 amino acids, herein
denoted as POVTG,,, the amino acid sequence of whichis
presented in SEQ ID NO:48. The amino acid sequence of
D. immitis POVTG,,, (i.e., SEQ ID NO:44) predicts that
POvTG,7, has an estimated molecular weight of about 20.8
kD andan estimated pI of about 4.6.
Example 16
This Example demonstrates that proteins of the present
invention possess transglutaminase activity. The trans-
glutaminase activity of column-purified nematode trans-
glutaminase (PIS-PDiTG,,,) was determined in a microtiter
plate assay essentially as previously herein described. In
brief, microtiter wells were coated with 1% dimethylcasein,
(available from Sigma) at room temperature overnight;
uncoated sites were blocked with 1% (w/v) nonfat dry milk.
The following reaction mixtures were contained in a total
volumeof 200 zl: 100 mM Tris/HCl] pH 8.5, 10 mM CaCl,
(except where otherwise indicated), 10 mM dithiothreitol, 1
mM amine donor substrate 5(biotinamido) pentylamine













tions were performed at 55° C.(or as herein indicated) for
2 hours and transglutaminase-catalyzed conjugation of BPT
into dimethylcasein was determined by streptavidin-
peroxidase and orthophenyldiamine as a reporter system.
The enzyme activity (expressed as mU) of extracts was
determined relative to the activity of purified guinea pig
liver transglutaminase (available from Sigma) tested in the
same microtiter plate. Several biochemial factors required
for transglutaminase activity of PHIS-PDiTG,.. were also




Effect of enzyme concentration on PHIS-PDiTGy,activity
Concentration of PHIS-PDiTGy¢g Activity
(ug/ml) (mU + SEM)





Effect of Ca?* on transglutaminaseactivity of PHIS-PDiTG,¢. (15 #g/ml)
 
Concentration of Ca?* Activity
(mM) (mU + SEM)
0.0 2.1 + 1.0
0.5 65.7 = 0.3
2.0 110.6 + 1.0
4.0 125.8 + 0.0





Effect of EDTA on transglutaminase activity of PHIS-PDiTGy.¢¢
(15 ug/ml)
Concentration of EDTA Activity
(mM) (mU + SEM)
0.0 79.8 + 9.6
0.5 34.1 + 2.8
2.0 6.6 + 0.2
4.0 4.8 + 2.3
8.0 0.69 + 0.0
TABLE 10
Effect of temperature on transglutaminase activity of PHIS -PDiTGy¢g
(15 ug/ml)
Temperature Activity
CC) (mU + SEM)
37 8.2 + 3.1
45 14.3 #31
55 52.6 + 13








Effect of dithiothreitol (DTT) on transglutaminase activity of
PHIS-PDiTGy.o (15 g/ml)
Activity
Concentration of DTT mU + SEM
(ug/ml) +DIT -DIT
10.0 55.0 + 8.0 98.6 + 2.0
15.0 83.0 + 6.6 149.0 + 5.7
20.0 123.0 + 3.0 161.0 + 3.0
TABLE 12
Effect of inhibitors on transglutaminase activity of PHIS-PDiTGueg
(15 we/ml)
Concentration Activity
Inhibitor (mM) (mU + SEM)
None 81.2 + 3.3
Monodansylcadaverine 2.0 48.3 + 4.0
4.0 44.6 + 5.1
Putrescine 2.0 36.5 + 3.9
4.0 35.3 + 4.3
Cystamine 0.5 46.4 + 4.6
1.0 28.3 + 2.2
As can be seen from the results presented above, PHIS-
PDiTG,., was able to cross-link BPT to dimethylcasein and
the rate of cross-linking activity was concentration depen-
dent (Table 7). Furthermore, the transglutaminase activity of
PHIS-PDiTG,¢, was Ca?*-dependent (Table 8) and was
inhibited by EDTA (Table 9) and EGTA (data not shown).
Interestingly, the PHIS-PDiTG,,, was found to be highly
thermostable with optimum activity observed at 55° C.
(Table 10). Dithiothreitol (DTT, available from Sigma) was
not absolutely essential for transglutaminaseactivity. In fact,
PHIS-PDiTG,,;, was more active in the absence of DTT
(Table 11). The known inhibitors of transglutaminase such
as monodansylcadaverine, putrescine, cystamine and
iodoacetamide inhibited the transglutaminase activity of
PHIS-PDiTG,., (Table 12).
Example 17
This Example demonstrates the transglutaminase activity
for bovine protein disulfide isomerase (PDI).
Sequence analysis of nDiTG,,, showed significant
homology between the protein encoded by nDiTG and
known PDIs. Therefore, bovine PDI wastested to see if it
has transglutaminase activity. Transglutaminase activity of
PDI (Bovine PDI, available from Sigma) was determined in
a microtiter plate assay as described above. Theresults of the
 
assays are given in Tables 13, 14 and 15.
TABLE 13
Transglutaminase activity of bovine protein disulfide isomerase (PDI)
Concentration of PDI Transglutaminase activity
(ug/ml) (mU + SEM)
2.5 57.4 + 3.0
5.0 93.1 + 7.3
10.0 119.9 + 7.1












Effect of EDTA (10 mM)on transglutaminase activity of
bovine protein disulfide isomerase (PDI)
Concentration of PDI Transglutaminase activity
 
(ug/ml) (mU + SEM)
2.5 1.5 +01
5.0 0.0 + 0.0
10.0 0.0 + 0.0
15.0 0.0 + 0.0
TABLE 15
 
Effect of temperature on transglutaminase activity of PDI (15 ug/ml
Temperature Activity
CC) (mU + SEM)
37 30.3 + 1.0
45 47.2 +25
55 92.1 + 4.3
65 67.0 + 2.9
 
The data presented in these Tables demonstrate that,
surprisingly, bovine PDI was able to cross-link BPT to
dimethylcasein and that the rate of cross-linking activity was
concentration dependent (Table 13). The transglutaminase
activity of bovine PDI was Ca?*-dependent and was inhib-
ited EDTA (Tables 14). Like PHIS-PDiTG,.,, boyine PDI
had optimum transglutaminase activity at 55° C. (Table 15).
Example 18
This Example discloses a novel protein disulfide
isomerase (PDI) activity of a nemateode transglutaminase
protein of the present invention.
The protein disulfide isomerase activity of PHIS-
PDiTG,,, was determined essentially as described by Lam-
bert and Freedman (Biochem. J 213:235, 1983). Briefly,
known amounts of purified bovine liver PDI and PHIS-
PDiTG,., were incubated for 2 min. at 30° C. in 0.1 ml of
sodium-phosphate buffer (50 mM,pH 7.5) containing 10uM
DTT and 2.5 mM EDTA.10 ul of “scrambled” RNase (5
mg/ml stock, available from Sigma) was then to the above
mixture and the incubation was continued for an additional
10 min. 10 wl samples were drawn from each reaction
mixture, and added immediately to 3 ml of pre-chilled TKM
buffer (50 mM Tris HC1/25 mM KCI/5 MM MgCl,, pH 7.5)
and assayed for RNaseactivity at 30° C. in the presence of
0.25 mg yeast RNA (Sigma) by measuring the increase in
Aso for 2 min. in a Beckman DU-600 spectrophotometer.
Theresults of these assays are presented in Tables 16 and 17.
TABLE 16
 
PDI activity of PHIS-PDiTG,,.. and purified PDI from bovine liver
PDI activity* (Mean + SDProtein concentration
(ug/ml) PDI PHIS-PDiTGige
0.5 10.90 + 1.4 2.84 0.3
1.0 9.84 + 0.9 22.84 + 0.9
2.5 27.36 + 2.8 34.36 # 3.5
5.0 39.70 # 0.4 33.60 # 5.2





PDIactivity of PHIS-PDiTG,.. and purified PDI from bovine liver
Protein concentration PDIactivity* (Mean + SD 5
(ug/ml) PDI PHIS-PDiTGise,
*The PDI activity was determined as described (Lambert, N. and
Freedman, R.B., 1983, Biochem. J 213, pp. 235-243), and was expressed
as the change in A5¢, relative to A>g) min.“[AA min“*], measured using a 10




Effect_of transglutaminase inhibitors on PDI activity 15
Inhibitor PDI Activity* (Mean + SD
(1 mM) PDI PHIS-PDITGjoe
None 27.4 + 2.8 34.4 + 3.5 20
MDC 24.0 + 2.0 41.2 + 2.9
Cystamine 26.4 + 2.9 33.3 + 1.8
**The PDI activity was determined as described (Lambert, N. and
Freedman, R. B., 1983, Biochem. J. 213, pp. 235-243), and was expressed
as the change in Ay¢, relative to Asgg min.* [AA min““*], measured using
a Beckman DU-600 dual wavelength spectrophotometer. 25
PHIS-PDiTG,,.was capable of reactivating “scrambled”
RNase, and this effect was time- and dose-dependent (Table
16). However, the PDI activity of PHIS-PDiTG,,. was not
inhibited by transglutaminase inhibitors (Table 17). 30
Example 19
This Example describesultra-structural studies of molting
inhibition of D. immitis L, by the transglutaminase pseudo
substrate monodansylcadaverine (MDC). 35
As herein described, MDCata final concentration of 100
HM completely inhibits the molting of D. immitis L, to L,.
The ultra structural events in larval molting inhibition were
studied by culturing D. immitis larvae in the presence of 40
MDC and observing the effects on development. Larvae
cultured in the presence of MDC were collected every 24 hr.
for 6 days, fixed using standard procedures and embedded in
resin. Ultra-microtomesections of larvae were prepared and
then examined by electron microscopy. The L, cuticle in
untreated controls started separating from the new L,cuticle
after 24 hr. in culture and molted by 72 hr. In contrast, the
MDCtreated L, failed to show any separation between the
L, and L, cuticles. In addition, the L, cuticle and the
accompanying hypodermis were much thinner in MDC
treated worms than in controls. Finally, the MDC treated
larvae failed to molt even on day 6 whereas most of the
larvae in control cultures had molted to L, by day six.
Example 20
55
This Example describes the identification of native D.
immitis transglutaminase protein by immunoblotanalysis.
Rabbit anti-DiTG IgG was used to identify a native D.
immitis transglutaminase protein in D. immitis extracts as
follows. The material in crude extracts from D. immitis 60
larvae, adult male and female worms, and excretory-
secretory (E-S) products from larvae and adults were sepa-
rated by separating 5 ug protein per lane on a 10-well,
420% gradient Tris-glycine SDS-PAGEgelat 200 volts for
1 hour. The separated proteins were then transferred to a 65
nitrocellulose membrane by standard methods. After
transfer, the membrane was blocked in 5% (w/v) nonfat dry
52
milk for 1 hr. at 37° C. The membrane wasincubated with
rabbit anti-DiTG IgGata dilution of 1:2500 in Tris buffered
saline. After 1 hr. incubation at room temperature, the blot
was washed and antibody binding resolved using a
peroxidase-labeled goat anti-rabbit IgG secondary antibody
(available from Kirkegaard and Perry Laboratories) and the
substrate NBT/BCIP (available from Sigma). Rabbit anti-
DiTG IgG recognized a 56 kD native D. immitis protein in
D. immitis adult male, female and larval extracts. In
addition, a 57 kD D. immitis protein was identified in the
larval E-S products, but not in the adult E-S.
Example 21
This Example describes immunoblot analysis of bovine
protein disulfide isomerase using rabbit anti-DiTG IgG as
the primary antibody.
Antibodies raised against PHIS-PDiTG,,. were analyzed
for cross-reactivity with bovine PDI as follows. Bovine PDI
(100 ng) was separated by SDS-PAGEandtransferred to a
nitrocellulose filter essentially as previously described. The
nitrocellulose filter containing bovine PDI was probed with
rabbit anti-DiTG. Rabbit anti-DiTG failed to react with
bovine PDI.
Example 22
This Example describes the immuno-localization of
native antigen encoded by nDiTG,,9, by light microscopy.
Adult male and female D. immitis worms were fixed in
4% paraformaldehyde (available from Sigma) in 0.1 M
phosphate buffer, pH 7.2 overnight at 4° C. Fixed worms
were cut into 1-cm pieces, dehydrated and embedded in
paraffin. Thin sections (about 7 microns) of the worm were
then prepared using a microtome. The sections on glass
slides were de-paraffinized and dehydrated using graded
series of alcohol. The sections were then rehydrated in PBS,
andtreated for 1 hr. in 0.7% of 30% H,O, in PBScontaining
10% ethanol in order to block endogenousperoxidases. For
immuno-localization, the slides were blocked in PBS con-
taining 10% fetal calf serum (available from Sigma) and 3%
bovine serum albumin (available from Sigma) (PBS/FCS/
BSA) for 1 hr. at room temperature. The slides were then
flooded with a 1:1000 dilution of anti-DiTG IgG in PBS/
BSA,and incubated overnight at 4° C. The slides were then
rinsed thoroughly with PBS and the antibody binding
5 resolved using a peroxidase-labeled goat anti-rabbit IgG
secondary antibody, and the substrate 3',3'-
diaminobenzidine tetrahydrochloride (SigmaFast™ tablets,
available from Sigma). After color development, the slides
were dehydrated in graded series of alcohol and cleared in
9 xylene. The slides were then covered with cover slips and
observed under a Nikon MicroPhot-FXA™ microscope
(available from Nikon Corporation, Japan). Using anti-
DiTG IgG antibody, the native antigen corresponding to
nematode transglutaminase was localized mainly in the
contents and the walls of the male reproductive system. In
the females, reaction products were seen in the gut epithe-
lium and in the channels in the hypodermis. In addition,
labeling was seen in the afibrillar muscle cells in males and
in some areas of uterine walls in females.
Example 23
This Example demonstrates that D. immitis-infected cats,
D. immitis-infected dogs and immune dogs generate anti-
bodies that recognize a nematode transglutaminase protein
of the present invention.
Recombinant antigen PHIS-PDiTG,,, (100 ul/well; 1.0
ug/ml in 0.06 M carbonate buffer, pH 9.6) was incubated in
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Immulon® 2 microtiter plates (Dynatech Laboratories,
Alexandria, Va.) overnight at 4° C. Plates were blocked with
0.01 M PBS(pH 7.4) with 0.05% Tween 20 (available from
Sigma) and 5% fetal calf serum (PBS/T/FCS)for 1 hr. at 37°
C. Sera from infected and immune animals, diluted 1:25 in
PBS/T/FCS,were addedto the first row of the ELISA plates
and two-fold dilution wascarried out. After 1 hr. incubation
at 37° C., the plates were washed with PBS/T and a
peroxidase-conjugated anti-dog IgG antibody (1:5000)
(available from Sigma) was added to detect binding of the
primary antibody. After 1 hr. incubation, the plates were
washed and substrate was added (o-phenyldiamine, avail-
able from Amresco®, Solon, Ohio) with H,0,. The enzyme
reaction was stopped after 5 min. at room temperature with
4M H,SO,. Optical density (OD) was compared with a PBS
blank at 490 nm using a SpectraMax™ 250 ELISA reader




Immune dogs (n=4) (immune dogs are defined as
described in PCT Publication No. WO 94/15593, published
Jul. 21, 1994, by Grieveet al.), D., infected dog (n=8), and
infected cats (n=6) had detectable levels of IgG antibodiesto
PHIS-PDiTG,,.. In infected dogs and cats, the mean anti-
body levels were significantly higher at days 140-160 days
post infection than antibody levels earlier in the infection.
Specific antibody response to PHIS-PDiTG,,, coincided
with the onset of maturity of developing wormsin the host.
While various embodiments of the present invention have
been described in detail, it is apparent that modifications and
adaptions of those embodiments will occur to those skilled
in theart. It is to be expressly understood, however, that such
modifications and adaptations are within the scope of the




(iii) NUMBER OF SEQUENCES: 59
(2) INFORMATION FOR SEQ ID NO:1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(ix) FEATURE:
(A) NAME/KEY: Xaa = Unknown
(B) LOCATION: 18
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
Asp Gly Asp Val Met Lys Phe Thr Asp Ala Asp Phe Lys Glu Gly Ile
1 5 10
Lys Xaa Tyr Asp
20
(2) INFORMATION FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
15
Asp Gly Asp Val Met Lys Phe Thr Asp Ala Asp Phe Lys Glu Gly Ile
1 5 10
Lys Pro Tyr Asp Val Leu Leu Val Lys Phe Tyr Ala Pro
20 25
(2) INFORMATION FOR SEQ ID NO:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear






(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
Tyr Gln Tyr Asp Leu Leu Pro Met Phe Val Val Tyr Gly Lys
1 5 10
(2) INFORMATION FOR SEQ ID NO:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
Met Asp Ala Thr Ala Asn Asp Val Pro Pro Pro Phe Gln Val Gln Gly
1 5 10 15
Phe Pro Thr
(2) INFORMATION FOR SEQ ID NO:5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 707 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear




(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:
ATG AAA TTT ACA GAT GCG GAC TTC AAG GAG GGA ATT AAA CCA TAT GAT 48
Met Lys Phe Thr Asp Ala Asp Phe Lys Glu Gly Ile Lys Pro Tyr Asp
1 5 10 15
GTA TTA CTT GTG AAA TTT TAT GCA CCA TGG TGC GGA CAC TGC AAA AAG 96
Val Leu Leu Val Lys Phe Tyr Ala Pro Trp Cys Gly His Cys Lys Lys
20 25 30
ATA GCA CCA GAA TIT GAA AAA GCA GCA ACC AAA CTT TTA CAG AAT GAT 144
Ile Ala Pro Glu Phe Glu Lys Ala Ala Thr Lys Leu Leu Gln Asn Asp
35 40 45
CCG CCT ATT CAT TTA GCA GAG GTT GAC TGT ACG GAG GAG AAG AAA ACT 192
Pro Pro Ile His Leu Ala Glu Val Asp Cys Thr Glu Glu Lys Lys Thr
50 55 60
TGC GAT GAA TAC GGT GTT AGT GGC TTC CCG ACT TTG AAA ATT TIC CGT 240
Cys Asp Glu Tyr Gly Val Ser Gly Phe Pro Thr Leu Lys Ile Phe Arg
65 70 75 80
AAG GGA GAA CTA GCA CAG GAT TAT GAT GGT CCG AGA GTA GCA GAA GGT 288
Lys Gly Glu Leu Ala Gln Asp Tyr Asp Gly Pro Arg Val Ala Glu Gly
85 90 95
ATT GTG AAA TAT ATG CGT GGA CAG GCA GGT CCA TCA GCT ACA GAA ATT 336
Ile Val Lys Tyr Met Arg Gly Gln Ala Gly Pro Ser Ala Thr Glu Ile
100 105 110
AAT ACA CAA CAA GAA TTC GAA AAA ATG TTG CAA GCC GAT GAC GTT ACT 384
Asn Thr Gln Gln Glu Phe Glu Lys Met Leu Gln Ala Asp Asp Val Thr
115 120 125
ATT TGT GGA TTT TTC GAA GAG AAC AGC AAG TTA AAA GAC TCA TTC TTA 432
Ile Cys Gly Phe Phe Glu Glu Asn Ser Lys Leu Lys Asp Ser Phe Leu
130 135 140
AAA GTT GCG GAT ACA GAA AGA GAT CGT TTT AAG TTT GTG TGG ACA TCA 480
Lys Val Ala Asp Thr Glu Arg Asp Arg Phe Lys Phe Val Trp Thr Ser





































AAA CAA ATT CTG GAA TCA AGG GGA TAC AAT
Lys Gln Ile Leu Glu Ser Arg Gly Tyr Asn
165 170
CAA CCG AAG AAA TTT CAT AAT AAA TIT GAA
Gln Pro Lys Lys Phe His Asn Lys Phe Glu
180 185
GAT GGA AAT TAC GAC ACA GAC AAG ATT AAA
Asp Gly Asn Tyr Asp Thr Asp Lys Ile Lys
195 200
ACA AAT GGG CTT GIT GGT ATA CGA ACG GCC
Thr Asn Gly Leu Val Gly Ile Arg Thr Ala
210 215
GAT CTA CTT CCG ATG TTC GTC GTC TAT GGC
Asp Leu Leu Pro Met Phe Val Val Tyr Gly
230 235
INFORMATION FOR SEQ ID NO:6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 235 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:
Lys Phe Thr Asp Ala Asp Phe Lys Glu Gly
5 10
Leu Leu Val Lys Phe Tyr Ala Pro Trp Cys
20 25
Ala Pro Glu Phe Glu Lys Ala Ala Thr Lys
Pro Ile His Leu Ala Glu Val Asp Cys Thr
50 55
Asp Glu Tyr Gly Val Ser Gly Phe Pro Thr
70 75
Gly Glu Leu Ala Gln Asp Tyr Asp Gly Pro
85 90
Val Lys Tyr Met Arg Gly Gln Ala Gly Pro
100 105
Thr Gln Gln Glu Phe Glu Lys Met Leu Gln
115 120
Cys Gly Phe Phe Glu Glu Asn Ser Lys Leu
130 135
Val Ala Asp Thr Glu Arg Asp Arg Phe Lys
150 155
Lys Gln Ile Leu Glu Ser Arg Gly Tyr Asn
165 170
Gln Pro Lys Lys Phe His Asn Lys Phe Glu
180 185
Asp Gly Asn Tyr Asp Thr Asp Lys Ile Lys
195 200
Thr Asn Gly Leu Val Gly Ile Arg Thr Ala
210 215
Asp Leu Leu Pro Met Phe Val Val Tyr Gly
230 235










































































































































(A) LENGTH: 707 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:
TTGCCATAGA CGACGAACAT CGGAAGTAGA TCATACTGAT AACGGTTTTC GGCCGTTCGT 60
ATACCAACAA GCCCATTTGT TTCGTGTAGG AGAAATTCTT TAATCTTGTC TGTGTCGTAA 120
TTTCCATCAT ACTTGAATTC ATTTGGTTCA AATTTATTAT GAAATTTCTT CGGTTGATAT 180
GCGACGATAT CATCATTGTA TCCCCTTGAT TCCAGAATTT GTTTATTTGA TGTCCACACA 240
AACTTAAAAC GATCTCTTTC TGTATCCGCA ACTTTTAAGA ATGAGTCTTT TAACTTGCTG 300
TTCTCTTCGA AAAATCCACA AATAGTAACG TCATCGGCTT GCAACATTTT TTCGAATTCT 360
TGTTGTGTAT TAATTTCTGT AGCTGATGGA CCTGCCTGTC CACGCATATA TTTCACAATA 420
CCTTCTGCTA CTCTCGGACC ATCATAATCC TGTGCTAGTT CTCCCTTACG GAAAATTTTC 480
AAAGTCGGGA AGCCACTAAC ACCGTATTCA TCGCAAGTTT TCTTCTCCTC CGTACAGTCA 540
ACCTCTGCTA AATGAATAGG CGGATCATTC TGTAAAAGTT TGGTTGCTGC TTTTTCAAAT 600
TCTGGTGCTA TCTTTTTGCA GTGTCCGCAC CATGGTGCAT AAAATTTCAC AAGTAATACA 660
TCATATGGTT TAATTCCCTC CTTGAAGTCC GCATCTGTAA ATTTCAT 707
(2) INFORMATION FOR SEQ ID NO:8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 705 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:
ATGAAATTTA CAGATGCGGA CTTCAAGGAG GGAATTAAAC CATATGATGT ATTACTTGTG 60
AAATTTTATG CACCATGGTG CGGACACTGC AAAAAGATAG CACCAGAATT TGAAAAAGCA 120
GCAACCAAAC TTTTACAGAA TGATCCGCCT ATTCATTTAG CAGAGGTTGA CTGTACGGAG 180
GAGAAGAAAA CTTGCGATGA ATACGGTGTT AGTGGCTTCC CGACTTTGAA AATTTTCCGT 240
AAGGGAGAAC TAGCACAGGA TTATGATGGT CCGAGAGTAG CAGAAGGTAT TGTGAAATAT 300
ATGCGTGGAC AGGCAGGTCC ATCAGCTACA GAAATTAATA CACAACAAGA ATTCGAAAAA 360
ATGTTGCAAG CCGATGACGT TACTATTTGT GGATTTTTCG AAGAGAACAG CAAGTTAAAA 420
GACTCATTCT TAAAAGTTGC GGATACAGAA AGAGATCGTT TTAAGTTTGT GTGGACATCA 480
AATAAACAAA TICTGGAATC AAGGGGATAC AATGATGATA TCGTCGCATA TCAACCGAAG 540
AAATTTCATA ATAAATTTGA ACCAAATGAA TTCAAGTATG ATGGAAATTA CGACACAGAC 600
AAGATTAAAG AATTTCTCCT ACACGAAACA AATGGGCTTG TTIGGTATACG AACGGCCGAA 660
AACCGTTATC AGTATGATCT ACTTCCGATG TTCGTCGTCT ATGGC 705
(2) INFORMATION FOR SEQ ID NO:9:
(i) SEQUENCE CHARACTERISTICS:
705 nucleotides








(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:
GCCATAGACG ACGAACATCG GAAGTAGATC ATACTGATAA CGGTTTTCGG CCGTTCGTAT 60
ACCAACAAGC CCATTTGTTT CGTGTAGGAG AAATTCTTTA ATCTTGTCTG TGTCGTAATT 120
TCCATCATAC TTGAATTCAT TTGGTTCAAA TTTATTATGA AATTTCTTCG GTTGATATGC 180
GACGATATCA TCATTGTATC CCCTTGATTC CAGAATTTGT TTATTTGATG TCCACACAAA 240
CTTAAAACGA TCTCTTTCTG TATCCGCAAC TTTTAAGAAT GAGTCTTTTA ACTTGCTGTT 300
CTCTTCGAAA AATCCACAAA TAGTAACGTC ATCGGCTTGC AACATTTTTT CGAATTCTTG 360
TIGTGTATTA ATTTCTGTAG CTGATGGACC TGCCTGTCCA CGCATATATT TCACAATACC 420
TTICTGCTACT CTCGGACCAT CATAATCCTG TGCTAGTTCT CCCTTACGGA AAATTTTCAA 480
AGTCGGGAAG CCACTAACAC CGTATTCATC GCAAGTTTTC TTICTCCTCCG TACAGTCAAC 540
CTCTGCTAAA TGAATAGGCG GATCATTCTG TAAAAGTTTG GTTGCTGCTT TTTCAAATTC 600
TGGTGCTATC TITTTGCAGT GTCCGCACCA TGGTGCATAA AATTTCACAA GTAATACATC 660
ATATGGTTTA ATTCCCTCCT TGAAGTCCGC ATCTGTAAAT TTCAT 705
(2) INFORMATION FOR SEQ ID NO:10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1472 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear




(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:
T ATG CGT GGA CAG GCA GGT CCA TCA GCT ACA GAA ATT AAT ACA CAA CAA 49
Met Arg Gly Gln Ala Gly Pro Ser Ala Thr Glu Ile Asn Thr Gln Gln
1 5 10 15
GAA TTC GAA AAA ATG TTG CAA GCC GAT GAC GTT ACT ATT TGT GGA TIT 97
Glu Phe Glu Lys Met Leu Gln Ala Asp Asp Val Thr Ile Cys Gly Phe
20 25 30
TTC GAA GAG AAC AGC AAG TTA AAA GAC TCA TTC TTA AAA GTT GCG GAT 145
Phe Glu Glu Asn Ser Lys Leu Lys Asp Ser Phe Leu Lys Val Ala Asp
35 40 45
ACA GAA AGA GAT CGT TTT AAG TTT GTG TGG ACA TCA AAT AAA CAA ATT 193
Thr Glu Arg Asp Arg Phe Lys Phe Val Trp Thr Ser Asn Lys Gln Ile
50 55 60
CTG GAA TCA AGG GGA TAC AAT GAT GAT ATC GTC GCA TAT CAA CCG AAG 241
Leu Glu Ser Arg Gly Tyr Asn Asp Asp Ile Val Ala Tyr Gln Pro Lys
65 70 75 80
AAA TTT CAT AAT AAA TTT GAA CCA AAT GAA TTC AAG TAT GAT GGA AAT 289
Lys Phe His Asn Lys Phe Glu Pro Asn Glu Phe Lys Tyr Asp Gly Asn
85 90 95
TAC GAC ACA GAC AAG ATT AAA GAA TIT CTC CTA CAC GAA ACA AAT GGG 337
Tyr Asp Thr Asp Lys Ile Lys Glu Phe Leu Leu His Glu Thr Asn Gly
100 105 110
CTT GTT GGT ATA CGA ACG GCC GAA AAC CGT TAT CAG TAT GAT CTA CTT 385





CCG ATG TIT GTT GTG TAT GGC AAG GTT GAC TAT GAA TTG GAT CCA AAA 433
Pro Met Phe Val Val Tyr Gly Lys Val Asp Tyr Glu Leu Asp Pro Lys
130 135 140
GGT TCC AAC TAT TGG CGA AAT CGT GTT CTT ATG GTT GCA AAA GAT TAC 481
Gly Ser Asn Tyr Trp Arg Asn Arg Val Leu Met Val Ala Lys Asp Tyr
145 150 155 160
AAA AGG AAA GCA AAT TIT GCT ATG AGT AAC AAA GAA GAC TTC TCT TIT 529
Lys Arg Lys Ala Asn Phe Ala Met Ser Asn Lys Glu Asp Phe Ser Phe
165 170 175
GAT CTT GAT GAA TTT GGC TTA GCT AAT CGT AAA GAT ACC AAG CCG CTT 577
Asp Leu Asp Glu Phe Gly Leu Ala Asn Arg Lys Asp Thr Lys Pro Leu
180 185 190
GTT GCA GCA CGT AGC AAA AAA GGC AAA TTC TIT ATG AAA GAA GAA TTC 625
Val Ala Ala Arg Ser Lys Lys Gly Lys Phe Phe Met Lys Glu Glu Phe
195 200 205
AGT TTT AGC GTG GAA AAT TTG AAA AAA TTT GTC GAA GAT GTT ATT GGT 673
Ser Phe Ser Val Glu Asn Leu Lys Lys Phe Val Glu Asp Val Ile Gly
210 215 220
GAT AGA TTA GAA CCG TAT ATG AAG AGC GAA GAA GCA CCT GAA GAT CAG 721
Asp Arg Leu Glu Pro Tyr Met Lys Ser Glu Glu Ala Pro Glu Asp Gln
225 230 235 240
GGT GAT GTT AAG GTC GTT GTT GCT AAG ACA TIC CAA GAA ATG ATC ATG 769
Gly Asp Val Lys Val Val Val Ala Lys Thr Phe Gln Glu Met Ile Met
245 250 255
AAT GTG GAA AAG GAT GTT TTA ATC GAA TTT TAT GCT CCA TGG TGT GGC 817
Asn Val Glu Lys Asp Val Leu Ile Glu Phe Tyr Ala Pro Trp Cys Gly
260 265 270
CAC TGC AAA GCA CTC GCA CCG AAA TAT GAT GAA TTA GGC CAG AAA TTA 865
His Cys Lys Ala Leu Ala Pro Lys Tyr Asp Glu Leu Gly Gln Lys Leu
275 280 285
TCC GGT GAA CCA GGT GTT GTT ATT GCA AAA ATG GAC GCA ACA GCG AAT 913
Ser Gly Glu Pro Gly Val Val Ile Ala Lys Met Asp Ala Thr Ala Asn
290 295 300
GAT GTC CCA CCA CCA TTC CAA GTA CAA GGA TIT CCA ACT CTT TAC TGG 961
Asp Val Pro Pro Pro Phe Gln Val Gln Gly Phe Pro Thr Leu Tyr Trp
305 310 315 320
GTA CCG AAG AAT AAA AAA GAC AAA CCA GAG CCA TAC TCT GGT GGT CGA 1009
Val Pro Lys Asn Lys Lys Asp Lys Pro Glu Pro Tyr Ser Gly Gly Arg
325 330 335
GAA GTG GAT GAT TTT ATT AAA TAC ATC GCG AAG CAT GCA ACG GAA GAA 1057
Glu Val Asp Asp Phe Ile Lys Tyr Ile Ala Lys His Ala Thr Glu Glu
340 345 350
CTG AAG GGA TAC AAG AGA GAT GGA AAA CCG AAG AAG AAG GAA GAA TTG 1105
Leu Lys Gly Tyr Lys Arg Asp Gly Lys Pro Lys Lys Lys Glu Glu Leu
355 360 365
TAAAGGGTAA TAATGATGAA TTTTTAATTT GATGTGAACC CAAACAACCT CAGTTGCTTA 1165
TTGGTGGATA AATATTTAAA TCATTCCACA GAGCTGTGAT ATGAATTTTC AAATATGTTT 1225
TTTTTTGGTT TATTTTGATA AATTCATATT TTAAGTTGTT ATTTTTTAGT GCCTTAGGCT 1285
GTTTCATCAG TTGCCTTAGG CTATTTTGTC AGTTCGGAAT GTTTATTCCG TTAGCTTAGG 1345
CTTTTTTTTG TTITACCTTAT GTTACTGTTG TTATTGTATT ACTATTTTGC CCTTIGTTTTT 1405
TAAATTTTAA ATAAATTTTT TTTGGAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 1465
AAAAAAA 1472
(2) INFORMATION FOR SEQ ID NO:11:
(i) SEQUENCE CHARACTERISTICS:





(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:
Met Arg Gly Gln Ala Gly Pro Ser Ala Thr Glu Ile Asn Thr Gln Gln
1 5 10 15
Glu Phe Glu Lys Met Leu Gln Ala Asp Asp Val Thr Ile Cys Gly Phe
20 25 30
Phe Glu Glu Asn Ser Lys Leu Lys Asp Ser Phe Leu Lys Val Ala Asp
35 40 45
Thr Glu Arg Asp Arg Phe Lys Phe Val Trp Thr Ser Asn Lys Gln Ile
Leu Glu Ser Arg Gly Tyr Asn Asp Asp Ile Val Ala Tyr Gln Pro Lys
65 70 75 80
Lys Phe His Asn Lys Phe Glu Pro Asn Glu Phe Lys Tyr Asp Gly Asn
85 90 95
Tyr Asp Thr Asp Lys Ile Lys Glu Phe Leu Leu His Glu Thr Asn Gly
100 105 110
Leu Val Gly Ile Arg Thr Ala Glu Asn Arg Tyr Gln Tyr Asp Leu Leu
115 120 125
Pro Met Phe Val Val Tyr Gly Lys Val Asp Tyr Glu Leu Asp Pro Lys
130 135 140
Gly Ser Asn Tyr Trp Arg Asn Arg Val Leu Met Val Ala Lys Asp Tyr
145 150 155 160
Lys Arg Lys Ala Asn Phe Ala Met Ser Asn Lys Glu Asp Phe Ser Phe
165 170 175
Asp Leu Asp Glu Phe Gly Leu Ala Asn Arg Lys Asp Thr Lys Pro Leu
180 185 190
Val Ala Ala Arg Ser Lys Lys Gly Lys Phe Phe Met Lys Glu Glu Phe
195 200 205
Ser Phe Ser Val Glu Asn Leu Lys Lys Phe Val Glu Asp Val Ile Gly
210 215 220
Asp Arg Leu Glu Pro Tyr Met Lys Ser Glu Glu Ala Pro Glu Asp Gln
225 230 235 240
Gly Asp Val Lys Val Val Val Ala Lys Thr Phe Gln Glu Met Ile Met
245 250 255
Asn Val Glu Lys Asp Val Leu Ile Glu Phe Tyr Ala Pro Trp Cys Gly
260 265 270
His Cys Lys Ala Leu Ala Pro Lys Tyr Asp Glu Leu Gly Gln Lys Leu
275 280 285
Ser Gly Glu Pro Gly Val Val Ile Ala Lys Met Asp Ala Thr Ala Asn
290 295 300
Asp Val Pro Pro Pro Phe Gln Val Gln Gly Phe Pro Thr Leu Tyr Trp
305 310 315 320
Val Pro Lys Asn Lys Lys Asp Lys Pro Glu Pro Tyr Ser Gly Gly Arg
325 330 335
Glu Val Asp Asp Phe Ile Lys Tyr Ile Ala Lys His Ala Thr Glu Glu
340 345 350
Leu Lys Gly Tyr Lys Arg Asp Gly Lys Pro Lys Lys Lys Glu Glu Leu
355 360 365







(A) LENGTH: 1472 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:
TTITTTTITTIT TITTTTTTTT TITTTTTTTT TITTTITTTTT TICCAAAAAA AATTTATTTA 60
AAATTTAAAA AACAAGGGCA AAATAGTAAT ACAATAACAA CAGTAACATA AGGTAAACAA 120
AAAAAAGCCT AAGCTAACGG AATAAACATT CCGAACTGAC AAAATAGCCT AAGGCAACTG 180
ATGAAACAGC CTAAGGCACT AAAAAATAAC AACTTAAAAT ATGAATTTAT CAAAATAAAC 240
CAAAAAAAAA CATATTTGAA AATTCATATC ACAGCTCTGT GGAATGATTT AAATATTTAT 300
CCACCAATAA GCAACTGAGG TIGTTTGGGT TCACATCAAA TTAAAAATTC ATCATTATTA 360
CCCTTTACAA TTCTTCCTTC TICTTCGGTT TTCCATCTCT CTTGTATCCC TICAGTTCTT 420
CCGTTGCATG CTTCGCGATG TATTTAATAA AATCATCCAC TTCTCGACCA CCAGAGTATG 480
GCTCTGGTTT GTCTTTTTTA TTCTTCGGTA CCCAGTAAAG AGTTGGAAAT CCTTGTACTT 540
GGAATGGTGG TGGGACATCA TTCGCTGTTG CGTCCATTTT TGCAATAACA AAACCTGGTT 600
CACCGGATAA TTTCTGGCCT AATTCATCAT ATTTCGGTGC GAGTGCTTTG CAGTGGCCAC 660
ACCATGGAGC ATAAAATTCG ATTAAAACAT CCTTTTCCAC ATTCATGATC ATTTCTTGGA 720
ATGTCTTAGC AACAACGACC TTAACATCAC CCTGATCTTC AGGTGCTTCT TCGCTCTTCA 780
TATACGGTTC TAATCTATCA CCAATAACAT CTTCGACAAA TTTTTTCAAA TTTTCCACGC 840
TAAAACTGAA TTCTTCTTTC ATAAAGAATT TGCCTTTTTIT GCTACGTGCT GCAACAAGCG 900
GCTTGGTATC TTTACGATTA GCTAAGCCAA ATTCATCAAG ATCAAAAGAG AAGTCTTCTT 960
TGTTACTCAT AGCAAAATTT GCTTTCCTTT TGTAATCTTT TGCAACCATA AGAACACGAT 1020
TTCGCCAATA GTTGGAACCT TTTGGATCCA ATTCATAGTC AACCTTGCCA TACACAACAA 1080
ACATCGGAAG TAGATCATAC TGATAACGGT TTTCGGCCGT TCGTATACCA ACAAGCCCAT 1140
TIGTTTCGTG TAGGAGAAAT TCTTTAATCT TGTCTGTGTC GTAATTTCCA TCATACTTGA 1200
ATTCATTTGG TTCAAATTTA TTATGAAATT TCTTCGGTTG ATATGCGACG ATATCATCAT 1260
TGTATCCCCT TGATTCCAGA ATTTGTTTAT TTGATGTCCA CACAAACTTA AAACGATCTC 1320
TTTCTGTATC CGCAACTTTT AAGAATGAGT CTTTTAACTT GCTGTTCTCT TCGAAAAATC 1380
CACAAATAGT AACGTCATCG GCTTGCAACA TTITTTTCGAA TTCTTGTTGT GTATTAATTT 1440
CTGTAGCTGA TGGACCTGCC TGTCCACGCA TA 1472
(2) INFORMATION FOR SEQ ID NO:13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1107 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:
ATGCGTGGAC AGGCAGGTCC ATCAGCTACA GAAATTAATA CACAACAAGA ATTCGAAAAA 60
ATGTTGCAAG CCGATGACGT TACTATTTGT GGATTTTTCG AAGAGAACAG CAAGTTAAAA 120





AATAAACAAA TICTGGAATC AAGGGGATAC AATGATGATA TCGTCGCATA TCAACCGAAG 240
AAATTTCATA ATAAATTTGA ACCAAATGAA TTCAAGTATG ATGGAAATTA CGACACAGAC 300
AAGATTAAAG AATTTCTCCT ACACGAAACA AATGGGCTTG TTIGGTATACG AACGGCCGAA 360
AACCGTTATC AGTATGATCT ACTTCCGATG TTTGTTGTGT ATGGCAAGGT TGACTATGAA 420
TTGGATCCAA AAGGTTCCAA CTATTGGCGA AATCGTGTTC TTATGGTTGC AAAAGATTAC 480
AAAAGGAAAG CAAATTTTGC TATGAGTAAC AAAGAAGACT TCTCTTTTGA TCTTGATGAA 540
TTTGGCTTAG CTAATCGTAA AGATACCAAG CCGCTTGTTG CAGCACGTAG CAAAAAAGGC 600
AAATTCTTTA TGAAAGAAGA ATTCAGTTTT AGCGTGGAAA ATTTGAAAAA ATTTGTCGAA 660
GATGTTATTG GTGATAGATT AGAACCGTAT ATGAAGAGCG AAGAAGCACC TGAAGATCAG 720
GGTGATGTTA AGGTCGTTGT TGCTAAGACA TTCCAAGAAA TGATCATGAA TGTGGAAAAG 780
GATGTTTTAA TCGAATTTTA TGCTCCATGG TGTGGCCACT GCAAAGCACT CGCACCGAAA 840
TATGATGAAT TAGGCCAGAA ATTATCCGGT GAACCAGGTG TTIGTTATTGC AAAAATGGAC 900
GCAACAGCGA ATGATGTCCC ACCACCATTC CAAGTACAAG GATTTCCAAC TCTTTACTGG 960
GTACCGAAGA ATAAAAAAGA CAAACCAGAG CCATACTCTG GTGGTCGAGA AGTGGATGAT 1020
TTTATTAAAT ACATCGCGAA GCATGCAACG GAAGAACTGA AGGGATACAA GAGAGATGGA 1080
AAACCGAAGA AGAAGGAAGA ATTGTAA 1107
(2) INFORMATION FOR SEQ ID NO:14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1107 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:
TTACAATTCT TCCTTCTTCT TCGGTTTTCC ATCTCTCTTG TATCCCTTCA GTTCTTCCGT 60
TGCATGCTTC GCGATGTATT TAATAAAATC ATCCACTTCT CGACCACCAG AGTATGGCTC 120
TGGTTTGTCT TITTTATTCT TCGGTACCCA GTAAAGAGTT GGAAATCCTT GTACTTGGAA 180
TGGTGGTGGG ACATCATTCG CTGTTGCGTC CATTTTTGCA ATAACAACAC CTGGTTCACC 240
GGATAATTTC TGGCCTAATT CATCATATTT CGGTGCGAGT GCTTTGCAGT GGCCACACCA 300
TGGAGCATAA AATTCGATTA AAACATCCTT TTCCACATTC ATGATCATTT CTTGGAATGT 360
CTTAGCAACA ACGACCTTAA CATCACCCTG ATCTTCAGGT GCTTCTTCGC TCTTCATATA 420
CGGTTCTAAT CTATCACCAA TAACATCTTC GACAAATTTT TTCAAATTTT CCACGCTAAA 480
ACTGAATTCT TCTTTCATAA AGAATTTGCC TITTTTGCTA CGTGCTGCAA CAAGCGGCTT 540
GGTATCTTTA CGATTAGCTA AGCCAAATTC ATCAAGATCA AAAGAGAAGT CTTCTTTGTT 600
ACTCATAGCA AAATTTGCTT TCCTTTTGTA ATCTTTTGCA ACCATAAGAA CACGATTTCG 660
CCAATAGTTG GAACCTTTTG GATCCAATTC ATAGTCAACC TTGCCATACA CAACAAACAT 720
CGGAAGTAGA TCATACTGAT AACGGTTTTC GGCCGTTCGT ATACCAACAA GCCCATTTGT 780
TTCGTGTAGG AGAAATTCTT TAATCTTGTC TGTGTCGTAA TTTCCATCAT ACTTGAATTC 840
ATTTGGTTCA AATTTATTAT GAAATTTCTT CGGTTGATAT GCGACGATAT CATCATTGTA 900
TCCCCTTGAT TCCAGAATTT GTTTATTTGA TGTCCACACA AACTTAAAAC GATCTCTTTC 960






AATAGTAACG TCATCGGCTT GCAACATTTT TTICGAATTCT TGTTGTGTAT TAATTTCTGT
AGCTGATGGA CCTGCCTGTC CACGCAT
(2) INFORMATION FOR SEQ ID NO:15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: primer
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:
ATGAARTTYA CNGAYGCNGA YTTYAARGAR GG
(2) INFORMATION FOR SEQ ID NO:16:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 bases
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: primer
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:
TTINCCRTANA CNACRAACAT
(2) INFORMATION FOR SEQ ID NO:17:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 bases
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: primer
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:
AATTAACCCT CACTAAAGGG
(2) INFORMATION FOR SEQ ID NO:18:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 bases
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: primer
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:
GTAATACGAC TCACTATAGG GC
(2) INFORMATION FOR SEQ ID NO:19:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 bases
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: primer













(2) INFORMATION FOR SEQ ID NO:20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 bases
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: primer
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:
CTGTGGAATG ATTTAAATAT TTATCC 26
(2) INFORMATION FOR SEQ ID NO:21:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 bases
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: primer
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:
GTCCATTTTT GCAATAACAA CACC 24
(2) INFORMATION FOR SEQ ID NO:22:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: primer
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:
GGTTTAATTA CCCAAGTTTG AG 22
(2) INFORMATION FOR SEQ ID NO:23:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: primer
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:
TCCCTCCTTG AAGTCCGCAT CTGTAAATTT CAT 33
(2) INFORMATION FOR SEQ ID NO:24:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: primer
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:
CCGAGCTCGA GAATGAAATT TACAGATGCG GAC 33







(A) LENGTH: 42 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: primer
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:
CAGCCAAGCT TCTTACAATT CTTCCTICTT CTTCGGTTTT Cc 42
(2) INFORMATION FOR SEQ ID NO:26:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: primer
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:
GCTGATGGAC CTGCCTGTCC ACGC 24
(2) INFORMATION FOR SEQ ID NO:27:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 143 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear




(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:
GGTTTAATTA CCCAAGTTTG AGG ATG ACA CTG GTG AGG TTG TIT 44
Met Thr Leu Val Arg Leu Phe
1 5
GAT GCT TCG ATT TTT AAA TTA TTC TTG TTT CTG ATA TTG CCA 86
Asp Ala Ser Ile Phe Lys Leu Phe Leu Phe Leu Ile Leu Pro
10 15 20
TTA ACG AAT GCC GAT GGC GAT GTG ATG AAA TIT ACA GAT GCG 128
Leu Thr Asn Ala Asp Gly Asp Val Met Lys Phe Thr Asp Ala
25 30 35
GAC TTC AAG GAG GGA 143
Asp Phe Lys Glu Gly
40
(2) INFORMATION FOR SEQ ID NO:28:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 40 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:
Met Thr Leu Val Arg Leu Phe Asp Ala
1 5
Phe Leu Phe Leu Ile Leu Pro Leu Thr
15 20
Val Met Lys Phe Thr Asp Ala Asp Phe
30 35
Ser Ile Phe Lys Leu
10








(2) INFORMATION FOR SEQ ID NO:29:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 143 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:
TCCCTCCTTG AAGTCCGCAT CTGTAAATTT CATCACATCG CCATCGGCAT 50
TCGTTAATGG CAATATCAGA AACAAGAATA ATTTAAAAAT CGAAGCATCA 100
AACAACCTCA CCAGTGTCAT CCTCAAACTT GGGTAATTAA ACC 143
(2) INFORMATION FOR SEQ ID NO:30:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 120 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:
ATGACACTGG TGAGGTTGTT TGATGCTTCG ATTTTTAAAT TATTCTTGTT 50
TCTGATATTG CCATTAACGA ATGCCGATGG CGATGTGATG AAATTTACAG 100
ATGCGGACTT CAAGGAGGGA 120
(2) INFORMATION FOR SEQ ID NO:31:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 120 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:
TCCCTCCTTG AAGTCCGCAT CTGTAAATTT CATCACATCG CCATCGGCAT 50
TCGTTAATGG CAATATCAGA AACAAGAATA ATTTAAAAAT CGAAGCATCA 100
AACAACCTCA CCAGTGTCAT 120
(2) INFORMATION FOR SEQ ID NO:32:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1407 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear




(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:
ATG AAA TTT ACA GAT GCG GAC TTC AAG GAG GGA ATT AAA CCA 42











































































































































































































































































































































































































































































































































































































































GCA CGT AGC AAA AAA GGC AAA TTC TIT ATG AAA GAA GAA TTC 924
Ala Arg Ser Lys Lys Gly Lys Phe Phe Met Lys Glu Glu Phe
295 300 305
AGT TTT AGC GTG GAA AAT TTG AAA AAA TTT GTC GAA GAT GTT 966
Ser Phe Ser Val Glu Asn Leu Lys Lys Phe Val Glu Asp Val
310 315 320
ATT GGT GAT AGA TTA GAA CCG TAT ATG AAG AGC GAA GAA GCA 1008
Ile Gly Asp Arg Leu Glu Pro Tyr Met Lys Ser Glu Glu Ala
325 330 335
CCT GAA GAT CAG GGT GAT GTT AAG GTC GTT GTT GCT AAG ACA 1050
Pro Glu Asp Gln Gly Asp Val Lys Val Val Val Ala Lys Thr
340 345 350
TTC CAA GAA ATG ATC ATG AAT GTG GAA AAG GAT GTT TTA ATC 1092
Phe Gln Glu Met Ile Met Asn Val Glu Lys Asp Val Leu Ile
355 360
GAA TTT TAT GCT CCA TGG TGT GGC CAC TGC AAA GCA CTC GCA 1134
Glu Phe Tyr Ala Pro Trp Cys Gly His Cys Lys Ala Leu Ala
365 370 375
CCG AAA TAT GAT GAA TTA GGC CAG AAA TTA TCC GGT GAA CCA 1176
Pro Lys Tyr Asp Glu Leu Gly Gln Lys Leu Ser Gly Glu Pro
380 385 390
GGT GTT GTT ATT GCA AAA ATG GAC GCA ACA GCG AAT GAT GTC 1218
Gly Val Val Ile Ala Lys Met Asp Ala Thr Ala Asn Asp Val
395 400 405
CCA CCA CCA TTC CAA GTA CAA GGA TTT CCA ACT CTT TAC TGG 1260
Pro Pro Pro Phe Gln Val Gln Gly Phe Pro Thr Leu Tyr Trp
410 415 420
GTA CCG AAG AAT AAA AAA GAC AAA CCA GAG CCA TAC TCT GGT 1302
Val Pro Lys Asn Lys Lys Asp Lys Pro Glu Pro Tyr Ser Gly
425 430
GGT CGA GAA GTG GAT GAT TTT ATT AAA TAC ATC GCG AAG CAT 1344
Gly Arg Glu Val Asp Asp Phe Ile Lys Tyr Ile Ala Lys His
435 440 445
GCA ACG GAA GAA CTG AAG GGA TAC AAG AGA GAT GGA AAA CCG 1386
Ala Thr Glu Glu Leu Lys Gly Tyr Lys Arg Asp Gly Lys Pro
450 455 460
AAG AAG AAG GAA GAA TTG TAA 1407
Lys Lys Lys Glu Glu Leu
465
(2) INFORMATION FOR SEQ ID NO:33:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 468 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:
Met Lys Phe Thr Asp Ala Asp Phe Lys Glu Gly Ile Lys Pro
1 5 10
Tyr Asp Val Leu Leu Val Lys Phe Tyr Ala Pro Trp Cys Gly
15 20 25
His Cys Lys Lys Ile Ala Pro Glu Phe Glu Lys Ala Ala Thr
30 35 40
Lys Leu Leu Gln Asn Asp Pro Pro Ile His Leu Ala Glu Val
45 50 55






Ser Gly Phe Pro Thr Leu Lys Ile Phe Arg Lys Gly Glu Leu
75 80
Ala Gln Asp Tyr Asp Gly Pro Arg Val Ala Glu Gly Ile Val
Lys Tyr Met Arg Gly Gln Ala Gly Pro Ser Ala Thr Glu Ile
100 105 110
Asn Thr Gln Gln Glu Phe Glu Lys Met Leu Gln Ala Asp Asp
115 120 125
Val Thr Ile Cys Gly Phe Phe Glu Glu Asn Ser Lys Leu Lys
130 135 140
Asp Ser Phe Leu Lys Val Ala Asp Thr Glu Arg Asp Arg Phe
145 150
Lys Phe Val Trp Thr Ser Asn Lys Gln Ile Leu Glu Ser Arg
155 160 165
Gly Tyr Asn Asp Asp Ile Val Ala Tyr Gln Pro Lys Lys Phe
170 175 180
His Asn Lys Phe Glu Pro Asn Glu Phe Lys Tyr Asp Gly Asn
185 190 195
Tyr Asp Thr Asp Lys Ile Lys Glu Phe Leu Leu His Glu Thr
200 205 210
Asn Gly Leu Val Gly Ile Arg Thr Ala Glu Asn Arg Tyr Gln
215 220
Tyr Asp Leu Leu Pro Met Phe Val Val Tyr Gly Lys Val Asp
225 230 235
Tyr Glu Leu Asp Pro Lys Gly Ser Asn Tyr Trp Arg Asn Arg
240 245 250
Val Leu Met Val Ala Lys Asp Tyr Lys Arg Lys Ala Asn Phe
255 260 265
Ala Met Ser Asn Lys Glu Asp Phe Ser Phe Asp Leu Asp Glu
270 275 280
Phe Gly Leu Ala Asn Arg Lys Asp Thr Lys Pro Leu Val Ala
285 290
Ala Arg Ser Lys Lys Gly Lys Phe Phe Met Lys Glu Glu Phe
295 300 305
Ser Phe Ser Val Glu Asn Leu Lys Lys Phe Val Glu Asp Val
310 315 320
Ile Gly Asp Arg Leu Glu Pro Tyr Met Lys Ser Glu Glu Ala
325 330 335
Pro Glu Asp Gln Gly Asp Val Lys Val Val Val Ala Lys Thr
340 345 350
Phe Gln Glu Met Ile Met Asn Val Glu Lys Asp Val Leu Ile
355 360
Glu Phe Tyr Ala Pro Trp Cys Gly His Cys Lys Ala Leu Ala
365 370 375
Pro Lys Tyr Asp Glu Leu Gly Gln Lys Leu Ser Gly Glu Pro
380 385 390
Gly Val Val Ile Ala Lys Met Asp Ala Thr Ala Asn Asp Val
395 400 405
Pro Pro Pro Phe Gln Val Gln Gly Phe Pro Thr Leu Tyr Trp
410 415 420







Gly Arg Glu Val Asp Asp Phe Ile Lys Tyr Ile Ala Lys His
435 440 445
Ala Thr Glu Glu Leu Lys Gly Tyr Lys Arg Asp Gly Lys Pro
450 455 460
Lys Lys Lys Glu Glu Leu
465
(2) INFORMATION FOR SEQ ID NO:34:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1407 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:
TTACAATTCT TCCTTCTTCT TCGGTTTTCC ATCTCTCTTG TATCCCTTICA
GTTCTTCCGT TGCATGCTTC GCGATGTATT TAATAAAATC ATCCACTTCT
CGACCACCAG AGTATGGCTC TGGTTTGTCT TITTTATTCT TCGGTACCCA
GTAAAGAGTT GGAAATCCTT GTACTTGGAA TGGTGGTGGG ACATCATTCG
CTGTTGCGTC CATTTTTGCA ATAACAACAC CTGGTTCACC GGATAATTTC
TGGCCTAATT CATCATATTT CGGTGCGAGT GCTTTGCAGT GGCCACACCA
TGGAGCATAA AATTCGATTA AAACATCCTT TTCCACATTC ATGATCATTT
CTTGGAATGT CTTAGCAACA ACGACCTTAA CATCACCCTG ATCTTCAGGT
GCTTCTTCGC TCTTCATATA CGGTTCTAAT CTATCACCAA TAACATCTTC
GACAAATTTT TTCAAATTTT CCACGCTAAA ACTGAATTCT TCTTTCATAA
AGAATTTGCC TITTTTGCTA CGTGCTGCAA CAAGCGGCTT GGTATCTTTA
CGATTAGCTA AGCCAAATTC ATCAAGATCA AAAGAGAAGT CTTCTTTGTT
ACTCATAGCA AAATTTGCTT TCCTTTTGTA ATCTTTTGCA ACCATAAGAA
CACGATTTCG CCAATAGTTG GAACCTTTTG GATCCAATTC ATAGTCAACC
TTGCCATAGA CGACGAACAT CGGAAGTAGA TCATACTGAT AACGGTTTTC
GGCCGTTCGT ATACCAACAA GCCCATTTGT TTCGTGTAGG AGAAATTCTT
TAATCTTGTC TGTGTCGTAA TTTCCATCAT ACTTGAATTC ATTTGGTTCA
AATTTATTAT GAAATTTCTT CGGTTGATAT GCGACGATAT CATCATTGTA
TCCCCTTGAT TCCAGAATTT GTTTATTTGA TGTCCACACA AACTTAAAAC
GATCTCTTTC TGTATCCGCA ACTTTTAAGA ATGAGTCTTT TAACTTGCTG
TTCTCTTCGA AAAATCCACA AATAGTAACG TCATCGGCTT GCAACATTTT
TTCGAATTCT TGTTGTGTAT TAATTTCTGT AGCTGATGGA CCTGCCTGTC
CACGCATATA TTTCACAATA CCTTCTGCTA CTCTCGGACC ATCATAATCC
TGTGCTAGTT CTCCCTTACG GAAAATTTTC AAAGTCGGGA AGCCACTAAC
ACCGTATTCA TCGCAAGTTT TCTTCTCCTC CGTACAGTCA ACCTCTGCTA
AATGAATAGG CGGATCATTC TGTAAAAGTT TGGTTGCTGC TTTTTCAAAT
TCTGGTGCTA TCTTTTTGCA GTGTCCGCAC CATGGTGCAT AAAATTTCAC



































(2) INFORMATION FOR SEQ ID NO:35:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 440 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear




(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:
GGTTTAATTA CCCAAGTTTG AGG ATG GCG CAG TTG AGG CTG TIT 44
Met Ala Gln Leu Arg Leu Phe
1 5
AAT CAT GCT TCG GTT TTG AAT TTA TTC TTA TTA CTG GTA TTG 86
Asn His Ala Ser Val Leu Asn Leu Phe Leu Leu Leu Val Leu
10 15 20
CCG GTA GCA AAT GGC GAT GGT GAT GTG ATG AAA TTC ACA GAT 128
Pro Val Ala Asn Gly Asp Gly Asp Val Met Lys Phe Thr Asp
25 30 35
GCT GAT TTT AAG GAA GGA ATC AAA TCA TAT GAT GTA TTA CTT 170
Ala Asp Phe Lys Glu Gly Ile Lys Ser Tyr Asp Val Leu Leu
40 45
GTG AAA TIT TAT GCA CCA TGG TGT GGG CAC TGC AAG AAA CTG 212
Val Lys Phe Tyr Ala Pro Trp Cys Gly His Cys Lys Lys Leu
50 55 60
GCC CCA GAA TTT GAG AAG GCA GCA ACA AAA CTT TTA CAA AAT 254
Ala Pro Glu Phe Glu Lys Ala Ala Thr Lys Leu Leu Gln Asn
65 70 75
GAT CCA CCT ATT CAT TTA GCA GAT GTC GAT TGC ACA GAG GAA 296
Asp Pro Pro Ile His Leu Ala Asp Val Asp Cys Thr Glu Glu
80 85 90
AAG AAA ATT TGC GAT GAA TTC AGT GTT AGT GGT TTT CCG ACT 338
Lys Lys Ile Cys Asp Glu Phe Ser Val Ser Gly Phe Pro Thr
95 100 105
TTA AAA ATT TTC CGT AAG GGT GAA CTG GCT CAG GAT TAT GAT 380
Leu Lys Ile Phe Arg Lys Gly Glu Leu Ala Gln Asp Tyr Asp
110 115
GGC CCA CGA GTT GCA GAA GGT ATT GTT AAA TAT ATG CGT GGA 422
Gly Pro Arg Val Ala Glu Gly Ile Val Lys Tyr Met Arg Gly
120 125 130
CAG GCA GGT CCA TCA GCT 440
Gln Ala Gly Pro Ser Ala
135
(2) INFORMATION FOR SEQ ID NO:36:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 139 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:
Met Ala Gln Leu Arg Leu Phe Asn His Ala Ser Val Leu Asn
1 5 10





















Lys Phe Thr Asp Ala Asp Phe Lys
35
Asp Val Leu Leu Val
Cys Lys Lys Leu Ala
60
Leu Leu Gln Asn Asp
75
Cys Thr Glu Glu Lys
Gly Phe Pro Thr Leu
105











Tyr Met Arg Gly Gln Ala Gly Pro
130

































































































































CAGATGTCGA TTGCACAGAG GAAAAGAAAA TTTGCGATGA ATTCAGTGTT
AGTGGTTTTC CGACTTTAAA AATTTTCCGT AAGGGTGAAC TGGCTCAGGA
TTATGATGGC CCACGAGTTG CAGAAGGTAT TGTTAAATAT ATGCGTGGAC
AGGCAGGTCC ATCAGCT
(2) INFORMATION FOR SEQ ID NO:39
(i) SEQUENCE CHARACTERISTIC
(A) LENGTH:
(B) TYPE: nucleic aci
(C) STRANDEDNESS: sin
(D) TOPOLOGY: linear

















(2) INFORMATION FOR SEQ ID NO:40
(i) SEQUENCE CHARACTERISTIC
(A) LENGTH:
(B) TYPE: nucleic aci
(C) STRANDEDNESS: sin
(D) TOPOLOGY: linear





GAA AAC CGT TAT CAG TAT GAT CTG
Glu Asn Arg Tyr Gln Tyr Asp Leu
1 5
TAC AGC AAG ATT GAC TAT GAA TTG
Tyr Ser Lys Ile Asp Tyr Glu Leu
15 20
TAT TGG AGA AAT CGT GTT CTT ACA
Tyr Trp Arg Asn Arg Val Leu Thr
30 35
AGA AAA GCA TAT TIT GCT ATA AGT
Arg Lys Ala Tyr Phe Ala Ile Ser
45 50
TTT GAC CTT GAT GAA TIT GGC TTA
Phe Asp Leu Asp Glu Phe Gly Leu
60
AAA CCG CTT GTT GCA GCT CGT AGT


























CCA ATG TIT GTT GTG
Pro Met Phe Val Val
10
CCA AAA GGG TCC AAT
Pro Lys Gly Ser Asn
25
GCA AAG GAT TAC AGA
Ala Lys Asp Tyr Arg
40
AAG GAC GAT TTC TCA
Lys Asp Asp Phe Ser
55
GGT CGT AAA GAT ACT
Gly Arg Lys Asp Thr
AAA GGC AAA TTC TIC
























































































































































































(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION:
















































































































































































































































































(2) INFORMATION FOR SEQ ID NO:42:
(i) SEQUENCE CHARACTERISTICS:
537 nucleotides




(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:












































(xi) SEQUENCE DESCRIPTION: SEQ
GAA AAC CGT TAT CAG TAT GAT CTA CTT
Glu Asn Arg Tyr Gln T
5
yr Asp Leu Leu
TAT GGC AAG GTT GAC TAT GAA TTG GAT
Tyr Gly Lys Val Asp T
15
TAT TGG CGA AAT CGT G'
Tyr Trp Arg Asn Arg V
30
AGG AAA GCA AAT TIT G
Arg Lys Ala Asn Phe A
45
TTT GAT CTT GAT GAA T
Phe Asp Leu Asp Glu P
60
AAG CCG CTT GTT GCA G
Lys Pro Leu Val Ala A
75
ATG AAA GAA GAA TTC Al
yr Glu Leu Asp
20
TT CTT ATG GTT
al Leu Met Val
CT ATG AGT AAC
la Met Ser Asn
50
TT GGC TTA GCT
he Gly Leu Ala
65
CA CGT AGC AAA
la Arg Ser Lys



















































































































































































































































































































































































































































































































(2) INFORMATION FOR SEQ ID NO:45:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 537 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:
GTCCATTTTT GCAATAACAA CACCTGGTTC ACCGGATAAT TTCTGGCCTA 50
ATTCATCATA TTTCGGTGCG AGTGCTTTGC AGTGGCCACA CCATGGAGCA 100
TAAAATTCGA TTAAAACATC CTTTTCCACA TTICATGATCA TTTCTTGGAA 150
TGTCTTAGCA ACAACGACCT TAGCATCACC CTGATCTTCA GGTGCTTCTT 200
CGCTCTTCAT ATACGGTTCT AATCTATCAC CAATAACATC TTCGACAAAT 250
TTTTCCAAAT TTTCCACGCT GAATTCTTCT TTCATAAAGA ATTTGCCTTT 300
TTTGCTACGT GCTGCAACAA GCGGCTTGGT ATCTTTACGA TTAGCTAAGC 350
CAAATTCATC AAGATCAAAA GAGAAGTCTT CTTTGTTACT CATAGCAAAA 400
TTTGCTTTCC TITTGTAATC TTTTGCAACC ATAAGAACAC GATTTCGCCA 450
ATAGTTGGAA CCTTTTGGAT CCAATTCATA GTCAACCTTG CCATACACAA 500
CAAACATCGG AAGTAGATCA TACTGATAAC GGTTTTC 537
(2) INFORMATION FOR SEQ ID NO: 46:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1881 nucleotides
GGTTTAATTA CCCAAGTTTG AGG ATG ACA CTG GTG AGG
















































































































































































































AAA ACT TGC GAT GAA TAC GGT GTT AGT GGC TTC CCG ACT TTG 338
Lys Thr Cys Asp Glu Tyr Gly Val Ser Gly Phe Pro Thr Leu
95 100 105
AAA ATT TTC CGT AAG GGA GAA CTA GCA CAG GAT TAT GAT GGT 380
Lys Ile Phe Arg Lys Gly Glu Leu Ala Gln Asp Tyr Asp Gly
110 115
CCG AGA GTA GCA GAA GGT ATT GTG AAA TAT ATG CGT GGA CAG 422
Pro Arg Val Ala Glu Gly Ile Val Lys Tyr Met Arg Gly Gln
120 125 130
GCA GGT CCA TCA GCT ACA GAA ATT AAT ACA CAA CAA GAA TTC 464
Ala Gly Pro Ser Ala Thr Glu Ile Asn Thr Gln Gln Glu Phe
135 140 145
GAA AAA ATG TTG CAA GCC GAT GAC GTT ACT ATT TGT GGA TIT 506
Glu Lys Met Leu Gln Ala Asp Asp Val Thr Ile Cys Gly Phe
150 155 160
TTC GAA GAG AAC AGC AAG TTA AAA GAC TCA TIC TTA AAA GTT 548
Phe Glu Glu Asn Ser Lys Leu Lys Asp Ser Phe Leu Lys Val
165 170 175
GCG GAT ACA GAA AGA GAT CGT TIT AAG TIT GTG TGG ACA TCA 590
Ala Asp Thr Glu Arg Asp Arg Phe Lys Phe Val Trp Thr Ser
180 185
AAT AAA CAA ATT CTG GAA TCA AGG GGA TAC AAT GAT GAT ATC 632
Asn Lys Gln Ile Leu Glu Ser Arg Gly Tyr Asn Asp Asp Ile
190 195 200
GTC GCA TAT CAA CCG AAG AAA TTT CAT AAT AAA TIT GAA CCA 674
Val Ala Tyr Gln Pro Lys Lys Phe His Asn Lys Phe Glu Pro
205 210 215
AAT GAA TTC AAG TAT GAT GGA AAT TAC GAC ACA GAC AAG ATT 716
Asn Glu Phe Lys Tyr Asp Gly Asn Tyr Asp Thr Asp Lys Ile
220 225 230
AAA GAA TIT CTC CTA CAC GAA ACA AAT GGG CTT GTT GGT ATA 758
Lys Glu Phe Leu Leu His Glu Thr Asn Gly Leu Val Gly Ile
235 240 245
CGA ACG GCC GAA AAC CGT TAT CAG TAT GAT CTA CTT CCG ATG 800
Arg Thr Ala Glu Asn Arg Tyr Gln Tyr Asp Leu Leu Pro Met
250 255
TTC GTC GTC TAT GGC AAG GTT GAC TAT GAA TTG GAT CCA AAA 842
Phe Val Val Tyr Gly Lys Val Asp Tyr Glu Leu Asp Pro Lys
260 265 270
GGT TCC AAC TAT TGG CGA AAT CGT GTT CTT ATG GTT GCA AAA 884
Gly Ser Asn Tyr Trp Arg Asn Arg Val Leu Met Val Ala Lys
275 280 285
GAT TAC AAA AGG AAA GCA AAT TTT GCT ATG AGT AAC AAA GAA 926
Asp Tyr Lys Arg Lys Ala Asn Phe Ala Met Ser Asn Lys Glu
290 295 300
GAC TTC TCT TTT GAT CTT GAT GAA TIT GGC TTA GCT AAT CGT 968
Asp Phe Ser Phe Asp Leu Asp Glu Phe Gly Leu Ala Asn Arg
305 310 315
AAA GAT ACC AAG CCG CTT GTT GCA GCA CGT AGC AAA AAA GGC 1010
Lys Asp Thr Lys Pro Leu Val Ala Ala Arg Ser Lys Lys Gly
320 325
AAA TTC TIT ATG AAA GAA GAA TTC AGT TTT AGC GTG GAA AAT 1052
Lys Phe Phe Met Lys Glu Glu Phe Ser Phe Ser Val Glu Asn
330 335 340
TTG AAA AAA TTT GTC GAA GAT GTT ATT GGT GAT AGA TTA GAA 1094
Leu Lys Lys Phe Val Glu Asp Val Ile Gly Asp Arg Leu Glu
345 350 355
CCG TAT ATG AAG AGC GAA GAA GCA CCT GAA GAT CAG GGT GAT 1136





GTT AAG GTC GTT GTT GCT AAG ACA TTC CAA GAA ATG ATC ATG 1178
Val Lys Val Val Val Ala Lys Thr Phe Gln Glu Met Ile Met
375 380 385
AAT GTG GAA AAG GAT GTT TTA ATC GAA TTT TAT GCT CCA TGG 1220
Asn Val Glu Lys Asp Val Leu Ile Glu Phe Tyr Ala Pro Trp
390 395
TGT GGC CAC TGC AAA GCA CTC GCA CCG AAA TAT GAT GAA TTA 1262
Cys Gly His Cys Lys Ala Leu Ala Pro Lys Tyr Asp Glu Leu
400 405 410
GGC CAG AAA TTA TCC GGT GAA CCA GGT GTT GTT ATT GCA AAA 1304
Gly Gln Lys Leu Ser Gly Glu Pro Gly Val Val Ile Ala Lys
415 420 425
ATG GAC GCA ACA GCG AAT GAT GTC CCA CCA CCA TTC CAA GTA 1346
Met Asp Ala Thr Ala Asn Asp Val Pro Pro Pro Phe Gln Val
430 435 440
CAA GGA TTT CCA ACT CTT TAC TGG GTA CCG AAG AAT AAA AAA 1388
Gln Gly Phe Pro Thr Leu Tyr Trp Val Pro Lys Asn Lys Lys
445 450 455
GAC AAA CCA GAG CCA TAC TCT GGT GGT CGA GAA GTG GAT GAT 1430
Asp Lys Pro Glu Pro Tyr Ser Gly Gly Arg Glu Val Asp Asp
460 465
TTT ATT AAA TAC ATC GCG AAG CAT GCA ACG GAA GAA CTG AAG 1472
Phe Ile Lys Tyr Ile Ala Lys His Ala Thr Glu Glu Leu Lys
470 475 480
GGA TAC AAG AGA GAT GGA AAA CCG AAG AAG AAG GAA GAA TTG 1514
Gly Tyr Lys Arg Asp Gly Lys Pro Lys Lys Lys Glu Glu Leu
485 490 495
TAAAGGGTAA TAATGATGAA TTTTTAATTT GATGTGAACC CAAACAACCT 1564
CAGTTGCTTA TTGGTGGATA AATATTTAAA TCATTCCACA GAGCTGTGAT 1614
ATGAATTTTC AAATATGTTT TTTTTTGGTT TATTTTGATA AATTCATATT 1664
TTAAGTTGTT ATTTTTTAGT GCCTTAGGCT GTTTCATCAG TTGCCTTAGG 1714
CTATTTTGTC AGTTCGGAAT GTTTATTCCG TTAGCTTAGG CTTTTTTTITG 1764
TTTACCTTAT GTTACTGTTG TTATTGTATT ACTATTTTGC CCTTGTTTTT 1814
TAAATTTTAA ATAAATTTTT TTTGGAAAAA AAAAAAAAAA AAAAAAAAAA 1864
AAAAAAAAARA AAAAAAA 1881
(2) INFORMATION FOR SEQ ID NO:47:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 497 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:
Met Thr Leu Val Arg Leu Phe Asp Ala Ser Ile Phe Lys Leu
1 5 10
Phe Leu Phe Leu Ile Leu Pro Leu Thr Asn Ala Asp Gly Asp
15 20 25
Val Met Lys Phe Thr Asp Ala Asp Phe Lys Glu Gly Ile Lys
30 35 40
Pro Tyr Asp Val Leu Leu Val Lys Phe Tyr Ala Pro Trp Cys
45 50 55






Thr Lys Leu Leu Gln Asn Asp Pro Pro Ile His Leu Ala Glu
75 80
Val Asp Cys Thr Glu Glu Lys Lys Thr Cys Asp Glu Tyr Gly
Val Ser Gly Phe Pro Thr Leu Lys Ile Phe Arg Lys Gly Glu
100 105 110
Leu Ala Gln Asp Tyr Asp Gly Pro Arg Val Ala Glu Gly Ile
115 120 125
Val Lys Tyr Met Arg Gly Gln Ala Gly Pro Ser Ala Thr Glu
130 135 140
Ile Asn Thr Gln Gln Glu Phe Glu Lys Met Leu Gln Ala Asp
145 150
Asp Val Thr Ile Cys Gly Phe Phe Glu Glu Asn Ser Lys Leu
155 160 165
Lys Asp Ser Phe Leu Lys Val Ala Asp Thr Glu Arg Asp Arg
170 175 180
Phe Lys Phe Val Trp Thr Ser Asn Lys Gln Ile Leu Glu Ser
185 190 195
Arg Gly Tyr Asn Asp Asp Ile Val Ala Tyr Gln Pro Lys Lys
200 205 210
Phe His Asn Lys Phe Glu Pro Asn Glu Phe Lys Tyr Asp Gly
215 220
Asn Tyr Asp Thr Asp Lys Ile Lys Glu Phe Leu Leu His Glu
225 230 235
Thr Asn Gly Leu Val Gly Ile Arg Thr Ala Glu Asn Arg Tyr
240 245 250
Gln Tyr Asp Leu Leu Pro Met Phe Val Val Tyr Gly Lys Val
255 260 265
Asp Tyr Glu Leu Asp Pro Lys Gly Ser Asn Tyr Trp Arg Asn
270 275 280
Arg Val Leu Met Val Ala Lys Asp Tyr Lys Arg Lys Ala Asn
285 290
Phe Ala Met Ser Asn Lys Glu Asp Phe Ser Phe Asp Leu Asp
295 300 305
Glu Phe Gly Leu Ala Asn Arg Lys Asp Thr Lys Pro Leu Val
310 315 320
Ala Ala Arg Ser Lys Lys Gly Lys Phe Phe Met Lys Glu Glu
325 330 335
Phe Ser Phe Ser Val Glu Asn Leu Lys Lys Phe Val Glu Asp
340 345 350
Val Ile Gly Asp Arg Leu Glu Pro Tyr Met Lys Ser Glu Glu
355 360
Ala Pro Glu Asp Gln Gly Asp Val Lys Val Val Val Ala Lys
365 370 375
Thr Phe Gln Glu Met Ile Met Asn Val Glu Lys Asp Val Leu
380 385 390
Ile Glu Phe Tyr Ala Pro Trp Cys Gly His Cys Lys Ala Leu
395 400 405
Ala Pro Lys Tyr Asp Glu Leu Gly Gln Lys Leu Ser Gly Glu
410 415 420


















































































































































































































CACAAACTTA AAACGATCTC TTTCTGTATC CGCAACTTTT AAGAATGAGT 1350
CTTTTAACTT GCTGTTCTCT TCGAAAAATC CACAAATAGT AACGTCATCG 1400
GCTTGCAACA TTTTTTCGAA TICTTGTTGT GTATTAATTT CTGTAGCTGA 1450
TGGACCTGCC TGTCCACGCA TATATTTCAC AATACCTTCT GCTACTCTCG 1500
GACCATCATA ATCCTGTGCT AGTTCTCCCT TACGGAAAAT TTTCAAAGTC 1550
GGGAAGCCAC TAACACCGTA TTCATCGCAA GTTTTCTTCT CCTCCGTACA 1600
GTCAACCTCT GCTAAATGAA TAGGCGGATC ATTCTGTAAA AGTTTGGTTG 1650
CTGCTTTTTC AAATTCTGGT GCTATCTTTT TGCAGTGTCC GCACCATGGT 1700
GCATAAAATT TCACAAGTAA TACATCATAT GGTTTAATTC CCTCCTTGAA 1750
GTCCGCATCT GTAAATTTCA TCACATCGCC ATCGGCATTC GTTAATGGCA 1800
ATATCAGAAA CAAGAATAAT TTAAAAATCG AAGCATCAAA CAACCTCACC 1850
AGTGTCATCC TCAAACTTGG GTAATTAAAC C 1881
(2) INFORMATION FOR SEQ ID NO:49:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1494 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:
ATGACACTGG TGAGGTTGTT TGATGCTTCG ATTTTTAAAT TATTCTTGTT 50
TCTGATATTG CCATTAACGA ATGCCGATGG CGATGTGATG AAATTTACAG 100
ATGCGGACTT CAAGGAGGGA ATTAAACCAT ATGATGTATT ACTTGTGAAA 150
TTTTATGCAC CATGGTGCGG ACACTGCAAA AAGATAGCAC CAGAATTTGA 200
AAAAGCAGCA ACCAAACTTT TACAGAATGA TCCGCCTATT CATTTAGCAG 250
AGGTTGACTG TACGGAGGAG AAGAAAACTT GCGATGAATA CGGTGTTAGT 300
GGCTTCCCGA CTTTGAAAAT TTTCCGTAAG GGAGAACTAG CACAGGATTA 350
TGATGGTCCG AGAGTAGCAG AAGGTATTGT GAAATATATG CGTGGACAGG 400
CAGGTCCATC AGCTACAGAA ATTAATACAC AACAAGAATT CGAAAAAATG 450
TTGCAAGCCG ATGACGTTAC TATTTGTGGA TTTTTCGAAG AGAACAGCAA 500
GTTAAAAGAC TCATTCTTAA AAGTTGCGGA TACAGAAAGA GATCGTTTTA 550
AGTTTGTGTG GACATCAAAT AAACAAATTC TGGAATCAAG GGGATACAAT 600
GATGATATCG TCGCATATCA ACCGAAGAAA TTTCATAATA AATTTGAACC 650
AAATGAATTC AAGTATGATG GAAATTACGA CACAGACAAG ATTAAAGAAT 700
TTCTCCTACA CGAAACAAAT GGGCTTGTTG GTATACGAAC GGCCGAAAAC 750
CGTTATCAGT ATGATCTACT TCCGATGTTC GTCGTCTATG GCAAGGTTGA 800
CTATGAATTG GATCCAAAAG GTTCCAACTA TTGGCGAAAT CGTGTTCTTA 850
TGGTTGCAAA AGATTACAAA AGGAAAGCAA ATTTTGCTAT GAGTAACAAA 900
GAAGACTTCT CTTTTGATCT TGATGAATTT GGCTTAGCTA ATCGTAAAGA 950
TACCAAGCCG CTTGTTGCAG CACGTAGCAA AAAAGGCAAA TICTTTATGA 1000





GTTATTGGTG ATAGATTAGA ACCGTATATG AAGAGCGAAG AAGCACCTGA 1100
AGATCAGGGT GATGTTAAGG TCGTTGTTGC TAAGACATTC CAAGAAATGA 1150
TCATGAATGT GGAAAAGGAT GTTTTAATCG AATTTTATGC TCCATGGTGT 1200
GGCCACTGCA AAGCACTCGC ACCGAAATAT GATGAATTAG GCCAGAAATT 1250
ATCCGGTGAA CCAGGTGTTG TTATTGCAAA AATGGACGCA ACAGCGAATG 1300
ATGTCCCACC ACCATTCCAA GTACAAGGAT TTCCAACTCT TTACTGGGTA 1350
CCGAAGAATA AAAAAGACAA ACCAGAGCCA TACTCTGGTG GTCGAGAAGT 1400
GGATGATTTT ATTAAATACA TCGCGAAGCA TGCAACGGAA GAACTGAAGG 1450
GATACAAGAG AGATGGAAAA CCGAAGAAGA AGGAAGAATT GTAA 1494
(2) INFORMATION FOR SEQ ID NO:50:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1494 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:
TTACAATTCT TCCTTCTTCT TCGGTTTTCC ATCTCTCTTG TATCCCTTICA 50
GTTCTTCCGT TGCATGCTTC GCGATGTATT TAATAAAATC ATCCACTTCT 100
CGACCACCAG AGTATGGCTC TGGTTTGTCT TITTTATTCT TCGGTACCCA 150
GTAAAGAGTT GGAAATCCTT GTACTTGGAA TGGTGGTGGG ACATCATTCG 200
CTGTTGCGTC CATTTTTGCA ATAACAACAC CTGGTTCACC GGATAATTTC 250
TGGCCTAATT CATCATATTT CGGTGCGAGT GCTTTGCAGT GGCCACACCA 300
TGGAGCATAA AATTCGATTA AAACATCCTT TTCCACATTC ATGATCATTT 350
CTTGGAATGT CTTAGCAACA ACGACCTTAA CATCACCCTG ATCTTCAGGT 400
GCTTCTTCGC TCTTCATATA CGGTTCTAAT CTATCACCAA TAACATCTTC 450
GACAAATTTT TTCAAATTTT CCACGCTAAA ACTGAATTCT TCTTTCATAA 500
AGAATTTGCC TITTTTGCTA CGTGCTGCAA CAAGCGGCTT GGTATCTTTA 550
CGATTAGCTA AGCCAAATTC ATCAAGATCA AAAGAGAAGT CTTCTTTGTT 600
ACTCATAGCA AAATTTGCTT TCCTTTTGTA ATCTTTTGCA ACCATAAGAA 650
CACGATTTCG CCAATAGTTG GAACCTTTTG GATCCAATTC ATAGTCAACC 700
TTGCCATAGA CGACGAACAT CGGAAGTAGA TCATACTGAT AACGGTTTTC 750
GGCCGTTCGT ATACCAACAA GCCCATTTGT TTCGTGTAGG AGAAATTCTT 800
TAATCTTGTC TGTGTCGTAA TTTCCATCAT ACTTGAATTC ATTTGGTTCA 850
AATTTATTAT GAAATTTCTT CGGTTGATAT GCGACGATAT CATCATTGTA 900
TCCCCTTGAT TCCAGAATTT GTTTATTTGA TGTCCACACA AACTTAAAAC 950
GATCTCTTTC TGTATCCGCA ACTTTTAAGA ATGAGTCTTT TAACTTGCTG 1000
TTCTCTTCGA AAAATCCACA AATAGTAACG TCATCGGCTT GCAACATTTT 1050
TTCGAATTCT TGTTGTGTAT TAATTTCTGT AGCTGATGGA CCTGCCTGTC 1100
CACGCATATA TTTCACAATA CCTTCTGCTA CTCTCGGACC ATCATAATCC 1150






ACCGTATTCA TCGCAAGTTT TCTTCTCCTC CGTACAGTCA ACCTCTGCTA
AATGAATAGG CGGATCATTC TGTAAAAGTT TGGTTGCTGC TTTTTCAAAT
TCTGGTGCTA TCTTTTTGCA GTGTCCGCAC CATGGTGCAT AAAATTTCAC
AAGTAATACA TCATATGGTT TAATTCCCTC CTTGAAGTCC GCATCTGTAA
ATTTCATCAC ATCGCCATCG GCATTCGTTA ATGGCAATAT CAGAAACAAG












INFORMATION FOR SEQ ID NO:51:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 45 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear




(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:
GGC GAT GTG ATG AAA TTT ACA GAT GCG GAC TTC AAG GAG
Gly Asp Val Met Lys Phe Thr Asp Ala Asp Phe Lys Glu
5 10
INFORMATION FOR SEQ ID NO:52:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:
Gly Asp Val Met Lys Phe Thr Asp Ala Asp Phe Lys Glu
5 10
INFORMATION FOR SEQ ID NO:53:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 45 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:
TCCCTCCTTG AAGTCCGCAT CTGTAAATTT CATCACATCG CCATC
(2) INFORMATION FOR SEQ ID NO:54:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1416 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear





































































































































































































































































































































































































































































































































































































TGG CGA AAT CGT GTT CTT ATG GTT GCA AAA GAT TAC AAA AGG 798
Trp Arg Asn Arg Val Leu Met Val Ala Lys Asp Tyr Lys Arg
255 260 265
AAA GCA AAT TIT GCT ATG AGT AAC AAA GAA GAC TTC TCT TIT 840
Lys Ala Asn Phe Ala Met Ser Asn Lys Glu Asp Phe Ser Phe
270 275 280
GAT CTT GAT GAA TTT GGC TTA GCT AAT CGT AAA GAT ACC AAG 882
Asp Leu Asp Glu Phe Gly Leu Ala Asn Arg Lys Asp Thr Lys
285 290
CCG CTT GTT GCA GCA CGT AGC AAA AAA GGC AAA TTC TIT ATG 924
Pro Leu Val Ala Ala Arg Ser Lys Lys Gly Lys Phe Phe Met
295 300 305
AAA GAA GAA TTC AGT TTT AGC GTG GAA AAT TTG AAA AAA TIT 966
Lys Glu Glu Phe Ser Phe Ser Val Glu Asn Leu Lys Lys Phe
310 315 320
GTC GAA GAT GTT ATT GGT GAT AGA TTA GAA CCG TAT ATG AAG 1008
Val Glu Asp Val Ile Gly Asp Arg Leu Glu Pro Tyr Met Lys
325 330 335
AGC GAA GAA GCA CCT GAA GAT CAG GGT GAT GTT AAG GTC GTT 1050
Ser Glu Glu Ala Pro Glu Asp Gln Gly Asp Val Lys Val Val
340 345 350
GTT GCT AAG ACA TTC CAA GAA ATG ATC ATG AAT GTG GAA AAG 1092
Val Ala Lys Thr Phe Gln Glu Met Ile Met Asn Val Glu Lys
355 360
GAT GTT TTA ATC GAA TTT TAT GCT CCA TGG TGT GGC CAC TGC 1134
Asp Val Leu Ile Glu Phe Tyr Ala Pro Trp Cys Gly His Cys
365 370 375
AAA GCA CTC GCA CCG AAA TAT GAT GAA TTA GGC CAG AAA TTA 1176
Lys Ala Leu Ala Pro Lys Tyr Asp Glu Leu Gly Gln Lys Leu
380 385 390
TCC GGT GAA CCA GGT GTT GTT ATT GCA AAA ATG GAC GCA ACA 1218
Ser Gly Glu Pro Gly Val Val Ile Ala Lys Met Asp Ala Thr
395 400 405
GCG AAT GAT GTC CCA CCA CCA TTC CAA GTA CAA GGA TIT CCA 1260
Ala Asn Asp Val Pro Pro Pro Phe Gln Val Gln Gly Phe Pro
410 415 420
ACT CTT TAC TGG GTA CCG AAG AAT AAA AAA GAC AAA CCA GAG 1302
Thr Leu Tyr Trp Val Pro Lys Asn Lys Lys Asp Lys Pro Glu
425 430
CCA TAC TCT GGT GGT CGA GAA GTG GAT GAT TIT ATT AAA TAC 1344
Pro Tyr Ser Gly Gly Arg Glu Val Asp Asp Phe Ile Lys Tyr
435 440 445
ATC GCG AAG CAT GCA ACG GAA GAA CTG AAG GGA TAC AAG AGA 1386
Ile Ala Lys His Ala Thr Glu Glu Leu Lys Gly Tyr Lys Arg
450 455 460
GAT GGA AAA CCG AAG AAG AAG GAA GAA TTG 1416
Asp Gly Lys Pro Lys Lys Lys Glu Glu Leu
465 470
(2) INFORMATION FOR SEQ ID NO:55:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 472 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:






Gly Ile Lys Pro Tyr Asp Val Leu Leu Val Lys Phe Tyr Ala
15 20 25
Pro Trp Cys Gly His Cys Lys Lys Ile Ala Pro Glu Phe Glu
30 35 40
Lys Ala Ala Thr Lys Leu Leu Gln Asn Asp Pro Pro Ile His
45 50 55
Leu Ala Glu Val Asp Cys Thr Glu Glu Lys Lys Thr Cys Asp
60 65 70
Glu Tyr Gly Val Ser Gly Phe Pro Thr Leu Lys Ile Phe Arg
75 80
Lys Gly Glu Leu Ala Gln Asp Tyr Asp Gly Pro Arg Val Ala
85 90 95
Glu Gly Ile Val Lys Tyr Met Arg Gly Gln Ala Gly Pro Ser
100 105 110
Ala Thr Glu Ile Asn Thr Gln Gln Glu Phe Glu Lys Met Leu
115 120 125
Gln Ala Asp Asp Val Thr Ile Cys Gly Phe Phe Glu Glu Asn
130 135 140
Ser Lys Leu Lys Asp Ser Phe Leu Lys Val Ala Asp Thr Glu
145 150
Arg Asp Arg Phe Lys Phe Val Trp Thr Ser Asn Lys Gln Ile
155 160 165
Leu Glu Ser Arg Gly Tyr Asn Asp Asp Ile Val Ala Tyr Gln
170 175 180
Pro Lys Lys Phe His Asn Lys Phe Glu Pro Asn Glu Phe Lys
185 190 195
Tyr Asp Gly Asn Tyr Asp Thr Asp Lys Ile Lys Glu Phe Leu
200 205 210
Leu His Glu Thr Asn Gly Leu Val Gly Ile Arg Thr Ala Glu
215 220
Asn Arg Tyr Gln Tyr Asp Leu Leu Pro Met Phe Val Val Tyr
225 230 235
Gly Lys Val Asp Tyr Glu Leu Asp Pro Lys Gly Ser Asn Tyr
240 245 250
Trp Arg Asn Arg Val Leu Met Val Ala Lys Asp Tyr Lys Arg
255 260 265
Lys Ala Asn Phe Ala Met Ser Asn Lys Glu Asp Phe Ser Phe
270 275 280
Asp Leu Asp Glu Phe Gly Leu Ala Asn Arg Lys Asp Thr Lys
285 290
Pro Leu Val Ala Ala Arg Ser Lys Lys Gly Lys Phe Phe Met
295 300 305
Lys Glu Glu Phe Ser Phe Ser Val Glu Asn Leu Lys Lys Phe
310 315 320
Val Glu Asp Val Ile Gly Asp Arg Leu Glu Pro Tyr Met Lys
325 330 335
Ser Glu Glu Ala Pro Glu Asp Gln Gly Asp Val Lys Val Val
340 345 350
Val Ala Lys Thr Phe Gln Glu Met Ile Met Asn Val Glu Lys
355 360
Asp Val Leu Ile Glu Phe Tyr Ala Pro Trp Cys Gly His Cys
365 370 375



















Pro Gly Val Val Ile Ala Lys Met
400
Val Pro Pro Pro Phe
410






Gly Gly Arg Glu Val Asp Asp Phe
440
His Ala Thr Glu Glu
455
Pro Lys Lys Lys Glu
470























































































































































































































































































































































































































































































Gly Ile val val
15







Pro Trp His Leu Pro Phe
30














Leu Asp Asp Cys Lys Lys Ile Cys





Lys Glu Leu Ala Gln Pro val
85
Gly Asp Tyr Asp Gly Arg
Glu Ile Val Met
105
Gly Gln Ala Pro
100
Lys Tyr Arg Gly Gly
110
Ala
(2) INFORMATION FOR SEQ ID NO:59:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 339 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:
AGCTGATGGA CCTGCCTGTC CACGCATATA TTTAACAATA
CTCGTGGGCC ATCATAATCC TGAGCCAGTT CACCCTTACG
AAAGTCGGAA AACCACTAAC ACTGAATTCA TCGCAAATTT
TGTGCAATCG ACATCTGCTA AATGAATAGG TGGATCATTT
TIGTTGCTGC CTTCTCAAAT TCTGGGGCCA GTTTCTTGCA
CATGGTGCAT AAAATTTCAC AAGTAATACA TCATATGATT
























1. An isolated protein comprising an amino acid sequence
selected from the group consisting of SEQ ID NO:28, SEQ
ID NO:33, SEQ ID NO:47, SEQ ID NO:52, and SEQ ID
NO:55.
2. The protein of claim 1, wherein said protein comprises
a Dirofilaria immitis protein.
3. The protein of claim 1, wherein said protein is encoded
by a nucleic acid molecule having a nucleic acid sequence
selected from the group consisting of SEQ ID NO:27, SEQ
ID NO:30, SEQ ID NO:32, SEQ ID NO:46, SEQ ID NO:49,
SEQ ID NO:51, and SEQ ID NO:54.
4. The protein of claim 1, wherein said protein has
transglutaminase activity.
5. The protein of claim 1, wherein said protein has protein
disulfide isomerase activity.
6. An isolated protein encoded by a nucleic acid molecule
comprising a nucleic acid sequence selected from the group
consisting of: SEQ ID NO:27, SEQ ID NO:30, SEQ ID
NO:32, SEQ ID NO:46, SEQ ID NO:49, SEQ ID NO:51 and
SEQ ID NO:54.






8. A protein of claim 6, wherein said protein has protein
disulfide isomerase activity.
9. A protein of claim 1, wherein said protein is a non-
native protein.
10. A protein of claim 1, wherein said protein is chemi-
cally synthesized.
11. Aprotein of claim 1, wherein said protein is produced
in a cell transformed with a nucleic acid molecule encoding
a Dirofilaria immitis transglutaminase protein.
12. Acomposition comprising:(a) an excipient; and (b) an
isolated protein comprising an amino acid sequenceselected
from the group consisting of SEQ ID NO:28, SEQ ID
NO:33, SEQ ID NO:47, SEQ ID NO:52, and SEQ ID
NO:55.
13. The composition of claim 12, said protein being
capable of eliciting an immune response in a host animal.
14. The composition of claim 12, wherein said composi-
tion further comprises a componentselected from the group
consisting of an adjuvant and a carrier.
15. Amethodto identify a compound capable of inhibiting
transglutaminase activity, said method comprising (a) con-
tacting an isolated protein comprising an amino acid
sequence selected from the group consisting of SEQ ID
US 6,309,644 B1
127
NO:28, SEQ ID NO:33, SEQ ID NO:47, SEQ ID NO:52,
and SEQ ID NO:55 with a putative inhibitory compound
under conditions in which,in the absence of said compound,
said protein has transglutaminase activity; and (b) determin-
ing if said putative inhibitory compound inhibits said activ-
ity.
16. The method of claim 15, said method further com-
prising contacting an isolated host animal transglutaminase
protein with a putative nematode transglutaminase inhibi-
tory compound under conditions in which, in the absence of 10
said compound, said host animal transglutaminase protein
has transglutaminase activity; and determining if said puta-
tive inhibitory compound inhibits the host animal trans-
glutaminase activity.
17. Amethodto identify a compound capable of inhibiting 15
protein disulfide isomerase activity, said method comprising
(a) contacting an isolated protein comprising an amino acid
sequence selected from the group consisting of SEQ ID
128
NO:28, SEQ ID NO:33, SEQ ID NO:47, SEQ ID NO:52,
and SEQ ID NO:55 with a putative inhibitory compound
under conditions in which,in the absence of said compound,
said protein has protein disulfide isomerase activity; and (b)
determining if said putative inhibitory compound inhibits
said activity.
18. The method of claim 17, said method further com-
prising contacting an isolated host animal protein disulfide
isomerase protein with a putative nematode protein disulfide
isomerase inhibitory compound under conditions in which,
in the absence of said compound, said host animal protein
disulfide isomerase protein has protein disulfide isomerase
activity; and determining if said putative inhibitory com-
pound inhibits the host animal protein disulfide isomerase
activity.
